U.S. patent application number 09/562980 was filed with the patent office on 2003-01-16 for quinones as disease therapies.
Invention is credited to Blokhin, Andrei V., Frydman, Benjamin, Marton, Laurence J., Neder, Karen M., Sun, Jerry Shunneng.
Application Number | 20030013677 09/562980 |
Document ID | / |
Family ID | 26829845 |
Filed Date | 2003-01-16 |
United States Patent
Application |
20030013677 |
Kind Code |
A1 |
Blokhin, Andrei V. ; et
al. |
January 16, 2003 |
QUINONES AS DISEASE THERAPIES
Abstract
Novel quinones are provided, as well as compositions comprising
these novel quinones. Methods of using the novel quinones in
treatment of various indications including cancer are also
provided.
Inventors: |
Blokhin, Andrei V.;
(Madison, WI) ; Frydman, Benjamin; (Madison,
WI) ; Marton, Laurence J.; (Madison, WI) ;
Neder, Karen M.; (Madison, WI) ; Sun, Jerry
Shunneng; (Madison, WI) |
Correspondence
Address: |
MORRISON & FOERSTER LLP
755 PAGE MILL RD
PALO ALTO
CA
94304-1018
US
|
Family ID: |
26829845 |
Appl. No.: |
09/562980 |
Filed: |
April 27, 2000 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60131842 |
Apr 30, 1999 |
|
|
|
Current U.S.
Class: |
514/54 |
Current CPC
Class: |
C07C 45/00 20130101;
C07C 45/46 20130101; C07D 493/04 20130101; C07K 7/06 20130101; A61K
38/00 20130101; C07D 295/185 20130101; C07C 255/54 20130101; C07F
9/12 20130101; C07C 69/96 20130101; C07D 235/18 20130101; C07D
311/92 20130101; C07D 219/10 20130101; C07C 233/31 20130101; C07C
45/46 20130101; C07D 307/79 20130101; C07C 69/734 20130101; C07C
47/575 20130101; C07C 50/32 20130101; C07C 47/575 20130101; C07C
50/32 20130101; C07C 69/708 20130101; C07D 317/70 20130101; C07C
67/343 20130101; C07C 305/20 20130101; C07K 5/1013 20130101; C07C
46/00 20130101; C07C 67/343 20130101; C07C 237/22 20130101; C07F
9/65517 20130101; C07F 9/65522 20130101; A61K 47/65 20170801; C07D
307/92 20130101; C07C 46/00 20130101; C07C 229/22 20130101; C07D
207/34 20130101; C07C 45/00 20130101 |
Class at
Publication: |
514/54 |
International
Class: |
A61K 031/715 |
Claims
What is claimed is:
1. A compound of the formula: 151wherein A is selected from the
group consisting of --O-- and --CH.sub.2--; wherein M.sub.1 is
selected from the group consisting of a single bond and
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched alkyl,
C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8 cycloaryl; wherein
B is selected from the group consisting of --CH.sub.2--, --O--,
--C(.dbd.O)--O--; --O--C(.dbd.O)--, and --N(R.sub.1)--; wherein
R.sub.1 is selected from the group consisting of --H,
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched alkyl,
C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8 cycloaryl; wherein
M.sub.2 is selected from the group consisting of a single bond and
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched alkyl,
C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8 cycloaryl; wherein
D is selected from the group consisting of --H, --OH,
--N(R.sub.7)(R.sub.8), pentoses, hexoses, 152wherein R.sub.4 is
selected from the group consisting of --H, C.sub.1-C.sub.8 alkyl,
C.sub.1-C.sub.8 branched alkyl, C.sub.3-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 cycloaryl, --N(R.sub.9)(R.sub.10), and --CN; and
wherein R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are independently
selected from the group consisting of --H, C.sub.1-C.sub.8 alkyl,
C.sub.1-C.sub.8 branched alkyl, C.sub.3-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 cycloaryl, and 153
2. A compound according to the formula 154wherein x is an integer
between 1 and 2; and each K is independently selected from the
group consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkanol, C.sub.1-C.sub.8 alkoxy, 155and
where zero or two, but no more than two, vicinal K's in the
molecule represent single electrons which form a pi bond, thus
forming a double bond together with the existing sigma bond between
the two adjacent carbons bearing the two vicinal K's.
3. A compound of the formula 156wherein R is selected from the
group consisting of C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
cycloalkyl, C.sub.3-C.sub.8 cycloaryl, C.sub.1-C.sub.8 branched
alkyl, and C.sub.1-C.sub.8 alkanol.
4. A compound of the formula 157wherein Y is selected from the
group consisting of --H, --F, --Br, --Cl, and --I; and wherein
G.sub.1 and G.sub.2 are independently selected from the group
consisting of H, C.sub.1-C.sub.8 alkyl, 158and
--C(.dbd.O)--CH.sub.nX.sub.3-n where n is an integer from 0 to 3
and X is selected from the group consisting of F, Cl, Br, and
I.
5. A compound of the formula 159wherein M is selected from the
group consisting of --O--, --C(.dbd.O)--O--,
--O--(C.dbd.O)----C(.dbd.O)--N--, and --N--(C.dbd.O)--.
6. A compound of the formula 160wherein x is an integer between 1
and 2; each B is independently selected from the group consisting
of H, C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 cycloaryl, C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8
cycloalkyl, and C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloaryl;
and each K is independently selected from the group consisting of
H, OH, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl,
C.sub.1-C.sub.8 alkanol, C.sub.1-C.sub.8 alkoxy, and where zero or
two, but no more than two, vicinal K's in the molecule represent
single electrons which form a pi bond, thus forming a double bond
together with the existing sigma bond between the two adjacent
carbons bearing the two vicinal K's.
7. A compound of the formula 161wherein each B is independently
selected from the group consisting of H, C.sub.1-C.sub.8 alkyl,
C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 cycloaryl,
C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloalkyl, and
C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloaryl; and wherein R is
selected from the group consisting of C.sub.1-C.sub.8 alkyl and
C.sub.1-C.sub.8 alkanol.
8. A compound of the formula 162where M.sub.5 is C.sub.1-C.sub.8
alkyl, y is an integer from 1 to 6, and L is selected from the
group consisting of --O--K.sub.1 or --N(K.sub.1K.sub.2); where
K.sub.1 and K.sub.2 are independently selected from the group
consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkyl-COOH,
C.sub.1-C.sub.8 alkyl-COO-C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
alkyl-N(G.sub.1G.sub.2), and C.sub.1-C.sub.8
alkyl-N(G.sub.3)-C.sub.1-C.sub.8 alkyl-N(G.sub.4G.sub.5); and
wherein each of G.sub.1, G.sub.2, G.sub.3, G.sub.4, and G.sub.5 is
independently selected from the group consisting of H and
C.sub.1-C.sub.8 alkyl.
9. A compound of the formula: 163where z is an integer between one
and ten; G.sub.10 is selected from the group consisting of
C.sub.1-C.sub.8 alkyl; each M is independently selected from the
group consisting of C.sub.1-C.sub.8, alkyl; V is selected from the
group consisting of --C(.dbd.O)--N-- and --N--(C.dbd.O)--; and T is
selected from the group consisting of --COOM.sub.8 and
--CONM.sub.9M.sub.10, where each of M.sub.8, M.sub.9 and M.sub.10
are independently selected from the group consisting of H and
C.sub.1-C.sub.8 alkyl.
10. A compound of the formula 164where M.sub.12 is selected from
the group consisting of C.sub.1-C.sub.8 alkyl.
11. A compound of the formula 165where M.sub.14 and M.sub.15 are
independently selected from the group consisting of C.sub.1-C.sub.8
alkyl.
12. A compound of the formula 166where J is selected from the group
consisting of C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 cycloaryl, and C.sub.1-C.sub.8 branched alkyl.
13. A compound of the formula 167where R.sub.S is the side chain of
a naturally-occuring amino acid, attached in S or R
configuration.
14. A compound of the formula S-L-QUIN wherein S represents a
single amino acid or a peptide of at least two amino acids; L is a
linking group containing at least one carbon, oxygen, or nitrogen
atom attached covalently to both S and QUIN, or a nonentity; and
QUIN is a quinone, quinone derivative, hydroquinone, or
hydroquinone derivative.
15. A compound according to claim 14, wherein S or a portion
thereof, S-L or a portion thereof, or both S or a portion thereof
and then L or a portion thereof, are cleaved from the
quinone-containing remainder of the molecule by an enzyme.
16. A compound according to claim 15, wherein the enzyme is
prostate specific antigen.
17. A compound according to claim 14, wherein L is --O--, --NH--,
or --NH-(C.sub.1-C.sub.8 alkyl)-O--.
18. A compound according to claim 14, wherein L is
--NH-(C.sub.6H.sub.4)CH- .sub.2--O--(C.dbd.O)--NH-(C.sub.1-C.sub.8
alkyl)-O--.
19. A compound according to claim 14, wherein S is
X-Ser-Lys-Leu-Gln, wherein X is a protecting group or an
amino-terminal capping group, and the side chains of Ser, Lys, and
Gln may optionally be protected with protecting groups.
20. A compound of the formula S-L-QUIN wherein S represents a
single amino acid or a peptide of at least two amino acids; L is a
linking group containing at least one carbon, oxygen, or nitrogen
atom attached covalently to both S and QUIN, or a nonentity; and
QUIN is selected from the group consisting of the quinone compounds
of claim 13 and the compounds 168
21. A method for making a compound according to claim 14,
comprising the steps of a) covalently linking L to S, and b)
covalently linking L to QUIN, wherein steps a) and b) can be
performed in either order or simultaneously.
22. A compound of the formula 169wherein x is an integer between 1
and 2; W is selected from --H, --OH, --O-C.sub.1-C.sub.8 alkyl,
--O-C.sub.1-C.sub.8 alkyl-NH.sub.2, and --O-C.sub.1-C.sub.8
alkyl-NH-S, wherein S is a single amino acid or a peptide of two or
more amino acids; and each K is independently selected from the
group consisting of H, OH, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
alkenyl, C.sub.1-C.sub.8 alkanol, C.sub.1-C.sub.8 alkoxy, and where
zero or two, but no more than two, vicinal K's in the molecule
represent single electrons which form a pi bond, thus forming a
double bond together with the existing sigma bond between the two
adjacent carbons bearing the two vicinal K's.
23. A compound according to claim 22 of the formula 170wherein W is
selected from --H, --OH, --O-C.sub.1-C.sub.8 alkyl,
--O-C.sub.1-C.sub.8 alkyl-NH.sub.2, and --O-C.sub.1-C.sub.8
alkyl-NH-S, and wherein S is a single amino acid or a peptide of
two or more amino acids.
24. A compound according to claim 22, wherein W is
--O-C.sub.1-C.sub.8 alkyl-NH-S, wherein S is a single amino acid or
a peptide of two or more amino acids; wherein the group --NH--
forms an amide bond with the alpha-carboxy group of S when S is a
single amino acid and the group --NH-- forms an amide bond with the
C-terminal alpha-carboxy group of S when S is a peptide of two or
more amino acids.
25. A compound according to claim 23, wherein W is
--O-C.sub.1-C.sub.8 alkyl-NH-S, wherein S is a single amino acid or
a peptide of two or more amino acids; wherein the group --NH--
forms an amide bond with the alpha-carboxy group of S when S is a
single amino acid and the group --NH-- forms an amide bond with the
C-terminal alpha-carboxy group of S when S is a peptide of two or
more amino acids.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority benefit of co-pending
provisional patent application U.S. Serial No. 60/131,842, filed on
Apr. 30, 1999. The content of that application is hereby
incorporated by reference herein in its entirety.
STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH
[0002] Not applicable.
TECHNICAL FIELD
[0003] This invention relates to novel quinones. The invention also
relates to conjugates of quinones with various peptides. The
invention also relates to various medicinal and industrial uses of
these compounds, including the use of these compounds in treating
diseases such as cancer.
BACKGROUND OF THE INVENTION
[0004] The quinones are a large and varied group of natural
products found in all major groups of organisms. Quinones are a
group of aromatic dioxo compounds derived from benzene or
multiple-ring hydrocarbons such as naphthalene, anthracene, etc.
They are classified as benzoquinones, naphthoquinones,
anthraquinones, etc., on the basis of the ring system. The C.dbd.O
groups are generally ortho orpara, and form a conjugated system
with at least two C.dbd.C double bonds; hence the compounds are
colored, yellow, orange or red. Quinones with long isoprenoid side
chains, such as plastoquinone, ubiquinone and phytoquinone are
involved in the basic life processes of photosynthesis and
respiration. Quinones are biosynthesized from acetate/malonate via
shikimic acid. A few quinones are used as laxatives and worming
agents, and others are used a pigments in cosmetics, histology and
aquarrell paints. Quinones have a variety of medicinal and
industrial uses.
[0005] Many efficient antineoplastic drugs are either quinones
(anthracycline derivatives, mitoxantrone, actinomycin), quinonoid
derivatives (quinolones, genistein, bactracyclin), or drugs such as
etoposide that can easily be converted to quinones by in vivo
oxidation. Gantchev et al. (1997) Biochem. Biophys. Res. Comm.
237:24-27. The literature on quinone-DNA interactions is replete
with references to quinones having the potential to undergo redox
cycling with the formation of highly reactive oxygen species that
are thought to relate to their cytotoxicity. O'Brien (1991) Chem.
Biol. Interactions 80:1-41. It has also been shown that many
quinones are efficient modifiers of the enzymatic activity of
topoisomerase II, an enzyme essential for cell division.
[0006] Quinones are now widely used as anti-cancer, anti-bacterial
and anti-malarial drugs, as well as fungicides. The antitumor
activities of the quinones were revealed more than two decades ago
when the National Cancer Institute published a report in which
fifteen-hundred synthetic and natural quinones were screened for
their anticancer activities. Driscoll et al. (1974) Cancer Chemot.
Reports 4:1-362. Anti-cancer quinones include .beta.-Lapachone, a
plant product, which inhibits DNA topoisomerase II and induces cell
death with characteristics of apoptosis in human prostate and
promyelocytic leukemia cancer cell lines. Human breast and ovary
carcinoma showed sensitivity of the cytotoxic effect of
.beta.-lapachone without signs of apoptosis. Li et al. (1995)
Cancer Res. 55:3712-5; and Planchon et al. (1995) Cancer Res.
55:3706-11. 1,2-Naphthoquinone (3,4-b)dihydrofuran inhibits
neoplastic cell growth and proliferation of several cancers, such
as prostate, breast, colon, brain and lung, including multi-drug
resistant types. WO 97/31936. Furano-naphthoquinone derivatives and
other naphthoquinones and naphth-[2,3-d]-imidazole-4,9-dione
compounds are also useful in treating malignant tumors such as
those affecting the blood, breast, central nervous system, cervix,
colon, kidney, lung, prostate and skin. WO 97/30022 and JP Patent
No. 9235280. Anthraquinone derivatives with telomerase inhibitory
activity are also useful in treating leukemia, lung cancer,
myeloma, lymphoma, prostate, colon, head and neck, melanoma,
hepatocellular carcinoma, bladder, ovarian, breast and gastric
cancers. WO 98/25884 and WO 98/25885. Ansamycin benzoquinones are
useful in the treatment of primitive neuroectodermal tumors,
prostate cancer, melanoma and metastatic Ewing's sarcoma. WO
94/08578.
[0007] Quinones also have a number of other medicinal uses.
Terpenoid-type quinones are also useful as treatments for diabetes.
U.S. Pat. No. 5,674,900. Additional quinones can be used to treat
cirrhosis and other liver disorders. U.S. Pat. Nos. 5,210,239 and
5,385,942. Hydroquinone amines and quinone amines are also useful
for treating a number of conditions, including spinal trauma and
head injury. U.S. Pat. No. 5,120,843. Degenerative central nervous
system diseases, as well as vascular diseases, are treatable with
quinones such as Idebenone
[2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone] and
Rifamycin S. Mordente et al. (1998) Chem. Res. Toxicol. 11:54-63;
Rao et al. (1997) Free Radic. Biol. Med. 22:439-46; Cortelli et al.
(1997) J. Neurol. Sci. 148:25-31; and Mahadik et al. (1 996)
Prostaglandins Leukot. Essent. Fatty Acids 55:45-54. A vitamin K
analog, 6-cyclo-octylamino-5,8-- quinoline quinone shows efficacy
for treatment of leprosy and tuberculosis. U.S. Pat. No. 4,963,565.
Hydroquinone is used to treat skin pigmentation disorders. Clarys
et al. (1998) J. Dermatol. 25:412-4. Mitomycin C-related drug
indoloquinone EO9 has demonstrated cell killing against HL-60 human
leukemia cells, H661 human lung cancer cells, rat Walker tumor
cells and human HT29 colon carcinoma cells. Begleiter et al. (1997)
Oncol. Res. 9:371-82; and Bailey et al. (1997) Br. J. Cancer
76:1596-603. Quinones such as aloin, a C-glycoside derivative of
anthraquinone, accelerate ethanol oxidation and may be useful in
treating acute alcohol intoxication. Chung et al. (1996) Biochem.
Pharmacol. 52:1461-8 and Nanji et al. (1996) Toxicol. Appl.
Pharmacol. 140:101-7. Quinones capsaicin and resiniferatoxin
blocked activation of nuclear transcription factor NF-.kappa.B,
which is required for viral replication, immune regulation and
induction of various inflammatory and growth-regulatory genes.
Singh et al. (1996) J. Immunol. 157:4412-20. Antiretroviral and
antiprotozoan naphthoquinones are described in U.S. Pat. Nos.
5,780,514 and 5,783,598. Anthraquinones are also useful as
laxatives. Ashraf et al. (1994) Aliment. Pharmacol. Ther. 8:329-36;
and Muller-Lissner (1993) Pharmacol. 47 (Suppl. 1): 138-45.
[0008] A subset of quinones designated lapachones has been shown to
have activity against neoplastic cells, as described in U.S. Pat.
Nos. 5,969,163, 5,824,700, and 5,763,625. Antiviral activity (in
combination with xanthine) or reverse transcriptase inhibitory
activity for .beta.-lapachone is suggested in U.S. Pat. Nos.
5,641,773 and 4,898,870, while antifungal and trypanosidal activity
of .beta.-lapachone is suggested in U.S. Pat. Nos. 5,985,331 and
5,912,241.
[0009] Quinones can be administered alone or in conjunction with
other agents, such as 1,2-dithiole-3-thione. Begleiter et al.
(1997). Hydroxyquinone can be used in conjunction with glycol or
glyceryl esters of retinoic acid to treat skin disorders. WO
9702030. Combinational chemotherapy of carboquone, a benzoquinine
derivative, and cis-Platinum, diminishes the side effects of the
former. Saito (1988) Gan To Kagaku Ryoho 15:549-54.
[0010] Quinones also have various additional uses. A few quinones
are used as laxatives and worming agents, and others are used a
pigments in cosmetics, histology and aquarrell paints. Quinones
include 2,5-cyclohexadiene-1,4-dione, which is useful as an
oxidizing agent; in photography (U.S. Pat. No. 5,080,998); in
manufacturing dyes and hydroquinone; in tanning hides; in
strengthening animal fibers; and as a reagent.
[0011] In rapidly dividing cells such as tumor cells, cytotoxicity
due to quinone administration has been attributed to DNA
modification. However the molecular basis for the initiation of
quinone cytotoxicity in resting or non-dividing cells has been
attributed to the alkylation of essential protein thiol or amine
groups and/or the oxidation of essential protein thiols by
activated oxygen species and/or GSSG, glutathione disulfide.
Oxidative stress arises when the quinone is reduced by reductases
to a semiquinone radical which reduces oxygen to superoxide
radicals and reforms the quinone. This futile redox cycling and
oxygen activation forms cytotoxic levels of hydrogen peroxide and
GSSG is retained by the cell and causes cytotoxic mixed protein
disulfide formation. O'Brien (1991) Chem. Biol. Interact.
80:1-41.
[0012] Conjugation of quinones and glutathione (GSH) are sometimes
associated with the process of detoxification. Jeong et al. (1996)
Mol. Pharmacol. 50:592-8. For example, certain o-quinones
contribute to the neurodegenerative processes underlying
Parkinson's disease and schizophrenia. Glutathione transferase
(GST) M2-2, which conjugates glutathione and o-quinones, prevents
these processes. Baez et al. (1997) Biochem. J. 324:25-8. However,
in many cases, conjugation with GSH actually leads to quinone
bioactivation and toxicity. For example, the nephrotoxicity of
hydroquinone and bromobenzene is mediated via quinone-glutathione
conjugates. Jeong et al. (1996) Mol. Pharmacol. 50:592-8. The
formation of GSH conjugates is also involved in the bioactivation
of vicinal dihalopropane 1,2-dibromo-3-chloropropane. Hinson et al.
(1995) Can. J. Physiol. Pharm. 73:1407-13. Additional examples of
GSH conjugation potentiating the toxicity of quinones are described
in Fowler et al. (1991) Hum. Exp. Toxicol. 10:451-9; Mertens et al.
(1991) Toxicol. Appl. Pharmacol. 110:45-60; Puckett-Vaughn et al.
(1993) Life Sci. 52:1239-47; Dekant (1993) Toxicol. Lett.
67:151-160; Monks et al. (1994) Chem. Res. Toxicol. 7:495-502;
Monks (1995) Drug Metab. Rev. 27:93-106; and Eyer (1994) Environ.
Health Persp. 102 (Suppl. 6):123-32.
[0013] Because of the wide variety of biological processes in which
quinones play a critical role, it would be advantageous to develop
novel quinones for various uses, including disease treatment.
[0014] All references cited herein are hereby incorporated by
reference in their entirety.
SUMMARY OF THE INVENTION
[0015] The invention provides novel quinone compounds and methods
for use of the quinone compounds in treating diseases.
[0016] In one embodiment, the invention comprises compounds of the
formula 1
[0017] wherein A is selected from the group consisting of --O-- and
--CH.sub.2--; wherein M.sub.1 is selected from the group consisting
of a single bond and C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
branched alkyl, C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8
cycloaryl; wherein B is selected from the group consisting of
--CH.sub.2--, --O--, --C(.dbd.O)--O--; --O--C(.dbd.O)--, and
--N(R.sub.1)--; wherein R.sub.1 is selected from the group
consisting of --H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched
alkyl, C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8 cycloaryl;
wherein M.sub.2 is selected from the group consisting of a single
bond and C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched alkyl,
C.sub.3-C.sub.8 cycloalkyl, and C.sub.3-C.sub.8 cycloaryl; wherein
D is selected from the group consisting of --H, --OH,
--N(R.sub.7)(R.sub.8), pentoses, hexoses, 2
[0018] wherein R.sub.4 is selected from the group consisting of
--H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched alkyl,
C.sub.3-C.sub.8 cyclalkyl, C.sub.3-C.sub.8 cycloaryl,
--N(R.sub.9)(R.sub.10), and --CN; and wherein R.sub.7, R.sub.8,
R.sub.9 and R.sub.10 are independently selected from the group
consisting of --H, C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 branched
alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 cycloaryl, and
3
[0019] The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0020] In another embodiment, the invention comprises compounds of
the formula 4
[0021] wherein x is an integer between 1 and 2; and each K is
independently selected from the group consisting of H,
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkanol, C.sub.1-C.sub.8 alkoxy, 5
[0022] and where zero or two, but no more than two, vicinal K's in
the molecule represent single electrons which form a pi bond, thus
forming a double bond together with the existing sigma bond between
the two adjacent carbons bearing the two vicinal K's.
[0023] The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0024] In another embodiment, the invention comprises compounds of
the formula 6
[0025] wherein R is selected from the group consisting Of
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 cycloalkyl, C.sub.3-C.sub.8
cycloaryl, C.sub.1-C.sub.8 branched alkyl, and C.sub.1-C.sub.8
alkanol. The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0026] In another embodiment, the invention comprises compounds of
the formula 7
[0027] wherein Y is selected from the group consisting of --H, --F,
--Br, --Cl, and --I; and wherein G.sub.1 and G.sub.2 are
independently selected from the group consisting of H,
C.sub.1-C.sub.8 alkyl, 8
[0028] and --C(.dbd.O)--CH.sub.nX.sub.3-n, where n is an integer
from 0 to 3 and X is selected from the group consisting of F, Cl,
Br, and I. The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0029] In another embodiment, the invention comprises compounds of
the formula 9
[0030] wherein M is selected from the group consisting of
--O--,--C(.dbd.O)--O--, --O--(C.dbd.O)----C(.dbd.O)--N--, and
--N--(C.dbd.O)--. The invention also comprises the above compounds
in combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0031] In another embodiment, the invention comprises compounds of
the formula 10
[0032] wherein x is an integer between 1 and 2; each B is
independently selected from the group consisting of H,
C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8
cycloaryl, C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloalkyl, and
C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloaryl; and each K is
independently selected from the group consisting of H, OH,
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkanol, C.sub.1-C.sub.8 alkoxy, and where zero or two, but no more
than two, vicinal K's in the molecule represent single electrons
which form a pi bond, thus forming a double bond together with the
existing sigma bond between the two adjacent carbons bearing the
two vicinal K's. The invention also comprises the above compounds
in combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0033] In another embodiment, the invention comprises compounds of
the formula 11
[0034] wherein each B is independently selected from the group
consisting of H, C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 cycloaryl, C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8
cycloalkyl, and C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8 cycloaryl;
and wherein R is selected from the group consisting of
C.sub.1-C.sub.8 alkyl and C.sub.1-C.sub.8 alkanol. The invention
also comprises the above compounds in combination with a
pharmaceutically acceptable carrier. The invention also comprises
use of the above compounds to treat an indication characterized by
the proliferation of disease cells in an individual, comprising
administering to the individual a therapeutic amount of one or more
of the above compounds, optionally together with another
therapeutically effective compound or compounds.
[0035] In another embodiment, the invention comprises compounds of
the formula 12
[0036] where M.sub.5 is C.sub.1-C.sub.8 alkyl, y is an integer from
1 to 6, and L is selected from the group consisting of --O--K.sub.1
or --N(K.sub.1K.sub.2); where K.sub.1 and K.sub.2 are independently
selected from the group consisting of H, C.sub.1-C.sub.8 alkyl,
C.sub.1-C.sub.8 alkyl-COOH, C.sub.1-C.sub.8
alkyl-COO-C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8
alkyl-N(G.sub.1G.sub.2), and C.sub.1-C.sub.8
alkyl-N(G.sub.3)-C.sub.1-C.sub.8 alkyl-N(G.sub.4G.sub.5); and
wherein each of G.sub.1, G.sub.2, G.sub.3, G.sub.4, and G.sub.5 is
independently selected from the group consisting of H and
C.sub.1-C.sub.8 alkyl. The invention also comprises the above
compounds in combination with a pharmaceutically acceptable
carrier. The invention also comprises use of the above compounds to
treat an indication characterized by the proliferation of disease
cells in an individual, comprising administering to the individual
a therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0037] In another embodiment, the invention comprises compounds of
the formula 13
[0038] where z is an integer between one and ten; G.sub.10 is
selected from the group consisting of C.sub.1-C.sub.8 alkyl; each M
is independently selected from the group consisting of
C.sub.1-C.sub.8 alkyl; each V is selected from the group consisting
of --C(.dbd.O)--N-- and --N--(C.dbd.O)--; and T is selected from
the group consisting of --COOM.sub.8 and --CONM.sub.9M.sub.10,
where each of M.sub.8, M.sub.9 and M.sub.10 are independently
selected from the group consisting of H and C.sub.1-C.sub.8 alkyl.
The invention also comprises the above compounds in combination
with a pharmaceutically acceptable carrier. The invention also
comprises use of the above compounds to treat an indication
characterized by the proliferation of disease cells in an
individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0039] In another embodiment, the invention comprises compounds of
the formula 14
[0040] where M.sub.12 is selected from the group consisting of
C.sub.1-C.sub.8 alkyl.
[0041] In another embodiment, the invention comprises compounds of
the formula 15
[0042] where M.sub.14 and M.sub.15 are independently selected from
the group consisting of C.sub.1-C.sub.8 alkyl. The invention also
comprises the above compounds in combination with a
pharmaceutically acceptable carrier. The invention also comprises
use of the above compounds to treat an indication characterized by
the proliferation of disease cells in an individual, comprising
administering to the individual a therapeutic amount of one or more
of the above compounds, optionally together with another
therapeutically effective compound or compounds.
[0043] In another embodiment, the invention comprises compounds of
the formula 16
[0044] where J is selected from the group consisting of
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 cycloalkyl, C.sub.3-C.sub.8
cycloaryl, and C.sub.1-C.sub.8 branched alkyl. The invention also
comprises the above compounds in combination with a
pharmaceutically acceptable carrier. The invention also comprises
use of the above compounds to treat an indication characterized by
the proliferation of disease cells in an individual, comprising
administering to the individual a therapeutic amount of one or more
of the above compounds, optionally together with another
therapeutically effective compound or compounds.
[0045] In another embodiment, the invention comprises compounds of
the formula 17
[0046] where R.sub.s is the side chain of a naturally-occuring
amino acid. The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0047] In another embodiment, the invention embraces compounds of
the formula S-L-QUIN, where S represents a single amino acid or a
peptide of at least two amino acids, L is a linking group
containing at least one carbon, oxygen, or nitrogen atom attached
covalently to both S and QUIN, or a nonentity; and QUIN is a
quinone, quinone derivative, hydroquinone, or hydroquinone
derivative. In a preferred embodiment, S or a portion thereof, S-L
or a portion thereof, or both S or a portion thereof and then L or
a portion thereof, are cleaved from the quinone-containing
remainder of the molecule by an enzyme, such as the enzyme prostate
specific antigen. In another preferred embodiment, L is --O--,
--NH--, or --NH-(C.sub.1-C.sub.8 alkyl)-O--. In yet another
preferred embodiment, L is
--NH-(C.sub.6H.sub.4)CH.sub.2--O--(C.dbd.O)--NH-(C.sub.1-C.sub.8
alkyl)-O--. A preferred peptide for the S moiety is
X-Ser-Lys-Leu-Gln, where X is a protecting group or an
amino-terminal capping group, and the side chains of Ser, Lys, and
Gln may optionally be protected with protecting groups. The
invention also comprises the above compounds in combination with a
pharmaceutically acceptable carrier. The invention also comprises
use of the above compounds to treat an indication characterized by
the proliferation of disease cells in an individual, comprising
administering to the individual a therapeutic amount of one or more
of the above compounds, optionally together with another
therapeutically effective compound or compounds.
[0048] The invention also embraces compounds of the formula
S-L-QUIN, wherein S represents a single amino acid or a peptide of
at least two amino acids; L is a linking group containing at least
one carbon, oxygen, or nitrogen atom attached covalently to both S
and QUIN, or a nonentity; and QUIN is selected from the group
consisting of the any of the above-mentioned quinone compounds
which have a reactive group capable of being conjugated with an
amino or carboxyl group, as well as the compounds 18
[0049] The invention also comprises the above compounds in
combination with a pharmaceutically acceptable carrier. The
invention also comprises use of the above compounds to treat an
indication characterized by the proliferation of disease cells in
an individual, comprising administering to the individual a
therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0050] The invention also encompasses a method for making the
above-described compounds of formula S-L-QUIN, comprising the steps
of a) covalently linking L to S, and b) covalently linking L to
QUIN. Steps a) and b) can be performed in either order or
simultaneously.
[0051] The invention also encompasses compounds of the formula
19
[0052] where x is an integer between 1 and 2; W is selected from
--H, --OH, --O-C.sub.1-C.sub.8 alkyl, --O-C.sub.1-C.sub.8
alkyl-NH.sub.2, and --O-C.sub.1-C.sub.8 alkyl-NH-S, wherein S is a
single amino acid or a peptide of two or more amino acids; and each
K is independently selected from the group consisting of H, OH,
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8
alkanol, C.sub.1-C.sub.8 alkoxy, and where zero or two, but no more
than two, vicinal K's in the molecule represent single electrons
which form a pi bond, thus forming a double bond together with the
existing sigma bond between the two adjacent carbons bearing the
two vicinal K's. In a preferred embodiment, W is
--O-C.sub.1-C.sub.8 alkyl-NH-S, S is a single amino acid or a
peptide of two or more amino acids; and the group -NH- forms an
amide bond with the alpha-carboxy group of S when S is a single
amino acid. Alternatively, the group --NH-- forms an amide bond
with the C-terminal alpha-carboxy group of S when S is a peptide of
two or more amino acids. A preferred subset of the above compounds
are the compounds of the formula 20
[0053] where W is selected from --H, --OH, --O-C.sub.1-C.sub.8
alkyl, --O-C.sub.1-C.sub.8 alkyl-NH.sub.2, and --O-C.sub.1-C.sub.8
alkyl-NH-S, and wherein S is a single amino acid or a peptide of
two or more amino acids. In a preferred embodiment, W is
--O-C.sub.1-C.sub.8 alkyl-NH-S, S is a single amino acid or a
peptide of two or more amino acids, and the group --NH-- forms an
amide bond with the alpha-carboxy group of S when S is a single
amino acid. Alternatively, the group --NH-- forms an amide bond
with the C-terminal alpha-carboxy group of S when S is a peptide of
two or more amino acids. The invention also comprises the above
compounds in combination with a pharmaceutically acceptable
carrier. The invention also comprises use of the above compounds to
treat an indication characterized by the proliferation of disease
cells in an individual, comprising administering to the individual
a therapeutic amount of one or more of the above compounds,
optionally together with another therapeutically effective compound
or compounds.
[0054] The invention also includes all salts, stereoisomers, and
tautomers of the foregoing compounds, unless explicitly indicated
otherwise.
[0055] In another embodiment, the invention comprises any one or
more of the foregoing compounds, optionally in combination with
another therapeutic compound, combined with a pharmaceutically
acceptable excipient or carrier.
[0056] The invention also provides methods of treating an
indication comprising the step of administering to the individual
an effective amount of a composition comprising a novel quinone. In
one embodiment, the invention comprises a method of treating an
indication characterized by the proliferation of disease cells in
an individual comprising administering to the individual a
therapeutic amount of any of the foregoing compounds. In one
method, the indication is cancer. In various embodiments, the
cancer affects cells of the bladder, blood, brain, breast, colon,
digestive tract, lung, ovaries, pancreas, prostate gland, or skin.
In other embodiments, the indication can also include, but is not
limited to, Alzheimer's disease, epilepsy, multiple sclerosis,
problems associated with tissue grafts and organ transplants,
psoriasis, restenosis, stomach ulcers, or tissue overgrowth after
surgery. In other embodiments, the indication is an infection or
infestation of parasites, bacteria, fungi or insects.
BRIEF DESCRIPTION OF THE DRAWINGS
[0057] FIG. 1 depicts Scheme 1, illustrating the synthetic
preparation of certain compounds of the invention.
[0058] FIG. 2 depicts Scheme 2, illustrating the synthetic
preparation of additional compounds of the invention.
[0059] FIG. 3 depicts Scheme 3, illustrating the synthetic
preparation of additional compounds of the invention.
[0060] FIG. 4 depicts Scheme 4, illustrating the synthetic
preparation of additional compounds of the invention.
[0061] FIG. 5 depicts Scheme 5, illustrating the synthetic
preparation of additional compounds of the invention.
[0062] FIG. 6 depicts Scheme 6, illustrating the synthetic
preparation of additional compounds of the invention.
[0063] FIG. 7 depicts Scheme 7, illustrating the synthetic
preparation of additional compounds of the invention.
[0064] FIG. 8 depicts Scheme 8, illustrating the synthetic
preparation of additional compounds of the invention.
[0065] FIG. 9 depicts Scheme 9, illustrating the synthetic
preparation of additional compounds of the invention.
[0066] FIG. 10 depicts Scheme 10, illustrating the synthetic
preparation of additional compounds of the invention.
[0067] FIG. 11 depicts Scheme 11, illustrating the synthetic
preparation of additional compounds of the invention.
[0068] FIG. 12 depicts Scheme 12, illustrating the synthetic
preparation of additional compounds of the invention.
[0069] FIG. 13 depicts Scheme 13, illustrating synthetic
preparation of peptides conjugated to certain quinone
compounds.
[0070] FIG. 14 depicts Scheme 14, illustrating additional synthetic
preparation of peptides conjugated to certain quinone
compounds.
[0071] FIG. 15 depicts additional synthetic preparation of peptides
conjugated to certain quinone compounds, including attachment of a
linker group between the quinone and the peptide.
[0072] FIG. 16 depicts the attachment of doxorubicin to a peptide,
including attachment of a linker group between doxorubicin and the
peptide.
[0073] FIG. 17 depicts additional synthetic preparation of peptides
conjugated to certain quinone compounds, including attachment of a
linker group between the quinone and the peptide.
MODES FOR CARRYING OUT THE INVENTION
[0074] The present invention encompasses novel quinones and methods
of their use. Such methods include treating indications in an
individual comprising the step of administering to the individual
an effective amount of a novel quinone. The indications include
cancer. In various embodiments, the cancer affects cells of the
bladder, blood, brain, breast, colon, digestive tract, lung,
ovaries, pancreas, prostate gland, or skin. In other embodiments,
the indication can also include, but is not limited to, Alzheimer's
disease, epilepsy, multiple sclerosis, problems associated with
tissue grafts and organ transplants, psoriasis, restenosis, stomach
ulcers, or tissue overgrowth after surgery. In other embodiments,
the indication is an infection or infestation of parasites,
bacteria, fungi or insects. The invention also includes industrial
uses of these novel quinones, such as uses as pigments or dyes, as
laxatives and worming agents, in cosmetics, histology and
paint-making, in photography, in tanning hides, in strengthening
animal fibers, and as a reagent.
[0075] Definitions
[0076] By a "quinone" is meant any of a group of aromatic dioxo
compounds derived from benzene or multiple-ring hydrocarbons such
as naphthalene, anthracene, etc. They are classified as
benzoquinones, naphthoquinones, anthraquinones, etc., on the basis
of the ring system. The C.dbd.O groups are generally ortho orpara,
and form a conjugated system with at least two C.dbd.C double
bonds; hence the compounds are colored, yellow, orange or red. This
type of chromophore is found in many natural and synthetic
pigments. Exemplary quinones include 2,5-cyclohexadiene-1,4-dione,
which is useful as an oxidizing agent, in photography, in
manufacturing dyes and hydroquinone, in tanning hides, in
strengthening animal fibers, and as a reagent; and various
1,2-naphthoquinones, which have medicinal uses. Frydman et al.
(1997) Cancer Res. 57:620-627. By "hydroquinone" is meant the
reduced form of any quinone; for example, the reduced form of
1,4-benzoquinone is 1,4-dihydroxybenzene (p-dihydroxybenzene).
[0077] An "indication" includes any symptom or the like which
points out a suitable remedy or treatment or which shows the
presence of a disease. As used herein, an "indication" also
includes a "disease" itself, where a disease is a condition of an
organ, part, structure or system of the body in which there is
incorrect function resulting from the effect(s) of heredity,
infection, diet and/or environment. The indication can be
characterized by proliferation of diseased cells, such as cancer.
By "cancer" is meant the abnormal presence of cells which exhibit
relatively autonomous growth, so that they exhibit an aberrant
growth phenotype characterized by a significant loss of cell
proliferation control. Cancerous cells can be benign or malignant.
In various embodiments, the cancer affects cells of the bladder,
blood, brain, breast, colon, digestive tract, lung, ovaries,
pancreas, prostate gland, or skin. In other embodiments, the
indication can also include, but is not limited to, Alzheimer's
disease, epilepsy, multiple sclerosis, problems associated with
tissue grafts and organ transplants, psoriasis, restenosis, stomach
ulcers, or tissue overgrowth after surgery. In other embodiments,
the indication is an infection or infestation of parasites,
bacteria, fungi or insects.
[0078] By "DNA toposiomerase II" is meant is the scaffold protein
capable of cleaving double-stranded DNA, passing an uncut portion
of the DNA between the cut ends, and resealing the cut. DNA
topoisomerase II ("topo II") is critical in DNA replication,
because it can unknot tangles of DNA that would otherwise form as
the long parental strands unwind and daughter strands are
synthesized. During cleavage by topo II, the free 5' phosphates on
the DNA strands become covalently linked to tyrosine side chains of
the enzyme. Staining of metaphase chromosomes with fluorescent
antibodies raised against highly purified topo II demonstrates that
this enzyme is associated with the chromosome scaffold. Even in
interphase chromosomes, which are not as condensed as metaphase
chromosomes, the DNA remains associated with topo II and hence with
the chromosome scaffold. During interphase, proteins, including
topo II, are bound to fixed sites in mammalian DNA that are 30-90
kb apart. The binding sites for topo II are called
scaffold-associated regions (SARs), which occur between but not
within transcription units. DNA topoisomerase II is reviewed and
discussed in, for example, Austin et al. (1998) Bioessays
20:215-26; Larsen et al. (1996) Prog. Cell Cycle Res. 2:229-39;
Chaly et al. (1996) Chromosome Res. 4:457-66; Kimura et al. (1994)
J. Biol. Chem. 269:1173-6; and Roca et al. (1993) J. Biol. Chem.
268:14250-5.
[0079] An "individual" is a vertebrate, preferably a mammal, more
preferably a human. Mammals include, but are not limited to, farm
animals, sport animals, rodents, primates, and pets.
[0080] An "effective amount" or "therapeutic amount" is an amount
sufficient to effect beneficial or desired clinical results. An
effective amount can be administered in one or more
administrations. For purposes of this invention, an effective
amount of a quinone is an amount that is sufficient to palliate,
ameliorate, stabilize, reverse, slow or delay the progression of
the disease state. A therapeutic amount of a quinone of the present
invention is an amount sufficient to inhibit proliferation of
diseased cells. A quinone is considered to be an effective agent if
it is effective against at least one disease or in at least one
application, even if it is not effective against another disease or
in another application.
[0081] As used herein, "treatment" is an approach for obtaining
beneficial or desired clinical results. For purposes of this
invention, beneficial or desired clinical results include, but are
not limited to, alleviation of symptoms, diminishment of extent of
disease, stabilization (i.e., not worsening) of state of disease,
prevention of spread (i.e., metastasis) of disease, delay or
slowing of disease progression, amelioration or palliation of the
disease state, improvement in quality of enjoyment of life, and
remission (whether partial or total), whether detectable or
undetectable. "Treatment" can also mean prolonging survival as
compared to expected survival if not receiving treatment.
"Palliating" a disease means that the extent and/or undesirable
clinical manifestations of a disease state are lessened and/or time
course of the progression is slowed or lengthened, as compared to
not administering quinones of the present invention.
[0082] The invention includes all salts of the compounds described
herein. Particularly preferred are pharmaceutically acceptable
salts. Pharmaceutically acceptable salts are those salts which
retain the biological activity of the free acids or bases and which
are not biologically or otherwise undesirable. The desired salt may
be prepared by methods known to those of skill in the art by
treating an amine-containing quinone with an acid, or by treating
an acid-containing quinone with a base. Examples of inorganic acids
include, but are not limited to, hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of
organic acids include, but are not limited to, formic acid, acetic
acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,
sulfonic acids, and salicylic acid. Examples of bases include, but
are not limited to, sodium hydroxide and potassium hydroxide (which
yield sodium and potassium salts, respectively), triethylamine, and
t-butylamine.
[0083] The invention also includes all stereoisomers of the
compounds, including diastereomers and enantiomers, as well as
mixtures of stereoisomers, including, but not limited to, racemic
mixtures. Unless stereochemistry is explicitly indicated in a
structure, the structure is intended to embrace all possible
stereoisomers of the compound depicted.
[0084] The term "alkyl" refers to saturated aliphatic groups
including straight-chain, branched-chain, cyclic groups, and
combinations thereof, having the number of carbon atoms specified,
or if no number is specified, having up to 12 carbon atoms.
Examples of alkyl groups include, but are not limited to, groups
such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, t-butyl, n-pentyl, neopentyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, and adamantyl. Cyclic groups can consist
of one ring, including, but not limited to, groups such as
cycloheptyl, or multiple fused rings, including, but not limited
to, groups such as adamantyl or norbomyl. Alkyl groups may be
unsubstituted, or may be substituted with one or more substituents
including, but not limited to, groups such as halogen (fluoro,
chloro, bromo, and iodo), alkoxy, acyloxy, amino, hydroxyl,
mercapto, carboxy, benzyloxy, phenyl, benzyl, cyano, nitro,
thioalkoxy, carboxaldehyde, carboalkoxy and carboxamide, or a
functionality that can be suitably blocked, if necessary for
purposes of the invention, with a protecting group. Examples of
substituted alkyl groups include, but are not limited to,
--CF.sub.3, --CF.sub.2--CF.sub.3, and other perfluoro and perhalo
groups.
[0085] The term "alkenyl" refers to unsaturated aliphatic groups
including straight-chain, branched-chain, cyclic groups, and
combinations thereof, having the number of carbon atoms specified,
or if no number is specified, having up to 12 carbon atoms, which
contain at least one double bond (--C.dbd.C--). Examples of alkenyl
groups include, but are not limited to,
--CH.sub.2--CH.dbd.CH--CH.sub.3 and
--CH.sub.2--CH.sub.2-cyclohexenyl, there the ethyl group can be
attached to the cyclohexenyl moiety at any available carbon
valence. The term "alkynyl" refers to unsaturated aliphatic groups
including straight-chain, branched-chain, cyclic groups, and
combinations thereof, having the number of carbon atoms specified,
or if no number is specified, having up to 12 carbon atoms, which
contain at least one triple bond (--C.ident.C--). "Hydrocarbon
chain" or "hydrocarbyl" refers to any combination of
straight-chain, branched-chain, or cyclic alkyl, alkenyl, or
alkynyl groups, and any combination thereof. "Substituted alkenyl,"
"substituted alkynyl," and "substituted hydrocarbon chain" or
"substituted hydrocarbyl" refer to the respective group substituted
with one or more substituents, including, but not limited to,
groups such as halogen, alkoxy, acyloxy, amino, hydroxyl, mercapto,
carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy,
carboxaldehyde, carboalkoxy and carboxamide, or a functionality
that can be suitably blocked, if necessary for purposes of the
invention, with a protecting group.
[0086] "Aryl" or "Ar" refers to an aromatic carbocyclic group
having a single ring (including, but not limited to, groups such as
phenyl) or multiple condensed rings (including, but not limited to,
groups such as naphthyl or anthryl), and includes both
unsubstituted and substituted aryl groups. Substituted aryls can be
substituted with one or more substituents, including, but not
limited to, groups such as alkyl, alkenyl, alkynyl, hydrocarbon
chains, halogen, alkoxy, acyloxy, amino, hydroxyl, mercapto,
carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy,
carboxaldehyde, carboalkoxy and carboxamide, or a functionality
that can be suitably blocked, if necessary for purposes of the
invention, with a protecting group.
[0087] "Heteroalkyl," "heteroalkenyl," and "heteroalkynyl" refer to
alkyl, alkenyl, and alkynyl groups, respectively, that contain the
number of carbon atoms specified (or if no number is specified,
having up to 12 carbon atoms) which contain one or more heteroatoms
as part of the main, branched, or cyclic chains in the group.
Heteroatoms include, but are not limited to, N, S, O, and P; N and
O are preferred. Heteroalkyl, heteroalkenyl, and heteroalkynyl
groups may be attached to the remainder of the molecule either at a
heteroatom (if a valence is available) or at a carbon atom.
Examples of heteroalkyl groups include, but are not limited to,
groups such as --O--CH.sub.3, --CH.sub.2--O--CH.sub.3,
--CH.sub.2--CH.sub.2--O--CH.sub.3,
--S--CH.sub.2--CH.sub.2--CH.sub.3,
--CH.sub.2--CH(CH.sub.3)--S--CH.sub.3,
--CH.sub.2--CH.sub.2--NH--CH.sub.2-
--CH.sub.2--,1-ethyl-6-propylpiperidino, 2-ethylthiophenyl, and
morpholino. Examples of heteroalkenyl groups include, but are not
limited to, groups such as
--CH.dbd.CH--NH--CH(CH.sub.3)--CH.sub.2--. "Heteroaryl" or "HetAr"
refers to an aromatic carbocyclic group having a single ring
(including, but not limited to, examples such as pyridyl,
thiophene, or furyl) or multiple condensed rings (including, but
not limited to, examples such as imidazolyl, indolizinyl or
benzothienyl) and having at least one hetero atom, including, but
not limited to, heteroatoms such as N, O, P, or S, within the ring.
Heteroalkyl, heteroalkenyl, heteroalkynyl and heteroaryl groups can
be unsubstituted or substituted with one or more substituents,
including, but not limited to, groups such as alkyl, alkenyl,
alkynyl, benzyl, hydrocarbon chains, halogen, alkoxy, acyloxy,
amino, hydroxyl, mercapto, carboxy, benzyloxy, phenyl, benzyl,
cyano, nitro, thioalkoxy, carboxaldehyde, carboalkoxy and
carboxamide, or a functionality that can be suitably blocked, if
necessary for purposes of the invention, with a protecting group.
Examples of such substituted heteroalkyl groups include, but are
not limited to, piperazine, substituted at a nitrogen or carbon by
a phenyl or benzyl group, and attached to the remainder of the
molecule by any available valence on a carbon or nitrogen,
--NH--SO.sub.2-phenyl, --NH--(C.dbd.O)O-alkyl,
--NH--(C.dbd.O)O-alkyl-aryl, and --NH--(C.dbd.O)-alkyl. The
heteroatom(s) as well as the carbon atoms of the group can be
substituted. The heteroatom(s) can also be in oxidized form. Unless
otherwise specified, heteroalkyl, heteroalkenyl, heteroalkynyl, and
heteroaryl groups have between one and five heteroatoms and between
one and twenty carbon atoms.
[0088] The term "alkylaryl" refers to an alkyl group having the
number of carbon atoms designated, appended to one, two, or three
aryl groups.
[0089] The term "alkoxy" as used herein refers to an alkyl,
alkenyl, alkynyl, or hydrocarbon chain linked to an oxygen atom and
having the number of carbon atoms specified, or if no number is
specified, having up to 12 carbon atoms. Examples of alkoxy groups
include, but are not limited to, groups such as methoxy, ethoxy,
and t-butoxy.
[0090] The terms "halo" and "halogen" as used herein refer to Cl,
Br, F or I substituents.
[0091] "Protecting group" refers to a chemical group that exhibits
the following characteristics: 1) reacts selectively with the
desired functionality in good yield to give a protected substrate
that is stable to the projected reactions for which protection is
desired; 2) is selectively removable from the protected substrate
to yield the desired functionality; and 3) is removable in good
yield by reagents compatible with the other functional group(s)
present or generated in such projected reactions. Examples of
suitable protecting groups can be found in Greene et al. (1991)
Protective Groups in Organic Synthesis, 2nd Ed. (John Wiley &
Sons, Inc., New York). Preferred amino protecting groups include,
but are not limited to, benzyloxycarbonyl (CBz), t-butyloxycarbonyl
(Boc), t-butyldimethylsilyl (TBDIMS), 9-fluorenylmethyloxycarbonyl
(Fmoc), or suitable photolabile protecting groups such as
6-nitroveratryloxy carbonyl (Nvoc), nitropiperonyl,
pyrenylmethoxycarbonyl, nitrobenzyl, dimethyl dimethoxybenzil,
5-bromo-7-nitroindolinyl, and the like. Preferred hydroxyl
protecting groups include Fmoc, benzyl, t-butyl, TBDIMS,
photolabile protecting groups (such as nitroveratryl oxymethyl
ether (Nvom)), Mom (methoxy methyl ether), and Mem (methoxy ethoxy
methyl ether). Particularly preferred protecting groups include
NPEOC (4-nitrophenethyloxycarbonyl) and NPEOM
(4-nitrophenethyloxymethyloxycarb- onyl). Amino acid protecting
groups are well-known in the field of peptide synthesis, and
include groups such as those disclosed in Stewart, J. M. and Young,
J. D., Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical
Company: Rockford, Ill., 1984; Atherton, E. and Sheppard, R. C.,
Solid Phase Peptide Synthesis: A Practical Approach, IRL Press: New
York, 1989; Jones, J., The Chemical Synthesis of Peptides
(International Series of Monographs on Chemistry, No. 23),
Clarendon Press: Oxford, 1991; Bodanszky, M., The Practice of
Peptide Synthesis, Springer-Verlag: New York, 1984; Bodanszky, M.,
Peptide Chemistry: A Practical Textbook, 2nd Ed., Springer-Verlag:
New York, 1993; Bodanszky, M., Principles of Peptide Synthesis, 2nd
Ed., Springer-Verlag: New York, 1993; Synthetic Peptides: A User's
Guide (Grant, G. A., Ed.), W. H. Freeman: New York, 1992; and
Barany, G. and Merrifield, R. B., "Solid Phase Peptide Synthesis",
Chapter 1 (pp. 1-284) of The Peptides, Vol. 2, Academic Press: New
York, 1979. Additional publications include the 97/98 Novabiochem
Catalog and Peptide Synthesis Handbook and the Novabiochem
Combinatorial Chemistry Catalog (Calbiochem-Novabiochem, San Diego,
Calif.), and the user's manuals and synthesis bulletins for
Perkin-Elmer Applied Biosystems (Foster City, Calif.) peptide
synthesizers. Purification methods appropriate for peptides are
discussed in the references cited above, and in High-Performance
Liquid Chromatography of Peptides and Proteins: Separation,
Analysis and Conformation (Mant, C. T. and Hodges, R. S., Eds.),
CRC Press: Boca Raton, Fla., 1991. Materials for use in peptide
synthesis, such as protected amino acids, synthesis reagents,
solvents, and resin supports, are available commercially from a
number of suppliers, including Calbiochem-Novabiochem, San Diego,
Calif.; Advanced Chemtech, Louisville, Ky.; Bachem Bioscience,
Inc., King of Prussia, Pa.; Sigma Chemical Company, St. Louis, Mo.;
Richelieu Biotechnologies, Inc., Montreal, Quebec, Canada;
Peninsula Laboratories, Inc., Belmont, Calif.; Perkin-Elmer Applied
Biosystems, Inc., Foster City, Calif.; and Peptides International,
Louisville, Ky.
[0092] An "amino-capping group" or "amino-terminal capping group"
or "N-terminal capping group" is a group that covalently links to
an amino group. Examples of amino-capping groups include, but are
not limited to, 4-morpholinocarbonyl, acetyl, and
trifluoroacetyl.
[0093] Novel quinones
[0094] The present invention encompasses novel quinones. While not
wishing to be bound by any particular theory explaining quinone
toxicity, the inventors suggest that the novel quinones can be
designed based on the suspected DNA topoisomerase II-poisoning
activity of quinones. Alternatively, quinone toxicity may be
related to the compound's potential to undergo redox cycling with
the formation of highly reactive oxygen species. O'Brien (1991)
Chem. Biol. Interactions 80:1-41. In the next step, the quinone is
tested in vitro for efficacy in inhibiting proliferation of
diseased cells (such as tumor cells). If it is efficable, the
quinone is then tested in animals, such as nude mice with tumor
xenografts. Simultaneously, toxicity of the compound should be
determined. If the quinone is found to efficable and safe, testing
can then proceed to human trials.
[0095] In Vitro Testing of Novel Quinones
[0096] Novel quinones of the present invention can be tested in
vitro by any means known in the art. The quinones can be tested,
for example, for toxicity against a chosen cell line, such as a
tumor cell line.
[0097] In Vivo Testing of Novel Quinones
[0098] Following a showing of efficacy of the novel quinones in
vitro, these compounds can be tested in vivo. Typical tests
include, but are not limited to, examinations of the effects of
compound administration on animals, such as nude mice with tumor
xenografts.
[0099] Methods of Administrating Quinones
[0100] The novel quinone compounds of the present invention can be
administered to an individual via any route known in the art,
including, but not limited to, those disclosed herein. Preferably
administration of the novel quinones is intravenous. Other methods
of administration include but are not limited to, oral,
intrarterial, intratumoral, intramuscular, subcutaneous,
intraperitoneal, gastrointestinal, and directly to a specific or
affected organ. The novel quinone compounds described herein are
administratable in the form of tablets, pills, powder mixtures,
capsules, injectables, solutions, suppositories, emulsions,
dispersions, food premixes, and in other suitable forms. Additional
methods of administration are known in the art. The pharmaceutical
dosage form which contains the compounds described herein is
conveniently admixed with a non-toxic pharmaceutical organic
carrier or a non-toxic pharmaceutical inorganic carrier. Typical
pharmaceutically-acceptable carriers include, for example,
mannitol, urea, dextrans, lactose, potato and maize starches,
magnesium stearate, talc, vegetable oils, polyalkylene glycols,
ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl
oleate, isopropyl myristate, benzyl benzoate, sodium carbonate,
gelatin, potassium carbonate, silicic acid, and other
conventionally employed acceptable carriers. The pharmaceutical
dosage form can also contain non-toxic auxiliary substances such as
emulsifying, preserving, or wetting agents, and the like. A
suitable carrier is one which does not cause an intolerable side
effect, but which allows the novel quinone compounds to retain its
pharmacological activity in the body. Formulations for parenteral
and nonparenteral drug delivery are known in the art and are set
forth in Remington's Pharmaceutical Sciences, 18th Edition, Mack
Publishing (1990). Solid forms, such as tablets, capsules and
powders, can be fabricated using conventional tableting and
capsule-filling machinery, which is well known in the art. Solid
dosage forms can contain any number of additional non-active
ingredients known to the art, including excipients, lubricants,
dessicants, binders, colorants, disintegrating agents, dry flow
modifiers, preservatives, and the like. Liquid forms for ingestion
can be formulated using known liquid carriers, including aqueous
and non-aqueous carriers, suspensions, oil-in-water and/or
water-in-oil emulsions, and the like. Liquid formulations can also
contain any number of additional non-active ingredients, including
colorants, fragrance, flavorings, viscosity modifiers,
preservatives, stabilizers, and the like. For parenteral
administration, novel quinone compounds can be administered as
injectable dosages of a solution or suspension of the compound in a
physiologically acceptable diluent or sterile liquid carrier such
as water or oil, with or without additional surfactants or
adjuvants. An illustrative list of carrier oils would include
animal and vegetable oils (peanut oil, soy bean oil),
petroleum-derived oils (mineral oil), and synthetic oils. In
general, for injectable unit doses, water, saline, aqueous dextrose
and related sugar solutions, and ethanol and glycol solutions such
as propylene glycol or polyethylene glycol are preferred liquid
carriers. The pharmaceutical unit dosage chosen is preferably
fabricated and administered to provide a final concentration of
drug at the point of contact with the cancer cell of from 1 .mu.M
to 10 mM. More preferred is a concentration of from 1 to 100 .mu.M.
As with all pharmaceuticals, the optimal effective concentration of
novel quinone compounds will need to be determined empirically and
will depend on the type and severity of the disease, route of
administration, disease progression and health and mass or body
area of the patient. Such determinations are within the skill of
one in the art.
[0101] The following examples are provided to illustrate, but not
limit, the invention.
EXAMPLES
Example 1
Synthetic Preparation of Quinone Compounds
[0102] Preparation of quinones of the invention is described below
and depicted in the Figures.
[0103] New chemistry was developed in order to construct drugs
where the 1,2-naphthoquinone moiety is bound to a DNA minor groove
binder unit or a DNA intercalator. While not wishing to limit the
invention to any particular theory of operation, it is believed
that the 1,2-naphthoquinone derivatives "poison" topoisomerase II
and transform this essential DNA replication enzyme into a
nuclease-type enzyme that cleaves DNA. It is postulated that this
modification of topoisomerase II by the 1,2-naphthoquinones is very
likely due to the alkylation of the thiol residues of the enzyme by
the quinones (Michael additions).
[0104] Scheme 1 outlines derivatization reactions leading to
1,2-naphthoquinone intermediates. The silver salt of
2-hydroxy-1,4-naphthoquinone was alkylated with the tert-butyl or
benzyl esters of 5-bromo-pentanoic acid to give either 1 or 2. The
benzyl ester 2 was transformed into the acid 3 by hydrogenolysis.
The silver salt was also alkylated with 6-bromohexanol to give 4,
or with 1,6-diiodohexane to give 5. The alcohol 4 treated with
triphosgene gives 6 (Scheme 2). The acid 3 can be derivatized by
reaction with 3-amino-1-methyl-5-methyloxyca- rbonylpyrrole (Baird
and Dervan (1996) J. Am. Chem. Soc. 118:6141) in the presence of
o-benzotriazol-1-yl-N,N,N ,N-tetramethyluronium hexafluorophosphate
(HBTU) and diisopropylethyl amine (DIEA) to give the amide 7. The
silver salt of 2-hydroxy-1,4-naphthoquinone reacted with pivalyl
chloride to give 8 (Scheme 2). Acid 3 was condensed with the
polypyrrole amide 9 (Baird and Dervan (1996) J. Am. Chem. Soc.
118:6141) after cleavage of the protecting t-butyl group with TFA.
The resulting product 10 is a molecule where the 1,2-naphthoquinone
moiety is covalently bound to a DNA minor groove binder (Scheme 3).
Alcohol 4 was condensed using the Mitsonobu reaction
(triphenylphosphine, diethyl acetylenedicarboxylate) with
4-hydroxy-benzonitrile to give 11. Iodide 5 was reacted with the
tetrabutyl ammonium salt of phenol to give 12.
[0105] The acid 3 was esterified with 3-dimethylaminophenol using
dicyclohexylcarbodiimide (DCC) and 4-dimethylamino pyridine (DMAP)
and gave 13. By reaction of 5 and the tetrabutylammonium salt of
Hoechst 33528 it was possible to obtain 14, where the quinone is
covalently bound to the DNA minor groove binder. By esterification
of 4 with 6-aminohexanoic acid (used as its BOC derivative and
deprotected with TFA) in the presence of DCC and DMAP, it was
possible to obtain 15 as its trifluoroacetate (Scheme 4). By
condensation of the acid 3 with the N-ethyl diamide 16, the
polyamide quinone 17 was prepared (Scheme 4).
[0106] A new class of 4-aminoalkyl substituted 1,2-naphthoquinones
was obtained following the outline depicted in Scheme 5. A
Vilsmeier reaction on 1,2-dimethoxynaphthalene gave the formyl
derivative 18. It was converted by reductive amination with
n-butylamine into 19. Treatment of 19 with acetyl chloride gave 20,
while treatment with trifluoroacetic anhydride gave 21 (Scheme 5).
Acylation of 19 with morpholino succinyl chloride gave 22. Cleavage
of the 1,2-dimethoxy groups of 19 with boron tribromide gave the
quinone 23 which was found to exist in the p-quinonemethine form.
Cleavage of the dimethoxy residues of 20 and 21 led to the expected
quinones 24 and 25. Cleavage of the methoxy residues of 22 gave the
quinone 26 (Scheme 5).
[0107] The 1,2-naphthoquinone residue was also covalently bound to
a porphyrin backbone, since porphyrins are known to concentrate in
cancer tissues. By reaction of the iodide 5 with the
tetrabutylammonium salt of meso-p-hydroxyphenylporphyrin, the
porphyrin quinone 27 was obtained (Scheme 6).
[0108] By esterification of 4,4',4",4'"-(21H,
23H-porphine-5,10,15,20-tetr- ayl)tetrakis(benzoic acid) with the
quinone alcohol 4 in the presence of EDCI (1,(3-dimethyl
aminopropyl)-3-ethylcarbodiimide) and DMAP it was possible to
prepare the quinone-porphyrin 28 (Scheme 7).
Synthesis of 1,2-naphthoguinones Bound to DNA Intercalators
[0109] It is known that 4-aminoacridine derivatives intercalate in
the DNA helix. Therefore syntheses of 1,2-naphthoquinone residues
bound to 4-aminoacridine derivatives were designed (Scheme 8). The
salt (6-hydroxyhexyl)triphenylphosphonium bromide was prepared by
the reaction of 6-bromohexanol with triphenylphosphine in refluxing
acetonitrile. Wittig reaction of
(6-hydroxyhexyl)triphenylphosphonium bromide with
4-acetamidobenzaldehyde produced alkene 29 as a mixture of E and Z
isomers. Reduction of the double bond (H.sub.2, Pd/C) and acidic
hydrolysis (2N HCl, MeOH) afforded 4-(7-hydroxyheptyl)-aniline 30.
Aniline 30 was reacted with 9-chloroacridine in MeOH in the
presence of triethylamine to give alcohol 31. Alcohol 31 was
converted to iodide 32 by reaction with methanesulfonyl chloride in
pyridine, followed by reaction with sodium iodide in acetone.
Reaction of iodide 32 with the silver salt of
2-hydroxy-1,4-naphthoquinone afforded quinone 33 as a mixture of
ortho- and para-quinone isomers. The ortho- and para-quinone
isomers could be separated and purified by column
chromatography.
[0110] A second approach to these types of compounds is shown in
Scheme 9. The isomer mixture 34 was converted to the iodide 35 by
reaction with methanesulfonyl chloride in CH.sub.2Cl.sub.2 in the
presence of pyridine, followed by a displacement with sodium iodide
in acetone. Reaction of 35 with triphenylphosphine in refluxing
acetonitrile afforded the phosphonium salt. A Wittig reaction
between the phosphonium salt and naphthaldehyde 18 produced diene
36 (as a mixture of double bond isomers). Reduction with H.sub.2
over Pd/C followed by hydrolysis (2N HCl, MeOH) gave aniline 37.
Aniline 37 was reacted with 9-chloroacridine in MeOH in the
presence of triethylamine to give 38. Cleavage of the methyl ethers
with boron tribromide gave quinone 39.
[0111] A third synthetic approach to a 1,2-naphthoquinone moiety
bound to an aminoacridine intercalator is depicted in Scheme 10.
Aminoacridine was protected with mesitylenesulfonyl chloride to
give 41, which was then alkylated with 1,5-dibromopentane to 42.
The latter is brought into reaction with the silver salt of
2-hydroxy-1,4-naphthoquinone and the quinone-acridine 43 was thus
obtained. Cleavage of the amide group using samarium iodide gave
44, the expected compound.
Synthesis of 1,2-naphthoguinol Phosphates
[0112] In order to obtain 1,2-naphthoquinone derivatives that
behave as "pro-drugs" the synthesis of quinol phosphates that can
be hydrolyzed by cell phosphatases to liberate the parent quinones
was carried out. Scheme 11 outlines the synthesis of the quinol
phosphates. The parent 1,2-naphthoquinone 46 was brought into
reaction with dibenzylphosphite to give a mixture of the two
possible regioisomers 47. By cleavage of the benzyl residues with
hydrogen in the presence of 10% Pd on charcoal the mixture of the
two possible quinol phosphates 48 was obtained. They were used as
such in the biological studies.
Synthesis of 8-hydroxy-.beta.-lapachone 55
[0113] Scheme 12 outlines the synthesis of 55, a phenol derivative
of .beta.-lapachone that could be used as a building block for the
construction of peptide derivatives of .beta.-lapachone. The
synthesis starts with the commercially available ester 49, that is
acetylated using a Friedel-Crafts reaction to give 50. Cyclization
of 50 in the presence of base and air gave the p-quinone 51.
Alkylation of 51 with dimethyl allyl bromide gave a mixture of the
C-alkyl derivative 52 and the O-alkyl derivative 53. They were
separated and on treatment of 52 with concentrated sulfuric acid,
the 8-methoxy-.beta.-lapachone 54 was obtained. Cleavage of the
methoxy group with boron tribromide gave the expected
.sigma.-naphthoquinone 55.
Synthesis of 1,2-naphthoguinone Bisulfite Adducts
[0114] Bisulfite adducts of 1,2-naphthoquinones were prepared as
"pro-drugs." They are stable in aqueous solutions at pH below 7 but
liberate the quinone core at pH above 7. Since biological media are
usually above pH 7, the bisulfite adducts led to a slow release of
the quinones after administration in an aqueous medium. A list of
selected bisulfite adducts is given in FIG. 1. General preparation
procedures are given in Experimental.
Synthesis of 1,2-naphthoguinone Peptides
[0115] 1,2-Naphthoquinone conjugates of tetra and hexapeptides were
prepared to obtain "prodrug" derivatives that can be cleaved by
prostatic PSA. The guidelines followed for the synthesis of the
peptides were based on the published results of Isaacs and
coworkers (Denmeade et al. Cancer Res. 1997, 57, 4924), where they
define the substrate specificity of PSA (prostate specific
antigen). The synthesis of a quinone tetrapeptide is outlined in
Scheme 13 for the 3-.beta.-alanyloxy-.beta.-lapachone (SL-11006)
conjugate. SL-11006 (Quin) was coupled to Boc-Gln with DCC in the
presence of 1-hydroxybenzotriazole to give Boc-Gln-Quin. Removal of
the Boc group from Boc-Gln-Quin with TFA in CH.sub.2Cl.sub.2 gave
TFA.multidot.Gln-Quin. Boc-Leu was coupled to TFA.multidot.Gln-Quin
with DCC in the presence of 1-hydroxybenzotriazole to give
Boc-Leu-Gln-Quin. Removal of the Boc group from Boc-Leu-Gln-Quin
with TFA in CH.sub.2Cl.sub.2 gave TFA.multidot.Leu-Gln-Quin.
Boc-Lys(N.epsilon.-Cbz) was coupled to TFA.multidot.Leu-Gln-Quin
with DCC in the presence of 1-hydroxybenzotriazole to give
Boc-Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Quin. Removal of the Boc group
from Boc-Lys(N.epsilon.-Cbz)-Leu-Gln-Quin with TFA in CHCl.sub.3
gave TFA.multidot.Lys(N.epsilon.-Cbz)-Leu-Gln-Quin.
Morpholino-Ser(OBn) was coupled to
TFA-Lys(N.epsilon.-Cbz)-Leu-Gln-Quin with DCC in the presence of
1-hydroxybenzotriazole to give
morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu-Gln-Quin. The side
chain protecting groups were removed by hydrogenolysis to yield
morpholino-Ser-Lys-Leu-Gln-Quin. During the hydrogenolysis, the
quinone was reduced to the hydroquinone, which reoxidized to the
quinone on exposure to air.
[0116] Morpholino-Ser(OBn) was prepared from N-Fmoc-Ser(OBn).
Esterification of N-Fmoc-Ser(OBn) with isobutylene in the presence
of a catalytic amount of H.sub.2SO.sub.4 afforded
N-Fmoc-Ser(OBn)-OtBu. The Fmoc group was removed with piperidine in
CH.sub.2Cl.sub.2 to produce Ser(OBn)-OtBu. Reaction of
Ser(OBn)-OtBu with 4-morpholinecarbonyl chloride in pyridine
yielded morpholino-Ser(OBn)-OtBu. Morpholino-Ser(OBn)-OtBu was
hydrolyzed with TFA in CH.sub.2Cl.sub.2 to yield
morpholine-Ser(OBn).
[0117] The synthesis of a tetrapeptide conjugate of
3-leucyloxy-.beta.-lapachone is outlined in Scheme 14.
Experimental
[0118] tert-Butyl
.delta.-[(1,2-dihydro-1,2-dioxonaphth-4-yl)oxy]valerate (1).
[0119] A mixture of tert-butyl 5-bromovalerate (1 g, 4.2 mmol) and
the silver salt of 2-hydroxy-1,4-naphthoquinone (0.8 g, 3.84 mmol)
in benzene (10 mL), was stirred for 24 h at 50.degree. C. The
reaction mixture was filtered through celite and the solvent was
removed in vacuo. The residue was purified by flash chromatography
(5% methanol in chloroform) to give a yellow solid (384 mg, 30%).
.sup.1H NMR (CDCl.sub.3) 8.12 (d, J=7.7 Hz, 1H), 7.89 (d, J=7.7 Hz,
1H), 7.70 (t, J=6.1 Hz, 1H), 7.59 (t, J=6.4 Hz, 1H), 5.95 (s, 1H),
4.17 (t, J=5.9 Hz, 2H), 2.35 (t, J=7.2 Hz, 2H), 1.90-2.05 (m, 2H),
1.78-1.90 (m, 2H), 1.47 (s, 9H).
[0120] Benzyl 5-[(1,2-dihydro-1,2-dioxonaphth-4-yl)oxy]valerate
(2).
[0121] A mixture of benzyl 5-bromovalerate (2.27 g, 8.4 mmol) and
the silver salt of 2-hydroxy-1,4-naphthoquinone (1.63 g, 5.81 mmol)
in benzene (8 mL) was stirred for 48 h at 55.degree. C. and
filtered through celite. The filtrate was diluted with diethyl
ether, extracted with a 20% aqueous solution of NaHSO.sub.3 then
basified to pH 10-11 with Na.sub.2CO.sub.3, and extracted with
CH.sub.2Cl.sub.2. Yellow solid (1.334 g, 63%). .sup.1H NMR
(CDCl.sub.3) 8.12 (d, J=7.5 Hz, 1H), 7.85 (d, J=7.7 Hz, 1H), 7.68
(t, J=7.5, 1H), 7.58 (t, J=7.7 Hz, 1H), 7.25-7.50 (m, 5H), 5.93 (s,
1H), 5.14 (s, 2H), 4.15 (t, J=5.7 Hz, 2H), 2.50 (t, J=7.0 Hz, 2H),
1.8-2.2 (m, 4H).
[0122] 5-[(1,2-Dioxo-1,2-dihydronaphth-4-yl)oxy]valeric Acid
(3).
[0123] Benzyl ester 2 (1.90 g, 5.22 mmol) was hydrogenated at 30
psi with Pd (400 mg) in ethyl acetate (120 mL) for 6 h. The
catalyst was removed by filtration through celite, the solvent was
evaporated in vacuo and the residue was oxidized with Ag.sub.2O
(1.45 g, 6.25 mmol) in Et.sub.2O by stirring for 10 h. Following
filtration and evaporation of the solvent the product was
crystallized from benzene to afford 0.53 g of pure material. The
mother liquor was purified by flash chromatography
(CH.sub.2Cl.sub.2/MeOH 15: 1), the product dissolved in
CH.sub.2Cl.sub.2, extracted with aqueous NaHCO.sub.3 solution,
acidified to pH 1 with 3% HCl and extracted back with
CH.sub.2Cl.sub.2 to give additional 0.25 g of pure material (total
yield 55%), mp 134-136.degree. C.; .sup.1H NMR (CDCl.sub.3) 8.12
(d, J=7.0 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.70 (t, J=7.5 Hz, 1H),
7.59 (t, J=7.4 Hz, 1H), 7.27 (s, 1H), 4.18 (t, J=5.9 Hz, 2H), 2.51
(t, J=7.0 Hz, 2H), 1.75-2.15 (m, 4H).
[0124] 1,2-Dihydro-4-(6-hydroxyhexyloxy)-1,2-dioxo-naphthalene
(4).
[0125] A mixture of 6-bromohexanol-1 (4.5 g, 24.85 mmol) and the
silver salt of 2-hydroxy-1,4-naphthoquinone (6.46 g, 23.01 mmol) in
benzene (24 mL) was stirred for 48 h at 60.degree. C. The reaction
mixture was worked up as described for 2 and crystallized from
hexane to afford a yellow solid (3.18 g, 50%). mp 96-98.degree. C.,
.sup.1H NMR (CDCl.sub.3) 8.12 (d, J=7.5 Hz, 1H), 7.87 (d, J=7.7 Hz,
1H), 7.70 (t, J=7.5 Hz, 1H), 7.58 (t, J=7.5 Hz, 1H), 5.95 (s, 1H),
4.15 (t, J=6.3 Hz, 2H), 3.69 (t, J=6.2 Hz, 2H), 1.92-1.97 (m, 2H),
1.3-1.8 (m, 7H).
[0126] 1,2-Dihydro-4-(6-iodohexyloxy)-1,2-dioxonaphthalene (5).
[0127] A mixture of 1,6-diiodohexane (10.14 g, 30 mmol) and the
silver salt of 2-hydroxy-1,4-naphthoquinone (2.81 g, 10 mmol) in
benzene (60 mL) was stirred for 12 h at room temperature. The
reacton mixture was filtered through Celite, concentrated in vacuo,
and purified by flash chromatography (hexane/EtOAc 4:1) to give a
yellow solid (2,19 g, 57%); mp 85-87.degree. C.; .sup.1H NMR
(CDCl.sub.3) 8.12 (dd, J=6.5, 1.0 Hz, 1H), 7.86 (dd, J=6.9, 0.9 Hz,
1H), 7.70 (dt, J=7.6, 1.5 Hz, 1H), 7.58 (dt, J=7.5, 1.3 Hz, 1H),
5.95 (s, 1H), 4.15 (t, J=6.3, 2H), 3.22 (t, J=6.9 Hz, 2H),
1.80-2.05 (m, 4H), 1.45-2.10 (m, 4H).
[0128] bis
[6-[(1,2-Dihydro-1,2-dioxonaphth-4-yl)oxy]hexyl]carbonate (6).
[0129] Pyridine (0.12 ml, 1.5 mmol) was added to a stirred solution
of the alcohol 4 (200 mg, 0.73 mmol) and
bis(trichloromethyl)carbonate (40 mg, 0.134 mmol) in
CH.sub.2Cl.sub.2 (5 mL) at 0.degree. C. The cooling bath was
removed, the reaction mixture was diluted with CH.sub.2Cl.sub.2,
washed with 3% HCl , brine, dried (Na.sub.2SO.sub.4) and purified
by column chromatography (benzene/EtOAc 4:1, 2:1). The product was
triturated with Et.sub.2O to afford a yellow solid (127 mg, 30%),
mp 78-82.degree. C. (decomp.). MS (LSIMS, 3-NBA) 576 (M.sup.++2),
401, 175; .sup.1H NMR (CDCl.sub.3) 8.09 (dd, J=6.0, 1.6 Hz, 1H),
7.85 (dd, J=7.8, 1.2 Hz, 1H), 7.71 (t, J=6.9 Hz, 1H), 7.58 (t,
J=6.2 Hz, 1H), 5.94 (s, 1H), 4.17 (t, J=6.0 Hz, 2H), 4.15 (t, J=5.6
Hz, 2H), 1.85-2.10 (m, 2H), 1.65-1.85 (m, 2H), 1.40-1.65 (m,
4H).
[0130]
N-(1-Methyl-5-methyloxycarbonylpyrrol-3-yl)-5-[(1,2-dihydro-1,2-dio-
xonaphth-4-yl)oxy]valeramide (7).
[0131] A solution of an acid 3 (334 mg, 1.22 mmol) in DMF (1.67 mL)
was treated with HBTU (462 mg, 1.22 mmol) followed by DIEA (452 mg,
3.5 mmol) and stirred for 5 min.
3-Amino-1-methyl-5-methyloxycarbonylpyrrol hydrochloride (232 mg,
1.22 mmol) and DIEA (378 mg, 3 mmol) were added to the reaction
mixture. The latter was stirred for 2 h, diluted with Et.sub.2O,
the precipitate was removed, dissolved in CHCl.sub.3, washed with
3% HCl, H.sub.2O, aqueous NaHCO.sub.3, H.sub.2O again, dried
(MgSO.sub.4) and purified by chromatography on alumina column
(CHCl.sub.3/MeOH 80:1, 50:1). The product was triturated with
Et.sub.2O/CHCl.sub.3 to obtain a yellow-red solid (200 mg, 40%); mp
122-.sub.123.degree. C. (decomp.): MS (LSIMS, 3-NBA) 410 (M.sup.+),
237 (M.sup.+-173). .sup.1H NMR (CDCl.sub.3) 8.08 (d, J=7.5 Hz, 1H),
7.86 (d, J=7.3 Hz, 1H), 7.68 (t, J=7.5 Hz, 1H), 7.57 (t, J=7.5 Hz,
1H), 7.38 (d, J=1.8 Hz, 1H), 7.34 (s, 1H), 6.65 (d, J=2 Hz, 1H),
5.95 (s, 1H), 4.19 (t, J=5.53 Hz, 2H), 3.88 (s, 3H), 3.80 (s, 3H),
2.46 (t, J=6.6 Hz, 2H), 1.90-2.15 (m, 4H).
[0132] 4-(tert-butylcarbonyloxy)-1,2-dihydro-1,2-dioxonaphthalene
(8).
[0133] A mixture of the silver salt of 2-hydroxy-1,4-naphthoquinone
(842 mg, 3 mmol), and pivaloyl chloride (434 mg, 3.6 mmol) in
benzene (5 mL) was stirred for 8 h at room temperature. The
reaction mixture was filtered through Celite, the precipitate
washed with EtOAc, and the combined organic solutions were
concentrated in vacuo and purified by flash chromatography
(EtOAc/hexane 1:10, 1:5). The product was recrystallized from
hexane to afford a yellow solid (190 mg, 25%); mp 125-126.degree.
C.; .sup.1H NMR (CDCl.sub.3) 8.15(dd, J=7.7, 1.1 Hz, 1H), 7.71(dt,
J=7.7, 1.5 Hz, 1H), 7.59 (dt, J=7.5, 1.2 Hz, 1H), 7.57 (dd, J=7.6,
1.1 Hz, 1H), 6.48 (s, 1H), 1.44 (s, 9H).
[0134]
N-[3-(Dimethylamino)propyl][3-[[3-[[3-[4-[(1,2-dihydro-1,2-dioxonap-
hth-4-yl)oxy]butylcarbonylamino]-1-methylpyrrol-5-yl]carbonylamino]-1-meth-
ylpyrrol-5-yl]carbonylamino]-1-methylpyrrol-5-yl]Carboxamide (10)
was prepared from acid 3 (61 mg, 0.222 mmol) and Boc-protected
pyrrolylamine 9 (84 mg, 0.148 mmol) using the procedure described
for 7. After the reaction was completed, the reaction mixture was
diluted with Et.sub.2O, the precipitate was removed, triturated
with hot EtOAc and crystallized from a CHCl.sub.3/Et.sub.2O
mixture. The product was a yellow solid (30 mg, 28%); mp
159-162.degree. C. (decomp.); .sup.1H NMR (DMSO-d.sub.6) 9.90 (s,
1H), 9.89 (s, 1H), 9.86 (s, 1H), 8.08 (bs, 1H), 7.97 (d, J=7.7 Hz,
1H), 7.87 (d, J=7.2 Hz, 1H), 7.81 (t, J=7.9 Hz, 1H), 7.68 (t,
J=7.2, 1H), 7.24 (s, 1H), 7.19 (s, 1H), 7.04 (s, 1H), 6.89 (s, 1H),
6.84 (s, 1H), 6.06 (s, 1H), 4.25 (t, J=5.8 Hz, 1H), 3.85 (s, 3H),
3.84 (s, 3H), 3.80 (s, 3H),3.12-3.30 (m, 2H), 2.25-2.45 (m, 4H),
2.19 (s, 6H), 1.72-2.00 (m, 4H), 1.60-1.70 (m, 2H).). MS (LSIMS,
3-NBA) 725.2 (M.sup.++1).
[0135]
1,2-Dihydro-4-[6-[(4-cyanophenyl)oxy]hexyloxy]-1,2-dioxonaphthalene
(11).
[0136] A mixture of 4-hydroxybenzonitrile (87 mg, 0.73 mmol),
naphthoquinone 4 (200 mg, 0.73 mmol), PPh.sub.3 (191 mg, 0.73 mmol)
in dioxane (10 mL) was cooled to 10.degree. C. and treated with
DEAD (140 mg, 0.80 mmol). The reaction mixture was stirred for 10
h, concentrated in vacuo and purified by chromatography (5% EtOAc
in benzene) to afford 11 as a yellow solid (171 mg, 53%), .sup.1H
NMR (CDCl.sub.3) 8.13 (dd, J=7.3, 1.4 Hz, 1H), 8.86 (dd, J=7.7, 1.1
Hz, 1H), 7.67 (dt, J=7.5, 1.5 Hz 1H), 7.60 (dt, J=7.5, 1.5 Hz, 1H),
7.57 (d, J=8.8 Hz, 2H), 6.93 (d, J=8.9 Hz, 2H),5.96 (s, 1H), 4.17
(t, J=6.4 Hz, 2H), 4.03 (t, J=6.3 Hz, 2H), 1.80-2.05 (m, 4H),
1.58-1.68 (m, 4H).
[0137] 1,2-Dihydro-4-[6-(phenyloxy)hexyloxy]-1,2-dioxonaphthalene
(12).
[0138] Phenol (28 mg, 0.3 mmol) was treated with tetrabutylammonium
hydroxide (0.3 mL of 1.0 M solution in methanol) and the reaction
mixture was concentrated to dryness in vacuo. Iodonaphtoquinone 5
(115 mg, 0.3 mmol) in DMF (3 mL) was added to the
tetrabutylammonium salt, stirred for 48 h and quenched with
H.sub.2O (10 mL). The product was extracted with CHCl.sub.3, the
extract was washed with H.sub.2O, then brine, dried
(Na.sub.2SO.sub.4), and purified by chromatography (5% EtOAc in
benzene) to give 12 as a yellow solid (45 mg, 43%) .sup.1H NMR
(CDCl.sub.3) 8.13 (d, J=7.4 Hz, 1H), 7.86 (d, J=7.4 Hz, 1H), 7.67
(t, J=7.6 Hz, 1H), 7.61 (t, J=7.5 Hz, 1H),7.15-7.40 (m, 2H),
6.85-7.10 (m, 3H), 5.96 (s, 1H), 4.17 (t, J=6.5 Hz, 2H), 3.99 (t,
J=6.2 Hz), 1.70-2.10 (m, 4H), 1.35-1.70 (m, 4H).
[0139] 3-Dimethylaminophenyl
5-[(1,2-dihydro-1,2-dioxonaphth-4-yl)oxy]vale- rate (13).
[0140] A mixture of acid 3 (137 mg, 0.5 mmol),
3-dimethylaminophenol (82 mg, 0.6 mmol), DCC (103 mg, 0.5 mmol),
and DMAP (12 mg, 0.01 mmol) in THF (2 mL) was stirred for 2 h. The
reaction mixture was concentrated in vacuo, the residue dissolved
in benzene, washed with H.sub.2O and dried (Na.sub.2SO.sub.4).
Column chromatography (10% EtOAc) in benzene gave 13 as a yellow
solid (70 mg, 36%), .sup.1H NMR (CDCl.sub.3) 8.13, (d, J=7.3 Hz,
1H), 7.90 (d, J=7.4 Hz, 1H), 7.69 (t, J=6.1 Hz, 1H), 7.58 (t, J=7.6
Hz, 1H), 7.22 (dd, J=8.1, 8.1 Hz, 1H), 6.30-6.70 (m, 2H), 5.96 (s,
1H), 4.21 (t, J=5.6 Hz, 2H), 2.69 (t, J=6.5 Hz, 2H), 1.90-2.15 (m,
4H).
[0141]
2'-[4-[6-(1,2-Dihydro-1,2-dioxo-naphth-4-yl)oxyhexyl]oxyphenyl]-5-(-
4-methylpiperazin-1-yl)-2,5'-bi-1H-benzimidazole (14).
[0142] Hoechst 33258 (3.0 g, 5 mmol) was dissolved in a hot mixture
of isopropanol-water (24 mL/12 mL) and neutralized with ammonium
hydroxide (3 mL). The precipitate was filtered, triturated with
Et.sub.2O and dried in vacuo to obtain the free base of
bisbenzimidazole. A 1.0 M solution of Bu.sub.4NOH in MeOH (0.6 mL,
0.6 mmol) was added to the solution of bisbenzimidazole (1.635 g,
3.85 mmol) in MeOH (30 mL), stirred for 15 min and concentrated to
dryness in vacuo. Iodonaphthoquinone 5 (1.485 g, 3.87 mmol) in DMF
(30 mL) was added to the tetrabutyl ammonium salt and the mixture
was stirred for 48 h. The reaction mixture was suspended in
H.sub.2O, the crude product was filtered, washed with H.sub.2O,
dried and purified by flash chromatography (MeOH/CHCl.sub.3 1:9,
1:5) to afford 14 as a yellow solid (790 mg, 30%). .sup.1H NMR
(CDCl.sub.3/MeOH-d.sub.4) 8.21 (s, 1H), 8.09 (d, J=7.6 Hz, 1H),
8.05 (d, J=8.7 Hz, 2H), 7.85-7.95 (m, 2H), 7.48-7.75 (m, 4H), 7.14
(bs, 1H), 7.10-6.98 (m 3H), 4.21 (t, J=6.3 Hz, 2H), 4.08 (t, J=6.2
Hz, 2H), 2.65-2.75 (m, 4H), 2.40 (s, 3H), 1.80-2.15 (m, 4H),
1.60-1.75 (m, 4H). MS (LSIMS, 3-NBA) 725.2 (M.sup.++1).
[0143] Trifluoroacetate of
6-[(1,2-dihydro-1,2-dioxonaphth-4-yl)oxy]hexyl 6-aminohexanoate
(15).
[0144] [6-(tert-Butyloxycarbonyl)amino]hexanoic acid (139 mg, 0.6
mmol) was added into solution of DCC (113 mg, 0.55 mmol) and DMAP
(64 mg, 0.52 mmol) in CH.sub.2Cl.sub.2 (10 mL) at 0.degree. C. and
stirred for 15 min, when naphthoquinone 4 (137 mg, 0.5 mmol) was
added. The reaction mixture was stirred for 12 h at room
temperature, diluted with CH.sub.2Cl.sub.2, extracted 3 times with
an aqueous solution of KHSO.sub.4, then with a NaHCO.sub.3 solution
followed by brine, dried (MgSO.sub.4), and finally it was
concentrated to dryness in vacuo and triturated with Et.sub.2O. The
residue was dissolved in CH.sub.2Cl.sub.2 (3 mL), TFA (0.5 mL) was
added to the solution and the mixture stirred at 0.degree. C. for 1
h. All volatiles were removed in vacuo and the residue was
triturated in Et.sub.2O to give 15 (100 mg, 40%). as a dark yellow
oil. .sup.1H NMR (CDCl.sub.3) 8.90 (d, J=7.6 Hz, 1H), 7.99 (bs,
3H), 7.87 (d, J=7.8 Hz, 1H), 7.71 (t, J=7.6 Hz, 1H), 7.59 (t, J=7.5
Hz, 1H), 5.96 (s, 1H), 4.17 (t, J=6.3 Hz, 2H), 4.09 (t, J=6.2 Hz,
2H), 2.90-3.15 (m, 2H), 2.29 (t, J=7.1 Hz, 2H), 1.90-2.10 (m, 2H),
1.30-1.85 (m, 12H).
[0145]
1,2-Dihydro-1,2-dioxo-4-[4-[2-[3-[2-(ethylaminocarbonyl)ethylaminoc-
arbonyl]propyl=aminocarbonyl]ethylaminocarbonyl]butyloxy]naphthalene
(17).
[0146] Acid 3 (137 mg, 0.5 mmol) was dissolved in DMF (1 mL),
treated with HBTU (190 mg, 0.5 mmol) followed by DIEA (260 .mu.L,
1.5 mmol) and stirred for 10 min.
N-Ethyl[2-[3-(2-aminoethylcarbonylamino)
propylcarbonylamino]ethyl]carboxamide hydrochloride 16 (154 mg, 0.5
mmol) and DIEA (260 .mu.L, 1.5 mmol) were added to the reaction
mixture, the latter was stirred for 2 h, and the reaction mixture
was diluted with Et.sub.2O. The product was filtered and triturated
with CHCl.sub.3 to afford a yellow solid (100 mg, 38%), mp
145-170.degree. C. (decomp.) .sup.1H NMR (CDCl.sub.3, MeOH-d.sub.4)
8.10 (dd, J=7.6, 1.4 Hz, 1H), 7.92 (dd, J=7.8, 1.2 Hz, 1H), 7.72
(dt, J=7.7, 1.2 Hz, 1H), 7.62 (dt, 7.6, 1.3 Hz, 1H), 7.30-7.50 (m,
2H), 7.15 (bs, 1H), 5.97 (s, 1H), 4.20 (t, J=5.8 Hz, 2H), 3.35-3.50
(m, 4H), 3.10-3.30 (m, 4H), 3.32-3.42 (m, 4H), 2.30 (t, J=6.9 Hz,
2H), 2.19 (t, J=7.4 Hz, 2H), 1.75-2.05 (m, 4H), 1.78 (t, J=7.2,
2H), 1.13 (t, J=7.3, 3H). MS (FAB, NaI) 551.2 (M+Na), 529
(M.sup.++1).
[0147] 3,4-Dimethoxy-1-naphthaldehyde (18).
[0148] A mixture of 1,2-dimethoxynaphthalene (0.74 g, 4 mmol) and
DMF (0.8 mL, 10 mmol) in dichlorobenzene (0.8 mL) was stirred with
POCl.sub.3 at 100.degree. C. for 2h. The reaction mixture was
cooled to 0.degree. C., quenched with a cold aqueous solution of
NaOAc, diluted with H.sub.2O and extracted with benzene. The
extracts were dried (MgSO.sub.4), concentrated and in vacuo and
dichlorobenzene was removed by kugelrohr distillation at
110.degree. C./0.5 mm Hg. Column chromatography (20%EtOAc in
hexane) gave the product 18 (596 mg, 68%), which was used in the
following step without further purification. .sup.1H NMR
(CDCl.sub.3) 10.42 (s, 1H), 9.00-9.15 (m, 1H), 8.15-8.30 (m, 1H),
7.61 (s, 1H), 7.50-7.65 (m, 2H), 4.12 (s, 3H), 4.07 (s, 3H).
[0149] 4-Butylaminomethyl-1,2-dimethoxy-naphthalene (19).
[0150] A suspension of PtO.sub.2 (40 mg) in EtOH (2 mL) was stirred
with H.sub.2 at 25 psi for 30 min. Naphthaldehyde 18 (596 mg, 2.8
mmol) was dissolved in EtOH and added into the suspension followed
by the addition of butylamine (219 mg, 3 mmol). The reaction
mixture was hydrogenated for 6 h at 50 psi. The catalyst was
filtered through Celite, washed with acetone and the filtrate was
concentrated to dryness to give 19 as an oil (665 mg, 87%). The
product was utilized in the following step without further
purification. .sup.1H NMR (CDCl.sub.3) 8.16 (d, J=7.5 Hz, 1H), 7.99
(d, J=7.6 Hz, 2H), 7.40-7.60 (m, 2H), 7.35 (s, 1H), 4.19 (s, 2H),
4.00 (s, 3H), 3.98 (s, 3H), 2.76 (t, J=7.0 Hz, 2H), 1.64 (bs, 1H),
1.45-1.60 (m. 2H), 1.30-1.45 (m, 2H), 0.93 (t, J=7.2 Hz, 3H).
[0151] 4-(N-Acetyl-N-butylaminomethyl)-1,2-dimethoxy-naphthalene
(20).
[0152] Triethylamine (350 .mu.L, 2.5 mmol) was added to a solution
of aminonaphthalene 19 (250 mg, 0.9 mmol) and AcCl (90.mu.L, 1.27
mmol) in CH.sub.2Cl.sub.2 (5 mL) at 0.degree. C. The cooling bath
was removed after 10 min, the reaction mixture was stirred for 1h
at room temperature, diluted fivefold with CH.sub.2Cl.sub.2, washed
with an aqueous solution of NaHCO.sub.3 followed by 3% HCl, brine
and dried (MgSO.sub.4). The crude product (315 mg, 100%) obtained
after evaporation of the solvent was used in the following step
without further purification. .sup.1H NMR (CDCl.sub.3) 8.19, 8.15
(2d, J=7.6, 8.4 Hz, 1H), 8.97, 7.80 (2d, J=7.9, 8.2 Hz, 1H),
7.35-7.58 (m, 2H), 7.16, 7.04 (2s, 1H), 5.05, 4.95 (2s, 2H), 4.01,
3.99 (2s, 3H), 3.99, 3.96 (2s, 3H), 3.47, 3.13 (2t, J=7.4, 7.8 Hz,
2H), 2.20, 2.09 (2s, 3H), 1.15-1.70 (m, 4H), 0.91, 0.87 (2t, J=7.2,
7.3 Hz, 3H).
[0153]
4-(N-Butyl-N-trifluoroacetylaminomethyl)-1,2-dimethoxy-naphthalene
(21).
[0154] Naphthalene 19 (200 mg, 0.73 mmol) was acylated with
trifluoroacetyl anhydride (210 mg, 1 mmol) in the presence of TEA
(0.2 mL, 1.5 mmol) by raising the temperature during 3 h from
-40.degree. to 0.degree. C. The reaction mixture was diluted with
CH.sub.2Cl.sub.2, washed with aqueous NaHCO.sub.3, 3% HCl, brine
and finally dried (MgSO.sub.4). The crude product (266 mg, 99%) was
used in the following step without further purification. .sup.1H
NMR (CDCl.sub.3) 8.17-8.25 (m, 1H), 7.82 (t, J=7.7 Hz, 1H),
7.40-7.55 (m, 2H), 7.16, 7.03 (2s, 1H), 5.11, 5.08 (2s, 2H), 4.01,
4.03 (2s, 3H), 3.98, 3.96 (2s, 3H), 3.40, 3.25 (2t, J=7.5, 7.4 Hz,
2H), 1.45-2.75 (m, 2H), 1.10-1.45 (m, 2H), 0.89 (t, J=7.4, 3H).
[0155]
4-[N-Butyl-N-[3-(4-morpholinocarbonyl)ethylcarbonyl]aminomethyl]-1,-
2-dimethoxynaphthalene (22).
[0156] 3-(N-Morpholinocarbonyl)propionic acid (139 mg, 0.74 mmol)
in CH.sub.2Cl.sub.2 (5 mL) was heated to reflux with thionyl
chloride (440 mg, 3.7 mmol) for 1 h and all volatiles were
evaporated in vacuo. The residue was dissolved in anhydrous
CH.sub.2Cl.sub.2 (3 mL), cooled to 0.degree. C. and naphthalene 19
(100 mg, 0.37 mmol), followed by DMAP (45 mg, 0.37 mmol) and TEA
(140 .mu.L, 1 mmol) were added into the reaction mixture. After
stirring for 1 h at room temperature the reaction was quenched with
wet EtOAc (10 mL), washed with 3% HCl, aqueous NaHCO.sub.3, brine,
and dried (Na.sub.2SO.sub.4). Purification by chromatography
(15%EtOAc in hexane) gave 22 (160 mg, 98%). The product was used
directly in the next step. .sup.1H NMR (CDCl.sub.3) 8.19, 8.17 (2d,
J=7.7, 7.8 Hz, 1H), 7.92, 7.85 (2d, J=8.2, 8.05 Hz, 1H), 7.38-7.56
(m, 4H), 7.25, 7.17 (2s, 1H), 5.05, 5.03 (2s, 2H), 4.03, 4.00 (2s,
3H), 3.99, 3.98 (2s, 3H), 3.25-3.82 (m, 14H), 1.15-1.82 (m, 4H),
0.88. 0.85 (2t, J=7.1, 6.7 Hz, 3H).
[0157] Demethylation of dimethoxynaphthalenes with boron
tribromide.
4-(butylamino=methylene)-1,4-dihydro-2-hydroxy-1-oxo-naphthalene
(23).
[0158] A solution of dimethoxynaphthalene 19 (30 mg, 0.11 mmol) in
CH.sub.2Cl.sub.2 (2 mL) was treated with a 1M solution of BBr.sub.3
in CH.sub.2Cl.sub.2 (1.1 mL) at -78.degree. C. and stirred at this
temperature for 2h. The reaction mixture was placed in a freezer at
-10.degree. C. for 3 h, quenched with Et.sub.2O (1 mL) by stirring
for 15 min at room temperature and neutralized with aqueous
solution of NaHCO.sub.3. The product was extracted with EtOAc,
dried (MgSO.sub.4), and the solvent was removed in vacuo. The
residue was dissolved in Et.sub.2O, stirred for 10 h in an open
flask and purified by chromatography (5% MeOH in CHCl.sub.3).
Trituration with Et.sub.2O yielded the product23 (8 mg, 30%).
.sup.1HNMR(CDCl.sub.3) 9.05 (bs, 1H), 8.31 (d, J=8.1 Hz, 1H),
7.65-7.85 (m, 1H), 7.05-7.65 (m, 3H), 3.20-3.60 (m, 2H), 1.50-1.85
(m. 2H), 2.25-1.50 (m, 2H), 0.80-1.10 (m, 3H). HRMS (EI) 243.1250.
Calcd for C.sub.15H.sub.17NO.sub.2 243.1259.
[0159]
4-(N-Acetyl-N-butylaminomethyl)-1,2-dihydro-1,2-dioxonaphthalene
(24) was prepared from dimethoxynaphthalene 20 using the procedure
described for 23. The product (60%) was purified by chromatography
(1.5% MeOH in CHCl.sub.3) followed by trituration with Et.sub.2O.
.sup.1H NMR (CDCl.sub.3) 8.1 (dd, J=7.53, 1.2 Hz, 1H), 7.67 (dd,
J=7.7, 1.1 Hz, 1H), 7.50-7.62 (m, 2H), 6.21 (s, 1H), 4.68 (s, 2H),
3.35 (t, J=8.0 Hz, 2H), 2.25 (s, 3H), 1.50-1.75 (m, 2H), 1.15-1.50
(m, 2H), 0.96 (t, J=5.8, 3H). HRMS (EI) 285.1383. Calcd for
C.sub.17H.sub.19NO.sub.3 285.1365.
[0160]
4-(N-Butylaminomethyl-N-trifluorocetyl)-1,2-dihydro-1,2-dioxonaphth-
alene (25) was obtained from dimethoxynaphthalene 21 using the
procedure described for 23. The product (37%) was purified by
chromatography (3% MeOH in CHCl.sub.3) followed by trituration in
Et.sub.2O. .sup.1H NMR (CDCl.sub.3) 8.29 (d, J=7.13 Hz, 1H),
7.40-7.85 (m, 3H), 6.19 (s, 1H), 4.73 (s, 2H), 3.35-3.70 (m, 2H),
1.50-1.80 (m, 2H), 1.35-1.80 (m, 2H), 0.96 (t, J=7.2 Hz, 3H). HRMS
(EI) 339.1106. Calcd for C.sub.17H.sub.16F.sub.3NO.sub.3
339.1082.
[0161]
4-[[N-Butyl-N-(4-morpholino-4-oxobutyryl)amino]methyl]-1,2-dihydro--
1,2-dioxonaphthalene (26) was obtained from dimethoxynaphthalene 22
using the procedure described for 23. The product (10%) was
purified by chromatography (25%-40% EtOAc in hexane) followed by
trituration in Et.sub.2O. .sup.1H NMR (CDCl.sub.3) 8.19 (d, J=7.4
Hz, 1H), 7.70 (t, J=6.4 Hz, 1H), 7.59 (d, J=6.5 Hz, 1H), 7.50 (t,
J=7.9 Hz, 1H), 6.33 (s, 1H), 4.65 (s, 2H), 3.35-3.80 (m, 14 H),
1.65-1.85 (m, 2H), 1.25-1.50 (m, 2H), 0.96 (t, J=7.2 Hz, 3H).
[0162]
meso-Tetra[4-[6-[(1,2-dihydro-1,2-dioxonaphth-4-yl)oxy]hexyloxy]phe-
nyl]porphine (27).
[0163] A 1 M solution of Bu.sub.4NOH in MeOH (0.212 mL,) was added
to a stirred solution of meso-tetra(4-hydroxyphenyl)porphine (36
mg, 0.53 mmol) in MeOH (5 mL), stirring was kept for 10 min and the
mixture concentrated to dryness in vacuo. Naphthoquinone 5 (81 mg,
0.21 mmol) in DMF (2 mL) was added to the porphyrin, the solution
stirred for 48 h and diluted with H.sub.2O (20 mL). The product was
extracted with CHCl.sub.3, washed with brine, the solvent was
evaporated and the residue was triturated with Et.sub.2O.
Purification by flash chromatography (2-3% MeOH in CHCl.sub.3)
followed by recrystallization from CHCl.sub.3/Et.sub.2O (1:3)
afforded the product as a dark red solid (19.6 mg, 21%). .sup.1H
NMR (CDCl.sub.3) 8.86 (s, 8H), 8.01-8.15 (m, 12H), 7.9 (d, J=7.8
Hz, 4H), 7.68 (t, J=6.3 Hz, 4H), 7.55 (t, J=7.5 Hz, 4H), 7.27 (d,
J=7.8 Hz, 8H), 5.98 (s, 4H), 4.15-4.30 (m, 16 H), 1.80-2.10 (m,
16H), 1.65-1.80 (m, 16H). Anal. Calcd for
C.sub.108H.sub.94N.sub.4O.sub.16.time- s.1.5 H.sub.2O: C, 74.87; H,
5.43; N, 3.23. Found: C, 74.62; H, 5.57; N, 3.11.
[0164]
meso-Tetra[4-[6-[(1,2-dihydro-1,2-dioxanaphth-4-yl)oxyhexyl]oxycarb-
onyl]phenyl]porphyrin (28).
[0165] EDCI (518 mg, 2.7 mmol) was added at 0.degree. C. to a
mixture of meso-tetra(4-carboxyphenyl)porphyrin (500 mg, 0.63
mmol), alcohol 4 (831 mg, 3 mmol), and DMAP (159 mg, 1.3 mmol) in
CH.sub.2Cl.sub.2 (10 mL). The solution was stirred for 2 h, the
cooling bath was removed and the reaction mixture was left at room
temperature overnight. It was diluted with CH.sub.2Cl.sub.2, washed
with 2% HCl, H.sub.2O, aqueous solution of NaHCO.sub.3, H.sub.2O,
5% aqueous solution of NaHSO.sub.3, H.sub.2O, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The analytical sample
was prepared by column chromatography on silica (2% MeOH in
CHCl.sub.3). Mp 98-110.degree. C. (decomp.) Yield 572 mg, 50%.
.sup.1H NMR (CDCl.sub.3) 8.81 (s, 8H,), 8.45 (d, J=8.2 Hz, 8H),
8.30 (d, J=8.0 Hz, 8H), 8.09 (d, J=6.9 Hz, 4H), 7.89 (d, J=7.3 Hz,
4H), 7.70 (t, J=7.1 Hz, 4H), 7.56 (t, J=7.1 Hz, 4H), 5.98 (s, 4H),
4.56 (t, J=6.5 Hz, 8H), 4.21 (t, J=6.1 Hz, 8H), 1.85-2.20 (m, 16H),
1.60-1.80 (m, 16H). MS (MALDI) 1838 (M.sup.++23), 1817 (M.sup.++1).
Anal. Calcd for C.sub.112H.sub.94N.sub.4O.sub.20.times.4 H.sub.2O:
C, 71.18; H, 5.40; N, 2.97. Found: C, 71.27; H, 5.24; N, 3.03.
[0166] N-Acetyl-4-(7-hydroxy-1-heptenyl)-aniline (29).
[0167] A solution of 5.213 g (28.8 mmol) of 6-bromohexanol and 7.55
g (28.8 mmol) of triphenylphosphine in 50 mL of CH.sub.3CN was
refluxed for 24 hr. Evaporation of solvent yielded the crude
phosphonium salt, which was used directly in the next reaction. The
crude phosphonium salt and 4.690 g (28.7 mmol) of
4-acetamidobenzaldehyde were dissolved in a mixture of 150 mL of
CH.sub.2Cl.sub.2 and 150 mL of THF. To the cooled solution was
added 1.529 g (60.5 mmol) of 95% NaH as a slurry in
CH.sub.2Cl.sub.2 (10 mL). The reaction mixture was stirred in an
ice bath for 1 hr, then at room temperature for 19 hr. The mixture
was partitioned between 350 mL CH.sub.2Cl.sub.2 and 500 mL 1N HCl.
The aqueous phase was extracted with CH.sub.2Cl.sub.2 (4.times.100
mL). The CH.sub.2Cl.sub.2 extracts were combined, dried with
MgSO.sub.4, and evaporated to dryness. Column chromatography on
silica gel eluting first with 1% MeOH in CH.sub.2Cl.sub.2 and then
with 2% MeOH in CH.sub.2Cl.sub.2 afforded 4.913 g (69% from
6-bromohexanol) of alkene 29 as a mixture of E and Z isomers:
.sup.1H NMR (250 MHz, CDCl.sub.3, TMS) .delta. 7.5-7.4 (m,4H),
7.3-7.1 (m, 4H), 6.4-6.3 (m, 2H), 6.2-6.1 (m, 1H), 5.7-5.6 (m, 2H),
3.65 (t, J=6.5 Hz, 2H), 3.63 (t, J=6.5 Hz, 2H), 2.4-2.1 (m, 4H),
2.18 (s, 3H), 2.17 (s, 3H), 1.7-1.3 (m, 12H).
[0168] 4-(7-Hydroxyheptyl)-aniline (30).
[0169] To a solution of 4.913 g (19.9 mmol) of
N-acetyl-4-(7-hydroxy-1-hep- tenyl)-aniline 29 in 100 mL of 10%
MeOH in CH.sub.2Cl.sub.2 in a Parr bottle were added 490 mg of 10%
Pd/C. The bottle was placed on a hydrogenation apparatus and shaken
for 4 hr at 25 psi of hydrogen. Removal of catalyst by filtration
through a celite pad and evaporation of solvent afforded 5.294 g of
alkane: .sup.1H NMR (300 MHz, CDCl.sub.3, TMS) .delta. 7.80 (s,
NH), 7.38 (d, J=8 Hz, 2H), 7.09 (d, J=8 Hz, 2H), 3.61 (t, J=6.6 Hz,
2H), 2.54 (t, J=7.6 Hz, 2H), 2.12 (s, 3H), 1.6-1.5 (m, 4H), 1.4-1.3
(m, 6H).
[0170] A solution of the alkane in 40 mL of MeOH was mixed with 190
mL of 2N HCl. The reaction mixture was refluxed for 23 hr. Then the
reaction mixture was added to a cooled mixture of 190 mL 2N NaOH
and 200 mL CH.sub.2Cl.sub.2. The aqueous phase was extracted with
CH.sub.2Cl.sub.2 (4.times.100 mL). The CH.sub.2Cl.sub.2 extracts
were combined, dried with MgSO.sub.4, and evaporated to dryness, to
afford 3.579 g of aniline 30 (87% from alkene): .sup.1H NMR (300
MHz, CDCl.sub.3, TMS) .delta. 6.95 (d, J=8.3 Hz, 2H), 6.61 (d,
J=8.3 Hz, 2H), 3.60 (t, J=6.6 Hz, 2H), 2.48 (t, J=7.6 Hz, 2H),
1.6-1.5 (m, 4H), 1.4-1.3 (m, 6H).
[0171] N-(9-Acridinyl)-4-(7-hydroxyheptyl)-aniline (31).
[0172] To a solution of 636.9 mg (3.07 mmol) of
4-(7-hydroxyheptyl)-anilin- e 30 and 428 .mu.L (3.07 mmol) of
Et.sub.3N in 20 mL of MeOH were added 656.4 mg (3.07 mmol) of
9-chloroacridine. After stirring for 7 hr at room temperature, the
solvent was evaporated. Purification by column chromatography on
silica gel with 5% MeOH in CH.sub.2Cl.sub.2 gave 1.079 g (91%) of
N-(9-acridinyl)-4-(7-hydroxyheptyl)-aniline 31: .sup.1H NMR (300
MHz, CDCl.sub.3, TMS) .delta. 8.0-7.9 (m, 4H), 7.63 (t, J=7 Hz,
2H), 7.3-7.2 (m, 2H), 7.07 (d, J=8.3 Hz, 2H), 6.85 (d, J=8.3 Hz,
2H), 3.64 (t, J=6.6 Hz, 2H), 2.57 (t, J=7.6 Hz, 2H), 1.7-1.5 (m,
4H), 1.4-1.3 (m, 6H).
[0173] N-(9-acridinyl)-4-(7-iodoheptyl)-aniline (32).
[0174] To a solution of 604.1 mg (1.57 mmol) of
N-(9-acridinyl)-4-(7-hydro- xyheptyl)-aniline 31 in 20 mL of
pyridine cooled to 0.degree. C. was added 200 .mu.L (2.58 mmol) of
methanesulfonyl chloride. The reaction mixture was stirred at
0.degree. C. for 1 hr 20 min, then partitioned between 180 mL of
CH.sub.2Cl.sub.2 and 75 mL of water. The aqueous phase was
extracted with CH.sub.2Cl.sub.2 (3.times.30 mL). The
CH.sub.2Cl.sub.2 extracts were combined, washed with 40 mL of
saturated NaCl solution, dried with MgSO.sub.4, and evaporated to
dryness.
[0175] The sulfonate was dissolved in 20 mL of acetone. To the
solution was added 355.0 mg (2.37 mmol) of NaI, and the mixture was
refluxed for 8 hr, then stirred at room temperature for 16hr. The
reaction mixture was partitioned between 200 mL of ethyl acetate
and 100 mL of water. The organic phase was washed with 5% sodium
thiosulfate (3.times.30 mL). All aqueous phases were combined and
backextracted with 75 mL of ethyl acetate. Both ethyl acetate
phases were combined, dried with MgSO.sub.4, and evaporated to
dryness, to afford 600.2 mg (77%) of
N-(9-acridinyl)-4-(7-iodoheptyl)-aniline 32: .sup.1H NMR (300 MHz,
CDCl.sub.3, TMS) .delta. 8.0-7.9 (m, 4H), 7.66 (t, J=7 Hz, 2H),
7.3-7.2 (m, 2H), 7.06 (d, J=8 Hz, 2H), 6.81 (d, J=8 Hz, 2H), 3.18
(t, J=7 Hz, 2H), 2.57 (t, J=7.6 Hz, 2H), 1.9-1.8 (m, 2H), 1.7-1.7
(m, 2H), 1.4-1.3 (m, 6H).
[0176] Quinone-anilinoacridine (33) (SL-11064).
[0177] To a solution of 1.554 g (3.14 mmol) of
N-(9-acridinyl)-4-(7-iodohe- ptyl)-aniline 32 in a mixture of 40 mL
of CHCl.sub.3 and 2 mL of MeOH was added 1.765 g (6.28 mmol) of
silver salt. The reaction mixture was refluxed for 23 hr. The
reaction mixture was diluted with CH.sub.2Cl.sub.2, filtered, and
evaporated to dryness. Purification and separation of the para- and
orthoquinone isomers were accomplished using a series of columns on
silica gel using 5% MeOH in CH.sub.2Cl.sub.2, Et.sub.2O, and 10%
MeOH in CH.sub.2Cl.sub.2. Isolated 108.9 mg of 33 as a dark orange
solid.
[0178] N-Acetyl-4-(7-methanesulfonyl-1-heptenyl)-aniline.
[0179] To a cooled solution of 500 mg (2.02 mmol) of
N-acetyl-4-(7-hydroxy-1-heptenyl)-aniline 29 and 0.5 mL (6.18 mmol)
of pyridine in 10 mL of CH.sub.2Cl.sub.2 was added 240 .mu.L (3.10
mmol) of methane-sulfonyl chloride. The reaction mixture was
stirred at room temperature for 22 hr. The reaction mixture was
diluted with CH.sub.2Cl.sub.2, washed with 1N HCl (4.times.50 mL),
washed with saturated NaCl solution (50 mL), dried with MgSO.sub.4,
and evaporated to dryness. Column chromatography on silica gel with
5% MeOH in CH.sub.2Cl.sub.2 afforded 416.1 mg (63%) of mesylate
(mixture of E and Z isomers): .sup.1H NMR (250 MHz, CDCl.sub.3,
TMS) .delta. 7.47 (d, J=8 Hz), 7.43 (d, J=8 Hz), 7.29 (d, J=8 Hz),
7.22 (d, J=8 Hz), 6.4-6.3 (m), 6.2-6.0 (m), 5.7-5.6 (m), 4.23 (t,
J=6.6 Hz), 4.22 (t, J=6.6 Hz), 2.4-2.3 (m), 2.3-2.1 (m), 2.18 (s),
2.17 (s), 1.9-1.7 (m), 1.6-1.4 (m).
[0180] N-Acetyl-4-(7-iodo-1-heptenyl)-aniline (34).
[0181] To a solution of 2.641 g (8.11 mmol) of
N-acetyl-4-(7-methanesulfon- yl-1-heptenyl)-aniline in 60 mL of
acetone was added 1.832 g (12.2 mmol) of NaI. The reaction mixture
was refluxed for 19 hr. Then, filtration and evaporation of solvent
gave 3.410 g (quant) of iodide 34, which was used as is in the next
reaction.
[0182] Phosphonium iodide (35).
[0183] A solution of 3.410 g of
N-acetyl-4-(7-iodo-1-heptenyl)-aniline 34 and 2.143 g (8.17 mmol)
of triphenylphosphine in 70 mL of CH.sub.3CN was refluxed for 43
hr. Evaporation of solvent and column chromatography on silica gel
with 5% MeOH in CH.sub.2Cl.sub.2 yielded 4.781 g (95% from
mesylate) of phosphonium iodide 35.
[0184]
1-(3,4-Dimethoxy-1-naphthyl)-8-(4-acetamidophenyl)-1,7-octadiene
(36).
[0185] To a cooled solution of 3.17 g (5.12 mmol) of phosphonium
iodide 35 and 1.093 g (5.05 mmol) of 3,4-dimethoxy-1-naphthaldehyde
18 in 20 mL of THF and 25 mL of CH.sub.2Cl.sub.2 was added 130 mg
(5.14 mmol) of 95% NaH. The reaction mixture was stirred at room
temperature for 21 hr. The mixture was partitioned between 200 mL
1N HCl and 350 mL CH.sub.2Cl.sub.2. The aqueous phase was extracted
with CH.sub.2Cl.sub.2 (6.times.75 mL). The CH.sub.2Cl.sub.2
extracts were combined, dried with MgSO.sub.4, and evaporated to
dryness. Column chromatography on silica gel with 1% MeOH in
CH.sub.2Cl.sub.2 afforded 1.073 g (49%) of diene 36.
[0186]
1-(3,4-Dimethoxy-1-naphthyl)-8-(4-acetamidophenyl)-octane.
[0187] To a solution of 556.3 mg (1.29 mmol) of
1-(3,4-dimethoxy-1-naphthy- l)-8-(4-acetamidophenyl)-1,7-octadiene
36 in 20 mL of CH.sub.2Cl.sub.2 in a Parr bottle were added 55.4 mg
of 10% Pd/C. The bottle was placed on a hydrogenation apparatus and
shaken for 2.5 hr at 32 psi of hydrogen. Removal of catalyst by
filtration through a celite pad and evaporation of solvent afforded
554.6 mg (99%) of octane: .sup.1H NMR (250 MHz, CDCl.sub.3, TMS)
.delta. 8.14 (d, J=8 Hz, 1H), 7.94 (d, J=8 Hz, 1H), 7.5-7.4 (m,
1H), 7.4-7.3 (m, 3H), 7.12 (s 1H), 7.11 (d, J=8.2 Hz, 2H), 3.99 (s,
3H), 3.98 (s, 3H), 3.0-2.9 (m, 2H), 2.6-2.5 (m, 2H), 2.16 (s, 3H),
1.8-1.3 (m 12H).
[0188] 1-(3,4-Dimethoxy-1-naphthyl)-8-(4-aminophenyl)-octane
(37).
[0189] A solution of 554.6 mg (1.28 mmol) of
1-(3,4-dimethoxy-1-naphthyl)-- 8-(4-acetamidophenyl)-octane in 20
mL of MeOH was mixed with 21 mL of 2N HCl. The reaction mixture was
refluxed for 23 hr. Then the reaction mixture was partitioned
between 75 mL of CH.sub.2Cl.sub.2 and 21 mL of 2N NaOH. The aqueous
phase was extracted with CH.sub.2Cl.sub.2 (5.times.40 mL). The
CH.sub.2Cl.sub.2 extracts were combined, dried with MgSO.sub.4, and
evaporated to dryness. Column chromatography on silica gel with 1%
MeOH in CH.sub.2Cl.sub.2 gave 374.6 mg (75%) of aniline 37: .sup.1H
NMR (250 MHz, CDCl.sub.3, TMS) .delta. 8.14 (d, J=8 Hz, 1H), 7.94
(d, J=8 Hz, 1H), 7.47 (t, J=8 Hz, 1H), 7.37 (t, J=8 Hz, 1H), 7.12
(s, 1H), 6.96 (d, J=8 Hz, 2H), 6.62 (d, J=8 Hz, 2H), 3.99 (s, 3H),
3.97 (s, 3H), 3.1-3.0 (m, 2H), 2.5-2.4 (m, 2H), 1.8-1.3 (m
12H).
[0190] Naphthylacridine (38).
[0191] To a solution of 99 mg (2.53.times.10.sup.-4 mol) of
1-(3,4-dimethoxy-1-naphthyl)-8-(4-aminophenyl)-octane 37 and 35 mL
(2.51.times.10.sup.-4 mol) of Et.sub.3N in 4 mL of MeOH were added
54 mg (2.53.times.10.sup.-4 mol) of 9-chloroacridine. The reaction
mixture was stirred at room temperature for 20 hr. Evaporation of
solvent and column chromatography on silica gel with first 1% MeOH
in CH.sub.2Cl.sub.2 and then 3% MeOH in CH.sub.2Cl.sub.2 afforded
118.2 mg (82%) of acridine 38: .sup.1H NMR (250 MHz, CDCl.sub.3,
TMS) .delta. 8.14 (d, J=8 Hz, 1H), 8.0-7.9 (m, 5H), 7.66 (br t,
2H), 7.46 (t, J=8 Hz, 1H), 7.37 (t, J=8 Hz, 1H), 7.3-7.2 (m, 2H),
7.12 (s, 1H), 7.06 (d, J=8.4 Hz, 2H), 6.82 (d, J=8.4 Hz, 2H),
3.1-3.0 (m, 2H), 2.6-2.5 (m, 2H), 1.8-1.3 (m, 12H).
[0192] Quinone-acridine (39) (SL-11125).
[0193] To a solution of 546 mg (9.60.times.10.sup.-4 mol) of
acridine 38 in 15 mL of CH.sub.2Cl.sub.2 cooled to -68.degree. C.
was added 9.6 mL of 1M BBr.sub.3 in CH.sub.2Cl.sub.2. After 18.5 hr
at -10.degree. C., the reaction mixture was cooled to -68.degree.
C. and 10 mL of Et.sub.2O were added. After stirring at room
temperature for 30 min, 20 mL of saturated NaHCO.sub.3 solution
were added. The resulting precipitate was collected by filtration
and triturated twice with 50 mL of CH.sub.2Cl.sub.2 to give 555.9
mg of quinone 39: .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS) .delta.
9.11 (s), 8.59 (s), 8.14 (d, J=9 Hz), 8.0-7.9 (m), 7.82 (d, J=8
Hz), 7.4-7.2 (m), 6.98 (s), 2.87 (t, J=7 Hz), 2.65 (t, J=7 Hz),
1.7-1.5 (m), 1.4-1.3 (m).
[0194] N-(9-acridyl)-mesitylenesulfonamide (41).
[0195] To a suspension of 4.00 g (20.6 mmol) of 9-aminoacridine 40
in 350 mL of CHCl.sub.3 was added 2.9 mL (20.8 mmol) of Et.sub.3N
and 4.50 g (20.6 mmol) of mesitylenesulfonyl chloride. The reaction
mixture was refluxed for 72 hr. Then the reaction mixture was
filtered and the solvent was evaporated. The material was purified
by column chromatography on silica gel by eluting first with 1%
MeOH in CH.sub.2Cl.sub.2 and then with 5% MeOH in CH.sub.2Cl.sub.2
to yield 458.4 mg (6%) of sulfonamide 41 as an orange solid:
.sup.1H NMR (300 MHz, CDCl.sub.3, TMS) .delta. 9.25 (s, 1H), 8.77
(d, J=8 Hz, 2H), 7.46 (t, J=8 Hz, 2H), 7.21 (d, J=8 Hz, 2H), 7.15
(t, J=8 Hz, 2H), 7.02 (s, 2H), 2.78 (s, 6H), 2.36 (s, 3H).
[0196] N-(9-acridyl)-N-(5-bromopentyl)-mesitylenesulfonamide
(42).
[0197] A solution of 450 mg (1.20 mmol) of
N-(9-acridyl)-mesitylenesulfona- mide in 20 mL of DMF was placed
under an atmosphere of argon and cooled to 0.degree. C. To the
cooled solution was added 36 mg (1.42 mmol) of NaH (95%). The
reaction mixture was stirred at 0.degree. C. for 5 min and at room
temperature for 1 hr. Then the reaction mixture was cooled to
0.degree. C., and 1.65 mL (12.1 mmol) of 1,5-dibromopentane were
added. The reaction mixture was stirred at 70-80.degree. C. for 23
hr. The reaction mixture was cooled, and quenched with 20 mL of
water. The mixture was partitioned between CH.sub.2Cl.sub.2 and
water. The aqueous phase was washed with CH.sub.2Cl.sub.2
(2.times.20 mL). The CH.sub.2Cl.sub.2 washes were combined with the
organic phase, dried with MgSO.sub.4, and evaporated to dryness.
The material was purified by column chromatography on silica gel
with CH.sub.2Cl.sub.2 to afford 382.2 mg (60%) of bromide 42 as an
orange oil: .sup.1H NMR (300 MHz, CDCl-.sub.3, TMS) .delta. 8.25
(d, J=9 Hz, 2H), 7.94 (d, J=9 Hz, 2H), 7.76 (t, J=8 Hz, 2H), 7.45
(t, J=8 Hz, 2H), 6.87 (s, 2H), 4.0-3.9 (m, 2H), 3.27 (t, J=6.5 Hz,
2H), 2.30 (s, 3H), 2.22 (s, 6H), 1.8-1.6 (m, 4H), 1.4-1.3 (m,
2H).
[0198] Mesityl-acridine-quinone (43).
[0199] To a solution of 632.6 mg (1.20 mmol) of
N-(9-acridyl)-N(5-bromopen- tyl)-mesitylenesulfonamide 42 in 15 mL
of benzene was added 338.4 mg (1.20 mmol) of silver salt. The
reaction mixture was refluxed for 24 hr. The reaction mixture was
diluted with CH.sub.2Cl.sub.2 and filtered to remove insoluble
salts. The solvent was removed and the material was purified by
column chromatography on silica gel with Et.sub.2O to afford 333.1
mg (45%) of ortho-quinone 43 as an orange glassy solid: .sup.1H NMR
(300 MHz, CDCl.sub.3, TMS) .delta. 8.24 (d, J=9 Hz, 2H), 8.11 (d,
J=8 Hz, 1H), 7.95 (d, J=9 Hz, 2H), 7.8-7.7 (m, 3H), 7.7-7.5 (m,
2H), 7.5-7.4 (m, 2H), 6.86 (s, 2H), 5.85 (s, 1H), 4.1-4.0 (m, 4H),
2.29 (s, 3H), 2.21 (s, 6H), 1.9-1.5 (m, 4H), 1.5-1.4 (m, 2H).
[0200] Acridine-quinone (44) (SL-11059).
[0201] Under an atmosphere of argon, 151.4 mg (2.45.times.10.sup.-4
mol) of mesityl-acridine-quinone 43 was dissolved in 30 mL of 0.1 M
SmI.sub.2 in THF. Then, 2.2 mL (18.2 mmol) of DMPU were added
dropwise. The reaction mixture was refluxed for 24 hr. Filtration
to remove a precipitate and evaporation of solvent yielded an
orange oil, which was purified by column chromatography on silica
gel with 5% MeOH in CH.sub.2Cl.sub.2 to afford 48.7 mg (45%) of
acridine-quinone 44 as an orange glassy solid: .sup.1H NMR (300
MHz, DMSO-d.sub.6, TMS) .delta. 8.54 (d, J=8 Hz, 2H), 7.96 (t, J=7
Hz, 2H), 7.92 (d, J=7 Hz, 1H), 7.79 (d, J=8 Hz, 2H), 7.7-7.6 (m,
3H), 7.51 (t, J=8 Hz, 2H), 6.01 (s, 1H), 4.20 (t, J=6 Hz, 2H), 4.13
(t, J=7 Hz, 2H), 2.1-1.9 (m, 4H), 1.7-1.6 (m, 2H).
Synthesis of Quinol Phosphates
General Procedure
[0202] To a solution of 500 mg (2.05 mmol) of
4-pentyloxy-1,2-naphthoquino- ne 46 in 10 mL of benzene was added
2.3 mL (25.1 mmol) of dibenzylphosphite. The reaction mixture was
refluxed under nitrogen for 2.5 hr, after which the benzene was
removed. Column chromatography of the residue on silica gel with 1%
MeOH in CH.sub.2Cl.sub.2 afforded 729.3 mg (70%) of
aryldibenzylphosphate 47 (mixture of two regioisomers) as an orange
oil: R.sub.f=0.51, 0.66 (1% MeOH in CH.sub.2Cl.sub.2); .sup.1H NMR
(250 MHz, CDCl.sub.3, TMS) major regioisomer .delta. 8.1 (d), 8.0
(br, s), 7.8 (d), 7.4 (t), 7.3-7.1 (m), 6.50 (s), 5.3-5.0 (AB of
ABX, .delta..sub.A=5.16, .delta..sub.B=5.08, J.sub.AB=11.5 Hz,
J.sub.AX=8.3 Hz, J.sub.BX=8.8 Hz), 4.01 (t, J=6 Hz), 2.0-1.8 (m),
1.6-1.3 (m), 0.96 (t, J=7 Hz); .sup.13C NMR (52 MHz, CDCl.sub.3,
TMS) both regioisomers .delta. 153.4, 144.7, 135.6 (d, J=6.1 Hz,
minor regioisomer), 134.8 (d, J=5.5 Hz, major regioisomer),
128.7-127.7 (m), 127.2, 123.0, 122.2, 121.4, 119.8, 99.5, 71.0 (q,
J=4.8 Hz), 68.3, 28.8, 22.5.
[0203] To a solution of 1.637 g (3.23 mmol) of
aryldibenzylphosphate 47 in 40 mL of MeOH was added 150 mg of 10%
Pd/C. The reaction mixture was placed under an atmosphere of
hydrogen (balloon) and stirred at room temperature for 1 hr.
Removal of catalyst by filtration and evaporation of solvent
afforded phosphate as a brown oil. The phosphate was dissolved in 6
mL of benzene. Addition of 9 mL of hexane and cooling gave a
precipitate. The precipitate was collected by filtration, washed
with benzene/hexane=2:3, and dried, affording 797.3 mg (76%) of
arylphosphate 48 as a gray solid; R.sub.f=0.77 (MeOH); .sup.1H NMR
(250 MHz, acetone-d.sub.6, TMS) .delta. 8.13 (d, J=8 Hz, 1H), 7.96
(d, J=8 Hz, 1H), 7.49 (t, J=7 Hz, 1H), 7.32 (t, J=7 Hz, 1H), 6.59
(s, 1H), 4.13 (t, J=6 Hz, 1H), 2.0-1.8 (m, 2H), 1.6-1.3 (m, 4H),
0.96 (t, J=7 Hz, 3H); .sup.13C NMR (52 MHz, acetone-d.sub.6, TMS)
.delta. 153.3 (d, J=1.3 Hz), 145.8 (narrow t), 129.3 (d, J=3.3 Hz),
127.4, 123.2, 122.2, 121.6, 120.9, 100.0, 68.7, 29.2, 28.7, 22.7,
13.9.
[0204] Ethyl 2'-acetyl-5'-methoxyphenylacetate (50) Acetyl chloride
(21.3 mL, 300 mmol) was added to a mixture of AlCl.sub.3 (26.7 g,
200 mmol) and ethyl 3'-methoxyphenylacetate (49, 28.66 g, 147.6
mmol) in CS.sub.2 (200 mL) at 0.degree. C. The ice bath was removed
and the mixture was allowed to warm to 20.degree. C. with HCl gas
bubbling out. After stirring at 20.degree. C. for 30 min, the
mixture was refluxed for 30 min. Upon cooling down, the mixture was
added ice (200 g) and aqueous 2 N HCl (400 mL). The resulting
mixture was extracted with ethyl acetate (2.times.200 mL). The
extracts were washed with water (2.times.100 mL), dried over
MgSO.sub.4 and concentrated in vacuo. The residue was crystallized
from a mixture of ethyl acetate (20 mL) and hexanes (60 mL) to
afford 50 (30.60 g, 88%): .sup.1H NMR (CDCl.sub.3) .delta. 7.84
(1H, d, J=8.6 Hz), 6.86 (1H, dd, J=8.6, 2.6 Hz), 6.75 (1H, d, J=2.6
Hz), 4.17 (2H, q, J=7.1 Hz), 3.92 (2H, s), 3.86 (3H, s), 2.55 (3H,
s), 1.28 (3H, t, J=7.1 Hz); .sup.13C NMR (CDCl.sub.3) .delta.
199.04 (s), 171.44 (s), 162.22 (s), 137.70 (s), 132.97 (d), 129.48
(s), 118.68 (d), 111.84 (d), 60.60 (t), 55.39(q), 41.17 (t), 28.39
(q), 14.24(q).
[0205] 2-Hydroxy-7-methoxy-1,4-naphthoquinone(51).
[0206] Sodium ethoxide (10.40 g, 150 mmol) was added to a
suspension of 50 (30. 45 g, 128.90 mmol) in absolute alcohol
(200mL) at 20.degree. C. After stirring the mixture for 1 h, air
was bubbled in for 20 h. The mixture was concentrated in vacuo. The
residue was dissolved in water (500 mL), and extracted with diethyl
ether (200 mL). The ether layer was counter-extracted with water
(50 mL). The combined aqueous phase was acidified with concentrated
HCl (30 mL). The mixture was filtered to afford 51 (14.42 g, 55%):
.sup.1H NMR (DMSO-d6) .delta. 11.56 (1H, s, br), 7.89 (1H, d, J=8.5
Hz), 7.42 (1H, d, J=2.8 Hz), 7.36 (1H, dd, J=8.5, 2.8 Hz), 6.10
(1H, s), 3.92 (3H, s); .sup.13C NMR (DMSO-d6) .delta..184.07 (s),
181.20 (s), 162.92 (s), 159.16 (s), 132.35 (s), 127.82 (d), 125.16
(s), 120.02 (d), 110.85 (s), 109.94 (d), 55.90 (q).
[0207] 7- Methoxy-lapachol (52).
[0208] A mixture of K.sub.2CO.sub.3 (30 mmol) and 51 (10.21 g, 50
mmol) in HMPA (100 mL) was stirred for 30 min, when it became a
suspension. Dimethylallyl bromide (8.7 mL, 75 mmol) and KI (4.15 g,
25 mmol) were added, and stirring was continued for 20 h at
20.degree. C. The mixture was diluted with ice water (600 mL) and
concentrated HCl (30 mL), and extracted with ethyl acetate
(2.times.200 mL). Some solid was collected by filtration to afford
the first portion of 53 (0.628 g): .sup.1H NMR (CDCl.sub.3) 6 8.01
(1H, d, J=8.6 Hz), 7.56 (1H, d, J=2.7 Hz), 7.20 (1H, dd, J=8.6, 2.7
Hz), 6.09 (1H, s), 5.49 (1H, t, J=6.8 Hz), 4.57 (2H, d, J=6.8 Hz),
3.94 (3H, s), 1.81 (3H, s), 1.76 (3H, S). The ethyl acetate
extracts were pooled, extracted with saturated NaHCO.sub.3
(2.times.150 mL), and the resultant aqueous extracts were acidified
with concentrated HCl and filtered to recover 51 (2.10 g, 21%).
[0209] The main ethyl acetate extract was concentrated in vacuo.
The residue was dissolved in a mixture of 1 N NaOH (500 mL) and
diethyl ether (300 mL). After separation, the organic layer was
extracted with 1 N NaOH (100 mL) and concentrated in vacuo. The
residue was chromatographed on silica gel (10% ethyl acetate in
hexanes) to afford a second portion of 53 (3.43 g, 30% total).
[0210] The NaOH extracts were acidified by concentrated HCl (50
mL), and extracted with ethyl acetate (2.times.200 mL). The pooled
extracts were dried (MgSO.sub.4), concentrated in vacuo, and the
residue was purified by chromatography on silica gel (10% ethyl
acetate in hexanes) to afford 52 (4.39 g, 32%): .sup.1H NMR
(CDCl.sub.3) .delta. 8.05 (1H, d, J=8.6 Hz), 7.51 (1H, d, J=2.7
Hz), 7.20 (1H, dd, J=8.6, 2.7 Hz), 7.18 (OH, s), 5.20 (1H, tt,
J=6.7, 1.5 Hz), 3.93 (3H, s), 3.29 (2H, d, J=7.2 Hz), 1.79 (3H, s),
1.68 (3H, s); .sup.13C NMR (CDCl.sub.3) .delta. 183.99 (s), 181.85
(s), 163.28 (s), 152.51 (s), 133.71 (s), 131.18 (s), 129.04 (d),
126.23 (s), 123.28 (s), 120.69 (d), 119.82 (d), 109.82 (d), 55.89
(q), 25.77 (q), 22.60 (t), 17.90 (q).
[0211] 8-Methoxy-.beta.-lapachone (54) Concentrated H.sub.2SO.sub.4
(25 mL) was added to compound 52 (2.454 g) at 20.degree. C. After
stirring for 20 min, the mixture was diluted with ice water (500
mL). The resulting red precipitate 54 was collected by filtration,
washed with water, and dried in vacuo. It was obtained as a red
powder (2.36 g, 96%): .sup.1H NMR (CDCl.sub.3) .delta. 7.72 (1H, d,
J=8.6 Hz), 7.56 (1H, d, J=2.7 Hz), 7.12 (1H, dd, J=8.6, 2.7 Hz),
3.90 (3H, S), 2.55 (2H, t, J=6.7 Hz), 1.84 (2H, t, J=6.7 Hz), 1.46
(6H, S).
[0212] 8-Hydroxy-.beta.-lapachone (55) Boron tribromide (15.0 mL,
1.0 M in CH.sub.2Cl.sub.2) was added to a solution of 54 (1.05 g,
mmol) in anhydrous CH.sub.2Cl.sub.2 (40 mL) at 0.degree. C. After
stirring for 15 min, the mixture was allowed to warm to 20.degree.
C. and kept stirring for 2 h. Ice water (500 mL) was added, the
mixture was extracted with CHCl.sub.3 (3.times.100 mL), the
combined extracts were dried, and concentrated in vacuo. The
residue was treated with concentrated H.sub.2SO.sub.4 (20 mL) at
20.degree. C. The mixture was diluted with ice water (500 mL) and
extracted with CHCl.sub.3 (3.times.100 mL). The combined extracts
were reextracted with aqueous 5% NaHSO.sub.3 (3.times.150 mL). The
aqueous extracts were acidified with concentrated HCl (100 mL), and
extracted with CHCl.sub.3 (3.times.150 mL). The extracts were dried
and concentrated to afford 55 (270 mg, 27%): .sup.1H NMR
(CDCl.sub.3) .delta. 9.81 (OH, s), 7.64 (1H, d, J=8.5 Hz), 7.49
(1H, d, J=2.6 Hz), 7.06 (1H, dd, J=8.5, 2.6 Hz), 2.51 (2H, t, J=6.6
Hz), 1.84 (2H, t, J=6.6 Hz), 1.45 (6H, s); HRMS (m/z) calcd for
C.sub.15H.sub.14O.sub.4 258.0892, found 258.0885.
Preparation of 1,2-Naphthoquinone Bisulfite Adducts
[0213] General Procedure I.
[0214] The quinone was dissolved in 10% NaHSO.sub.3. After standing
for several hours at room temperature or with cooling, the
quinone-bisulfite adduct precipitated. The quinone-bisulfite was
collected by filtration and dried. The quinone-bisulfite was
stablized with addition of 300% its weight of sodium bisulfite.
[0215] General Procedure II.
[0216] The quinone is dissolved in 10% NaHSO.sub.3 in a volume of
solution such that there is no more than 300% weight excess of
NaHSO.sub.3 (relative to quinone-bisulfite). When the
quinone-bisulfite did not precipitate, it was recovered from the
solution by evaporation of the water in vacuo. This procedure gives
a quinone-bisulfite adduct with a 300% weight excess
NaHSO.sub.3.
Synthesis of Morpholino-Ser-Lys-Leu-Gln-.beta.-Ala-.beta.-Lapachone
(Scheme 13) Boc-Gln-.beta.-Ala-.beta.-Lapachone
[0217] To a solution of 1.000 g (2.437 mmol) of
.beta.-Ala-.beta.-Lapachon- e-TFA salt (SL-11006) and 600.3 mg
(2.437 mmol) of Boc-Gln in 10 mL of DMF was added 395.3 mg (2.925
mmol) of 1-hydroxybenzotriazole. The mixture was cooled in an ice
bath. Then 270 .mu.L (2.456 mmol) of N-methylmorpholine were added,
followed by 553.0 mg (2.680 mmol) of DCC. The reaction mixture was
stirred in the ice bath for 30 min and at room temperature for 6.5
hr. The reaction mixture was then diluted with CH.sub.2Cl.sub.2 and
filtered. The filtrate was washed with saturated NaHCO.sub.3 (50
mL), with 5% citric acid (3.times.50 mL), with saturated
NaHCO.sub.3 (2.times.50 mL), with saturated NaCl (50 mL), dried
with MgSO.sub.4, and evaporated to dryness. Purification by column
chromatography on silica gel with 5% MeOH in CH.sub.2Cl.sub.2
afforded 692.7 mg (51%) of peptide as an orange glassy solid:
R.sub.f=0.11 (5% MeOH in CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz,
acetone-d.sub.6, TMS) .delta. 8.00 (dd, J=7.6, 1.3 Hz, 1H), 7.9-7.7
(m, 2H), 7.64 (td, J=7.6, 1.3 Hz, 1H), 7.5-7.4 (br d, NH), 6.9 (br
s, NH), 6.2 (br s, NH), 5.2-5.1 (m, 1H), 4.1-4.0 (m, 1H), 3.5-3.4
(m, 2H), 2.7-2.5, (m, 4H), 2.3-2.2 (m, 2H), 2.0-1.8 (m, 2H), 1.53
(s, 3H), 1.51 (s, 3H), 1.39 (s, 9H); .sup.13C NMR (52 MHz,
acetone-d.sub.6, TMS) .delta. 179.8, 178.8, 175.0, 172.5, 171.6,
160.8, 156.2, 111.1, 135.6, 133.0, 131.6, 131.2, 128.7, 124.8,
80.8, 80.3, 79.2, 70.2, 54.8, 35.6, 34.7, 32.1, 28.4, 24.8, 23.2,
23.1.
[0218] Gln-.beta.-Ala-.beta.-Lapachone
[0219] To a solution of 681.9 mg (1.223 mmol) of
Boc-Gln-.beta.-Ala-.beta.- -Lapachone in 10 mL of CH.sub.2Cl.sub.2
was added 10 mL of TFA. The reaction mixture was stirred at room
temperature for 25-30 min. The solvent was removed in vacuo. Column
chromatography on silica gel with 10-20% MeOH in CH.sub.2Cl.sub.2
afforded 578.5 mg (83%) of the TFA salt as an orange glassy solid:
R.sub.f=0.55 (BuOH/H.sub.2O/AcOH=5:3:2), 0.05 (10% MeOH in
CH.sub.2Cl.sub.2), 0.24 (5% MeOH in CH.sub.2Cl.sub.2).
[0220] Boc-Leu-Gln-.beta.-Ala-.beta.-Lapachone
[0221] To a solution of 650.2 mg (1.138 mmol) of
Gln-.beta.-Ala-.beta.-Lap- achone-TFA salt and 263.0 mg (1.138
mmol) of Boc-Leu in 4.6 mL of DMF was added 184.5 mg (1.365 mmol)
of 1-hydroxybenzotriazole. The mixture was cooled in an ice bath.
Then 130 .mu.L (1.182 mmol) of N-methylmorpholine were added,
followed by 258.4 mg (1.252 mmol) of DCC. The reaction mixture was
stirred in the ice bath for 30 min and at room temperature for 6.5
hr. The reaction mixture was then diluted with CH.sub.2Cl.sub.2 and
filtered. The filtrate was washed with saturated NaHCO.sub.3 (30
mL), with 5% citric acid (4.times.30 mL), with saturated
NaHCO.sub.3 (3.times.30 mL), with saturated NaCl (30 mL), dried
with MgSO.sub.4, and evaporated to dryness. Purification by column
chromatography on silica gel with 5% MeOH in CH.sub.2Cl.sub.2
afforded 396.9 mg (51%) of peptide as a yellow-orange glassy solid:
R.sub.f=0.11 (5% MeOH in CH.sub.2Cl.sub.2), 0.45 (10% MeOH in
CH.sub.2Cl.sub.2), 0.81 (20% MeOH in CH.sub.2Cl.sub.2), 0.78
(BuOH/H.sub.2O/AcOH=5:3:2); .sup.1H NMR (250 MHz, acetone-d.sub.6,
TMS) .delta. 8.00 (d, J=7.5 Hz, 1H), 7.9-7.7 (m, 2H), 7.64 (t,
J=7.5 Hz, 1H), 7.5 (br d, NH), 6.9 (br s, NH), 6.3 (br s, NH),
5.2-5.1 (m, 1H), 4.4-4.2 (m, 1H), 4.1-4.0 (m, 1H), 3.6-3.3 (m, 2H),
2.7-2.5 (m, 4H), 2.3-2.2 (m, 2H), 2.0-1.8 (m, 2H), 1.8-1.7 (m, 1H),
1.6-1.5 (m, 2H), 1.53 (s, 3H), 1.51 (s, 3H), 1.39 (s, 9H), 1.0-0.9
(m, 6H); .sup.13C NMR (52 MHz, acetone-d.sub.6, TMS) .delta. 179.9,
179.0, 175.2, 173.4, 172.0, 171.5, 160.9, 156.8, 135.7, 133.1,
131.6, 131.2, 128.8, 124.9, 111.2, 80.9, 80.4, 79.5, 70.3, 54.5,
53.5, 41.7, 35.8, 34.8, 32.1, 28.5, 27.8, 25.4, 24.9, 23.4, 23.2,
21.9.
[0222] Leu-Gln-.beta.-Ala-.beta.-Lapachone
[0223] To a solution of 317.0 mg (4.725.times.10.sup.-4 mol) of
Boc-Leu-Gln-.beta.-Ala-.beta.-Lapachone in 4 mL of CH.sub.2Cl.sub.2
was added 4 mL of TFA. The reaction mixture was stirred at room
temperature for 25-30 min. The solvent was removed in vacuo. Column
chromatography on silica gel with 20% MeOH in CH.sub.2Cl.sub.2
afforded 277.3 mg (86%) of the TFA salt as an orange glassy solid:
R.sub.f=0.17 (10% MeOH in CH.sub.2Cl.sub.2), 0.39 (20% MeOH in
CH.sub.2Cl.sub.2), 0.74 (BuOH/H.sub.2O/AcOH=5:3:2).
[0224]
N.alpha.-Boc-Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-Lapachon-
e
[0225] To a solution of 277.3 mg (4.050.times.10.sup.-4 mol) of
Leu-Gln-.beta.-Ala-.beta.-Lapachone-TFA salt and 168.0 mg
(4.049.times.10.sup.-4 mol) of N.alpha.-Boc-Lys(N.epsilon.-Cbz) in
1.6 mL of DMF was added 65.7 mg (4.862.times.10.sup.-4 mol) of
1-hydroxybenzotriazole. The mixture was cooled in an ice bath. Then
50 .mu.L (4.548.times.10.sup.-4 mol) of N-methylmorpholine were
added, followed by 91.9 mg (4.454.times.10.sup.-4 mol) of DCC. The
reaction mixture was stirred in the ice bath for 30 min and at room
temperature for 6.5 hr. The reaction mixture was then diluted with
2 mL of CHCl.sub.3 and filtered. The filtrate was washed with
saturated NaHCO.sub.3 (20 mL), with 5% citric acid (4.times.20 mL),
with saturated NaHCO.sub.3 (3.times.20 mL), with saturated NaCl
(2.times.20 mL), dried with MgSO.sub.4, and evaporated to dryness.
Purification by column chromatography on silica gel with 10% MeOH
in CH.sub.2Cl.sub.2 afforded 167.5 mg (42%) of peptide as an orange
glassy solid: R.sub.f=0.08 (5% MeOH in CH.sub.2Cl.sub.2), 0.44 (10%
MeOH in CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS)
.delta. 8.0-7.7 (m, 6H, quinone-H5, H6, H7, H8, & NH's),
7.7-7.6 (m, NH), 7.5-7.4 (m, 2H, Cl-Cbz), 7.4-7.3 (m, 2H, Cl-Cbz),
7.20 (br s, NH), 6.73 (br s, NH), 6.90 (br d, J=7.9 Hz, NH), 5.07
(s, 3H), 4.3-4.2 (m, 1H), 4.2-4.1 (m, 1H), 3.9-3.8 (m, 1H), 3.3-3.2
(m, 2H), 3.0-2.9 (m, 2H), 2.8-2.7 (m, 2H), 2.6-2.4 (m, 2H), 2.1-2.0
(m, 2H), 1.8-1.3 (m, 11H), 1.43 (s, 3H), 1.39 (s, 3H), 1.36 (s,
9H), 0.85 (d, J=6.5 Hz, 3H), 0.81 (d, J=6.6 Hz, 3H); .sup.13C NMR
(52 MHz, DMSO-d.sub.6, TMS) .delta. 178.6, 177.8, 173.5, 173.4,
172.0, 171.7, 171.0, 170.5, 162.2, 155.7, 134.9, 134.5, 132.2,
131.4, 130.9, 129.9, 129.5, 129.2, 127.9, 127.2, 123.7, 79.7, 79.3,
78.0, 68.9, 62.4, 54.2, 52.0, 50.8, 40.7, 35.7, 33.5, 31.2, 30.7,
29.0, 28.1, 27.8, 24.1, 23.9, 23.0, 22.8, 22.7. 22.1, 21.4.
[0226] Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-Lapachone
[0227] To a suspension of 203.1 mg (2.099.times.10.sup.-4 mol) of
Boc-Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-Lapachone in 2 mL
of CHCl.sub.3 was added 1.7 mL of TFA (material dissolved). The
reaction mixture was stirred at room temperature for 20-25 min. The
solvent was removed in vacuo. Column chromatography on silica gel
with 20% MeOH in CH.sub.2Cl.sub.2 afforded 202.0 mg (98%) of the
TFA salt as an orange glassy solid: R.sub.f=0.10 (10% MeOH in
CH.sub.2Cl.sub.2), 0.40 (20% MeOH in CH.sub.2Cl.sub.2).
[0228]
Morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-L-
apachone
[0229] To a solution of 194.8 mg (1.985.times.10.sup.-4 mol) of
Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-Lapachone-TFA salt
and 61.2 mg (1.985.times.10.sup.-4 mol) of morpholino-Ser(OBn) in
1.0 mL of DMF was added 32.2 mg (2.383.times.10.sup.-4 mol) of
1-hydroxybenzotriazole. The mixture was cooled in an ice bath. Then
23 .mu.L (2.092.times.10.sup.-4 mol) of N-methylmorpholine were
added, followed by 45.1 mg (2.186.times.10.sup.-4 mol) of DCC. The
reaction mixture was stirred in the ice bath for 35 min and at room
temperature for 6 hr. The reaction mixture was then diluted with 2
mL of CH.sub.2Cl.sub.2 and filtered. The filtrate was washed with
5% citric acid (3.times.20 mL), with saturated NaHCO.sub.3
(3.times.20 mL), with saturated NaCl (20 mL), dried with
MgSO.sub.4, and evaporated to dryness. Purification by column
chromatography on silica gel with 10% MeOH in CH.sub.2Cl.sub.2
afforded 83.3 mg (36%) of peptide as an orange glassy solid:
R.sub.f=0.05 (5% MeOH in CH.sub.2Cl.sub.2), 0.41 (10% MeOH in
CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz, acetone-d.sub.6, TMS)
.delta. 8.0-7.7 (m, 7H, quinone-H5, H6, H7, H8, NH's), 7.7-7.6 (m,
NH), 7.5-7.2 (m, 10H, Cl-Cbz, OBn, NH), 6.75 (br s, NH), 6.60 (br
d, J=7.1 Hz, NH), 5.07 (s, 3H), 4.49 (s, 2H), 4.4-4.3 (m, 1H),
4.3-4.0 (m, 3H), 3.7-3.6 (m, 2H), 3.6-3.5 (m, 4H), 3.3-3.2 (m, 6H),
3.0-2.9 (m, 2H), 2.8-2.7 (m,2H), 2.5-2.4 (m, 2H), 2.1-2.0 (m, 2H),
1.8-1.3 (m, 11H), 1.43 (s, 3H), 1.38 (s, 3H), 0.82 (d, J=6.0 Hz,
3H), 0.78 (d, J=6.1 Hz, 3H).
[0230] Morpholino-Ser-Lys-Leu-Gln-.beta.-Ala-.beta.-Lapachone
(SL-11147)
[0231] To a solution of 78.3 mg (6.763.times.10.sup.-5 mol) of
morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu-Gln-.beta.-Ala-.beta.-Lapacho-
ne in 1.5 mL of MeOH/CH.sub.2Cl.sub.2=1:9 was added 30.6 mg 10%
Pd/C. Then 0.5 mL of MeOH and one drop of HCl were added. The
reaction mixture was placed under an atmosphere of H.sub.2
(balloon) and stirred at room temperature for 16 hr. Removal of
catalyst by filtration and evaporation of solvent afforded 64.5 mg
of crude quinone-tetrapeptide. The material was purified by prep
HPLC to yield 14.4 mg (24%): R.sub.f=0.04 (20% MeOH in
CH.sub.2Cl.sub.2).
[0232] N-Fmoc-Ser(OBn) T-Butyl Ester
[0233] Isobutylene was condensed into a 500 mL pressure bottle
until the volume was between 30 and 40 mL. A solution of 3.02 g
(7.23 mmol) of N-Fmoc-Ser(OBn) in 20 mL of THF was added, followed
by 2 mL of concentrated H.sub.2SO.sub.4. The bottle was securely
stoppered and shaken at room temperature for 24 hr. The reaction
mixture was poured into an ice-cold mixture of 150 mL of ethyl
acetate and 150 mL of saturated NaHCO.sub.3. The organic phase was
washed with water (3.times.50 mL) and dried with MgSO.sub.4. The
solvent was removed, and column chromatography on silica gel with
CH.sub.2Cl.sub.2 afforded 2.453 g (72%) of t-butyl ester as a
colorless oil: .sup.1H NMR (250 MHz, acetone-d.sub.6, TMS) .delta.
7.85 (d, J=7.5 Hz, 2H), 7.74 (d, J=7.3 Hz, 2H), 7.5-7.3 (m, 9H),
6.71 (br d, J=8.6 Hz, NH), 4.55 (ABq, .delta..sub.A=4.57,
.delta..sub.B=4.52, J.sub.AB=12 Hz, 2H), 4.4-4.2 (m, 4H), 3.9-3.7
(AB of ABX, .delta..sub.A=3.89, .delta..sub.B=3.75, J.sub.AB=9.5
Hz, J.sub.AX=4.6 Hz, J.sub.BX=3.6 Hz, 2H); .sup.13C NMR (52 MHz,
acetone-d.sub.6, TMS) .delta. 170.0, 156.8, 145.0, 144.9, 142.0,
129.0, 128.4, 128.3, 128.2, 127.8, 126.1, 120.7, 81.9, 73.6, 70.9,
67.3, 55.9, 47.9, 28.1.
[0234] Ser(OBn) T-Butyl Ester
[0235] To a solution of 3.049 g (6.44 mmol) of N-Fmoc-Ser(OBn)
t-butyl ester in 50 mL of CH.sub.2Cl.sub.2 was added 3 mL of
piperidine. The reaction mixture was stirred at room temperature
for 2.3 hr. Removal of solvent and column chromatography on silica
gel with 5% MeOH in CH.sub.2Cl.sub.2 yielded 1.306 g (81%) of
Ser(OBn) t-butyl ester as a colorless oil: R.sub.f=0.12 (2% MeOH in
CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz, acetone-d.sub.6, TMS)
.delta. 7.4-7.2 (m, 5H), 4.53 (Abq, .delta..sub.A=4.55,
.delta..sub.B=4.52, J.sub.AB=12 Hz, 2H), 3.7-3.6 (m, AB of ABX,
.delta..sub.A=3.68, .delta..sub.B=3.61, J.sub.AB=12 Hz,
J.sub.AX=4.9 Hz, J.sub.BX=4.4 Hz, 2H), 3.5-3.4 (m, X of ABX,
.delta..sub.X=3.45, 1H), 1.43 (s, 9H); .sup.13C NMR (52 MHz,
acetone-d.sub.6, TMS) .delta. 173.9, 139.5, 128.9, 128.2, 128.1,
80.7, 73.8, 73.5, 56.2, 28.1.
[0236] Morpholino-Ser(OBn) T-Butyl Ester
[0237] To a solution of 140.6 mg (5.59.times.10.sup.-4 mol) of
Ser(OBn) t-butyl ester in 4 mL of pyridine was added 66 .mu.L
(5.66.times.10.sup.-4 mol) of 4-morpholinecarbonyl chloride. After
stirring for 1 hr, the reaction mixture was partitioned between 75
mL of CH.sub.2Cl.sub.2 and 60 mL of water. The organic phase was
washed with saturated NaHCO.sub.3 (50 mL), with 1N HCl (2.times.50
mL), with saturated NaCl (50 mL), dried with MgSO.sub.4, and
evaporated to dryness. The crude amide was purified by column
chromatography on silica gel with ethyl acetate to yield 80.9 mg
(40%) of amide as a light orange oil: R.sub.f=0.58 (ethyl acetate),
0.60 (5% MeOH in CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz,
acetone-d.sub.6, TMS) .delta. 7.4-7.2(m, 5H), 5.8 (br d, NH), 4.53
(Abq, .delta..sub.A=4.55, .delta..sub.B=4.52, J.sub.AB=12 Hz, 2H),
4.5-4.4 (m, X of ABX, .delta..sub.X=4.47, 1H), 3.9-3.6 (m, AB of
ABX, .delta..sub.A=3.86, .delta..sub.B=3.69, J.sub.AB=9.4 Hz,
J.sub.AX4.4 Hz, J.sub.BX=3.7 Hz, 2H), 3.63-3.58 (m, 4H), 3.4-3.3
(m, 4H), 1.44 (s, 9H); .sup.13C NMR (52 MHz, acetone-d.sub.6, TMS)
.delta. 170.9, 157.9, 139.2, 129.0, 128.3, 128.2, 81.5, 73.5, 71.3,
67.0, 55.5, 44.9, 28.1.
[0238] Morpholino-Ser(OBn)
[0239] A solution of 80 mg (2.195.times.10.sup.-4 mol) of
morpholino-Ser(OBn) t-butyl ester in a mixture of 1.5 mL of
CH.sub.2Cl.sub.2 and 1.5 mL of TFA was stirred at room temperature
for 30 min. The solvent was removed in vacuo and the remaining TFA
was removed by repeated evaporation with acetone. The residue was
triturated with Et.sub.2O. The material was then filtered, washed
with Et.sub.2O, washed with 0.5 mL acetone, washed again with
Et.sub.2O, and dried to yield 41.8 mg (62%) of amino acid as an
off-white solid: R.sub.f=0.72 (BuOH/H.sub.2O/AcOH=5:3:2); .sup.1H
NMR (250 MHz, acetone-d.sub.6, TMS) .delta. 7.4-7.3 (m, 5H),
6.0-5.9 (br d, NH), 4.6-4.5 (m, 3H, OCH.sub.2Ph & X of ABX),
3.95-3.75 (m, AB of ABX, .delta..sub.A=3.90, .delta..sub.B=3.73,
J.sub.AB=9.6 Hz, J.sub.AX=4.9 Hz, J.sub.BX=3.9 Hz, 2H), 3.6-3.5 (m,
4H), 3.4-3.3 (m, 4H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS) d
172.4, 157.2, 138.2, 128.2, 127.4, 127.4, 72.0, 69.5, 65.9, 53.8,
43.9.
Synthesis of Morpholino-Ser-Lys-Leu-Gln-Leu-.beta.-Lapachone
(Scheme 14)
[0240] Boc-Leu-.beta.-Lapachone
[0241] A solution of 2.820 g (12.20 mmol) of Boc-Leu and 1.976 g
(12.19 mmol) of 1,1-carbonyldiimidazole in 33 mL of DMF was stirred
at room temperature for 20 min. To the solution was added 2.100 g
(8.130 mmol) of 3-hydroxy-.beta.-lapachone followed by 1.6 mL
(10.70 mmol) of DBU. After stirring at room temperature for 5 hr,
the reaction mixture was partitioned between 200 mL of water and
200 mL of CHCl.sub.3. The aqueous phase was washed with CHCl.sub.3
(4.times.50 mL). The CHCl.sub.3 extracts were combined, dried with
MgSO.sub.4, and evaporated to dryness. Column chromatography on
silica gel with 2% MeOH in CH.sub.2Cl.sub.2 afforded 2.038 g (53%)
of quinone as an orange glassy solid (and mixture of two
diastereomers): R.sub.f=0.45 (5% MeOH in CH.sub.2Cl.sub.2); .sup.1H
NMR (250 MHz, acetone-d.sub.6, TMS) .delta. 8.1-8.0 (m, 1H),
8.0-7.9 (m, 1H), 7.9-7.8 (m, 1H), 7.7-7.6 (m, 1H), 6.34 (br d, NH),
5.2-5.1 (m, 1H), 4.2-4.1 (m, 1H), 2.9-2.8 (m, 1H), 2.7-2.5 (m, 1H),
1.8-1.6 (m, 3H), 1.56 (s, 1.5H), 1.53 (s, 3H), 1.52 (s, 1.5H), 1.34
(s, 4.5H), 1.33 (s, 4.5H), 0.91 (d, J=7.0 Hz, 1.5H), 0.88 (d, J=6.7
Hz, 1.5H), 0.84 (d, J=6.3 Hz, 1.5H), 0.82 (d, J=6.1 Hz, 1.5H).
[0242] Leu-.beta.-Lapachone
[0243] To a solution of 2.017 mg (4.277 mmol) of
Boc-Leu-.beta.-Lapachone in 20 mL of CH.sub.2Cl.sub.2 was added 20
mL of TFA. The reaction mixture was stirred at room temperature for
30 min. The solvent was removed in vacuo. Column chromatography on
silica gel with 20% MeOH in CH.sub.2Cl.sub.2 afforded 2.507 g
(quant.) of the TFA salt as an orange glassy solid: R.sub.f=0.52
(10% MeOH in CH.sub.2Cl.sub.2), 0.82 (20% MeOH in
CH.sub.2Cl.sub.2); .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS) .delta.
8.6-8.5 (br s, NH), 8.0-7.9 (m, 1H), 7.9-7.8 (m, 2H), 7.7-7.6 (m,
1H), 5.3-5.2 (m, 1H), 4.1-4.0 (m, 1H), 2.8-2.5 (m, 2H), 1.8-1.5 (m,
3H), 1.52 (s, 1.5H), 1.49 (s, 1.5H), 1.43 (s, 3H), 0.83 (d, J=6.0
Hz, 3H), 0.66 (br t, 3H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS)
.delta. 178.7, 177.8, 169.2, 169.1, 160.0, 159.7, 135.1, 135.1,
131.5, 131.4, 131.1, 131.0, 129.8, 129.8, 127.9, 123.9, 123.8,
109.6, 109.3, 79.4, 79.1, 71.1, 70.9, 50.6, 50.4, 39.0, 24.0, 23.9,
22.9, 22.3, 22.1, 22.0, 21.8, 21.7, 21.1.
[0244] Boc-Gln-Leu-.beta.-Lapachone
[0245] To a solution of 2.235 g (3.895 mmol) of Leu-p-Lapachone-TFA
salt and 959.1 mg (3.894 mmol) of Boc-Gln in 15.6 mL of DMF was
added 631.4 mg (4.673 mmol) of 1-hydroxybenzotriazole. The mixture
was cooled in an ice bath. Then 760 .mu.L (6.912 mmol) of
N-methylmorpholine were added, followed by 883.9 mg (4.284 mmol) of
DCC. The reaction mixture was stirred in the ice bath for 30 min
and at room temperature for 5.8 hr. The reaction mixture was then
diluted with 8 mL of CH.sub.2Cl.sub.2 and filtered. The filtrate
was washed with 5% citric acid (3.times.50 mL), with saturated
NaHCO.sub.3 (3.times.50 mL), with saturated NaCl (50 mL), dried
with MgSO.sub.4, and evaporated to dryness. Purification by column
chromatography on silica gel with 5% MeOH in CH.sub.2Cl.sub.2
afforded 1.555 g (66%) of peptide as an orange glassy solid:
R.sub.f=0.19 (5% MeOH in CH.sub.2Cl.sub.2), 0.09 (5% MeOH in
CHCl.sub.3), 0.37 (10% MeOH in CHCl.sub.3); .sup.1H NMR (250 MHz,
DMSO-d.sub.6, TMS) .delta. 8.24 (br d, J=7 Hz, NH), 8.17 (br d, J=7
Hz, NH), 8.0-7.9 (m, 1H), 7.8-7.7 (m, 2H), 7.7-7.6 (m, 1H), 7.22
(br s, NH), 6.83 (br d, J=8 Hz, NH), 6.76 (br s, NH), 5.1-5.0 (m,
1H), 4.3-4.1 (m, 1H), 3.9-3.8 (m, 1H), 2.8-2.6 (m, 1H), 2.6-2.4 (m,
1H), 2.1-2.0 (m, 2H), 1.8-1.4 (m, 5H), 1.47 (s, 1.5H), 1.43 (s,
1.5H), 1.42 (s, 1.5H), 1.40 (s, 1.5H), 1.36 (s, 9H), 0.86 (d, J=6.3
Hz, 1.5H), 0.79 (d, J=6.2 Hz, 1.5H), 0.73 (br t, 3H); .sup.13C NMR
(52 MHz, DMSO-d.sub.6, TMS) .delta. 178.7, 177.8, 177.7, 173.7,
172.0, 171.7, 171.5, 159.9, 159.7, 155.1, 135.1, 135.0, 131.5,
131.4, 131.0, 130.9, 129.8, 129.7, 127.9, 127.8, 123.8, 109.8,
109.6, 79.5, 79.3, 77.9, 69.6, 69.4, 53.7, 53.6, 50.5, 50.4, 31.4,
28.1, 27.6, 27.4, 24.2, 24.1, 24.0, 22.6, 22.5, 22.1, 21.9, 21.6,
21.2.
[0246] Gln-Leu-.beta.-Lapachone
[0247] To a solution of 1.519 g (2.533 mmol) of
Boc-Gln-Leu-.beta.-Lapacho- ne in 12 mL of CH.sub.2Cl.sub.2 was
added 11 mL of TFA. The reaction mixture was stirred at room
temperature for 30 min. The solvent was removed in vacuo. Column
chromatography on silica gel with 20% MeOH in CH.sub.2Cl.sub.2
afforded 1.976 mg (quant) of the TFA salt as an orange glassy
solid; .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS) .delta. 8.97 (br d,
J=6.5 Hz, NH), 8.90 (br d, J=7.0 Hz, NH), 8.30 (br s, NH), 8.0-7.9
(m, 1H), 7.9-7.8 (m, 2H), 7.7-7.6 (m, 1H), 7.45 (br s, NH), 6.98
(br s, NH), 5.2-5.1 (m, 1H), 4.3-4.2 (m, 1H), 3.9-3.8 (m, 1H),
2.8-2.7 (m, 1H), 2.5-2.4 (m, 1H), 2.2-2.1 (m, 2H), 2.0-1.8 (m, 2H),
1.7-1.5 (m, 3H), 1.49 (s, 1.5H), 1.44 (s, 1.5H), 1.42 (s, 1.5H),
1.41 (s, 1.5H), 0.87 (d, J=6.3 Hz, 1.5H), 0.81 (d, J=6.3 Hz, 1.5H),
0.75 (d, J=5.8 Hz, 1.5H), 0.73 (d, J=5.8 Hz, 1.5H); .sup.13C NMR
(52 MHz, DMSO-d.sub.6, TMS) .delta. 178.7, 177.8, 177.8, 173.5,
171.3, 171.1, 168.7, 168.7, 159.9, 159.8, 135.1, 131.5, 131.4,
131.1, 131.0, 129.9, 129.8, 128.0, 123.8, 109.7, 109.5, 79.5, 79.3,
69.9, 69.8, 51.7, 51.6, 50.8, 50.8, 30.3, 26.8, 24.2, 24.1, 22.7,
22.5. 22.2, 22.0, 21.9, 21.6, 21.2.
[0248] Boc-Leu-Gln-Leu-.beta.-Lapachone
[0249] To a solution of 1.949 g (max 2.533 mmol) of
Gln-Leu-.beta.-Lapachone-TFA salt and 585.7 mg (2.533 mrnmol) of
Boc-Leu in 10 mL of DMF was added 410.6 mg (3.038 mmol) of
1-hydroxybenzotriazole. The mixture was cooled in an ice bath. Then
685 .mu.L (6.230 mmol) of N-methylmorpholine were added, followed
by 574.7 mg (2.785 mmol) of DCC. The reaction mixture was stirred
in the ice bath for 30 min and at room temperature for 5.5 hr. The
reaction mixture was then diluted with CHCl.sub.3 and filtered. The
filtrate was washed with 5% citric acid (5.times.50 mL), with
saturated NaHCO.sub.3 (4.times.70 mL), with saturated NaCl (70 mL),
dried with MgSO.sub.4, and evaporated to dryness. Purification by
column chromatography on silica gel with 5% MeOH in CHCl.sub.3
afforded 1.221 g (68%, from Boc-Gln-Leu-.beta.-Lapachone) of
peptide as an orange glassy solid: R.sub.f=0.09 (5% MeOH in
CHCl.sub.3), 0.29 (7% MeOH in CHCl.sub.3); .sup.1H NMR (250 MHz,
DMSO-d.sub.6, TMS) .delta. 8.36 (br d, NH), 8.30 (br d, NH),
8.0-7.9 (m, 1H), 7.9-7.7 (m, 2H), 7.7-7.6 (m, 1H), 7.19 (br s, NH),
6.90 (br s, NH), 6.75 (br d, NH), 5.1-5.0 (m, 1H), 4.3-4.1 (m, 2H),
4.0-3.9 (m, 1H), 2.8-2.7 (m, 1H), 2.5-2.4 (m, 1H), 2.1-2.0 (m, 2H),
1.8-1.4 (m, 8H), 1.47 (s, 1.5H), 1.43 (s, 1.5H), 1.41 (s, 1.5H),
1.40 (s, 1.5H), 1.37 (s, 4.5H) 1.35 (s, 4.5H), 0.9-0.8 (m, 7.5H),
0.78 (d, J=6.2 Hz, 1.5H), 0.73 (d, J=5.5 Hz, 1.5H), 0.71 (d, J=5.3
Hz, 1.5H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS) .delta. 178.7,
177.8, 177.7, 173.6, 173.6, 172.3, 171.5, 171.4, 171.3, 159.9,
159.7, 155.2, 135.0, 131.5, 131.4, 131.0, 130.9, 129.8, 129.8,
127.9, 127.9, 123.8, 109.7, 109.6, 79.5, 79.3, 78.0, 69.6, 69.5,
52.8, 51.4, 50.5, 50.5, 40.7, 31.2, 28.1, 24.2, 24.1, 22.9, 22.6,
22.5, 22.1, 22.0, 21.9, 21.6, 21.4, 21.2.
[0250] Leu-Gln-Leu-.beta.-Lapachone
[0251] To a solution of 1.196 g (1.678 mmol) of
Boc-Leu-Gln-Leu-.beta.-Lap- achone in 8 mL of CH.sub.2Cl.sub.2 was
added 8 mL of TFA. The reaction mixture was stirred at room
temperature for 30 min. The solvent was removed in vacuo. Column
chromatography on silica gel with 20% MeOH in CHCl.sub.3 afforded
1.430 g (quant) of the TFA salt as an orange glassy solid:
R.sub.f=0.04 (10% MeOH in CHCl.sub.3), 0.10 (15% MeOH in
CHCl.sub.3), 0.19 (20% MeOH in CHCl.sub.3). ; .sup.1H NMR (250 MHz,
DMSO-d.sub.6, TMS) .delta. 8.46 (br d, J=6.6 Hz, NH), 8.41 (br d,
J=7.2 Hz, NH), 8.0-7.9 (m, lH), 7.9-7.8 (m, 2H), 7.7-7.6 (m, 1H),
7.26 (br s, NH), 6.77 (br s, NH), 5.1-5.0 (m, 1H), 4.3-4.1 (m, 2H),
3.5-3.4 (m, 1H), 2.8-2.7 (m, 1H), 2.5-2.4 (m, 1H), 2.1-2.0 (m, 2H),
1.9-1.4 (m, 8H), 1.47 (s, 1.5H), 1.43 (s, 1.5H), 1.41 (s, 1.5H),
1.40 (s, 1.5H), 0.9-0.8 (m, 7.5H), 0.78 (d, J=6.1 Hz, 1.5H), 0.74
(d, J=5.9 Hz, 1.5H), 0.72 (d, J=5.5 Hz, 1.5H); .sup.13C NMR (52
MHz, DMSO-d.sub.6, TMS) .delta. 178.7, 177.8, 177.8, 173.6, 171.6,
171.4, 171.2, 159.9, 159.8, 135.1, 131.5, 131.4, 131.1, 131.0,
129.9, 129.8, 127.9, 123.9, 109.8, 109.6, 79.6, 79.3, 69.6, 69.5,
51.9-51.6, 51.6, 50.5, 42.3-41.8, 31.2, 28.2, 28.0, 24.2, 24.1,
23.7, 22.8, 22.7, 22.6, 22.1, 21.9, 21.8, 21.6, 21.3, 21.2.
[0252]
Na-Boc-Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Leu-.beta.-Lapachone
[0253] To a solution of 1.400 g (max 1.643 mmol) of
Leu-Gln-Leu-.beta.-Lapachone-TFA salt and 681.6 mg (1.643 mmol) of
Noc-Boc-Lys(N.epsilon.-Cl-Cbz) in 6.6 mL of DMF was added 266.3 mg
(1.971 mmol) of 1-hydroxybenzotriazole. The mixture was cooled in
an ice bath. Then 380 .mu.L (3.456 mmol) of N-methylmorpholine were
added, followed by 372.9 mg (1.807 mmol) of DCC. The reaction
mixture was stirred in the ice bath for 30 min and at room
temperature for 5.5 hr. The reaction mixture was then diluted with
CHCl.sub.3 and filtered. The filtrate was washed with 5% citric
acid (4.times.50 mL), with saturated NaHCO.sub.3 (4.times.50 mL),
with saturated NaCl (65 mL), dried with MgSO.sub.4, and evaporated
to dryness. Purification by column chromatography on silica gel
with 5% MeOH in CHCl.sub.3 afforded 897.4 mg (54%) of peptide as an
orange glassy solid: R.sub.f=0.10 (5% MeOH in CHCl.sub.3); .sup.1H
NMR (250 MHz, DMSO-d.sub.6, TMS) .delta. 8.31 (br d, J=7 Hz, NH),
8.25 (br d, J=7 Hz, NH), 8.0-7.9 (m, 2H (1 quinone-H+1 NH)),
7.8-7.7 (m, 3H (2 quinone-H+1 NH)), 7.7-7.6 (m, 1H (quinone-H)),
7.5-7.4 (m, 2H), 7.4-7.3 (m, 3H (2 Cl-Ph-H+1 NH)), 7.19 (br s, NH),
6.90 (br d, J=8 Hz, NH), 6.77 (br s, NH), 5.1-5.0 (m, 4H), 4.3-4.1
(m, 3H), 3.9-3.8 (m, 1H), 3.0-2.9 (m, 2H), 2.8-2.7 (m, 1H), 2.5-2.4
(m, 1H), 2.1-2.0 (m, 2H), 1.9-1.4 (m, 14H), 1.47 (s, 1.5H), 1.42
(s, 1.5H), 1.41 (s, 1.5H), 1.40 (s, 1.5H), 1.37 (s, 9H), 0.9-0.8
(m, 7.5H), 0.77 (d, J=6.2 Hz, 1.5H), 0.73 (d, J=5.7 Hz, 1.5H), 0.70
(d, J=5.6 Hz, 1.5H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS)
.delta. 178.7, 177.8, 177.7, 173.6, 171.8, 171.6, 171.4, 171.3,
159.9, 159.7, 155.7, 155.3, 135.0, 134.5, 132.2, 131.5, 131.4,
131.0, 130.9, 129.8, 129.8, 129.5, 129.1, 127.9, 127.8, 127.2,
123.8, 109.7, 109.6, 79.5, 79.3, 78.0, 69.6, 69.5, 62.4, 54.3,
51.6, 50.7, 50.5, 50.4, 41.0, 40.1, 31.3, 29.0, 28.1, 27.9, 27.7,
24.2, 24.1, 24.0, 23.9, 23.0, 22.7, 22.6, 22.5, 22.1, 22.0, 21.9,
21.6, 21.5, 21.2.
[0254] Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Leu-.beta.-Lapachone
[0255] To a solution of 1.196 g (1.678 mmol) of
Boc-Lys(N.epsilon.-Cl-Cbz)- -Leu-Gln-Leu-.beta.-Lapachone in 6 mL
of CH.sub.2Cl.sub.2 was added 5 mL of TFA. The reaction mixture was
stirred at room temperature for 30 min. The solvent was removed in
vacuo. Column chromatography on silica gel with 15% MeOH in
CHCl.sub.3 afforded 568.9 mg (65%) of the TFA salt as an orange
glassy solid: R.sub.f=0.09 (10% MeOH in CHCl.sub.3), 0.23 (15% MeOH
in CHCl.sub.3), 0.38 (20% MeOH in CHCl.sub.3).; .sup.1H NMR (250
MHz, DMSO-d.sub.6, TMS) .delta. 8.28 (br d, J=7 Hz, NH), 8.23 (br
d, J=7 Hz, NH), 8.1-8.0 (m, NH), 8.0-7.9 (m, 2H (1 quinone-H+1
NH)), 7.8-7.7 (m, 2H), 7.7-7.6 (m, 1H), 7.5-7.4 (m, 2H), 7.4-7.3
(m, 3H (2 Cl-Ph-H+1NH)), 7.23 (br s, NH), 6.78 (br s, NH), 5.1-5.0
(m, 4H), 4.3-4.1 (m, 4H), 3.0-2.9 (m, 2H), 2.8-2.7 (m, 1H), 2.5-2.4
(m, 1H), 2.1-2.0 (m, 2H), 1.9-1.4 (m, 14H), 1.47 (s, 1.5H), 1.42
(s, 1.5H), 1.41 (s, 1.5H), 1.39 (s, 1.5H), 0.9-0.8 (m, 7.5H), 0.77
(d, J=6.2 Hz, 1.5H), 0.73 (d, J=5.8 Hz, 1.5H), 0.71 (d, J=5.6 Hz,
1.5H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS) .delta. 178.7,
177.8, 177.7, 173.7, 171.8, 171.6, 171.4, 171.3, 159.9, 159.7,
155.7, 135.0, 134.6, 132.2, 131.5, 131.4, 131.0, 130.9, 129.9,
129.8, 129.5, 129.2, 127.9, 127.8, 127.2, 123.8, 109.7, 109.6,
79.5, 79.3, 69.6, 69.4, 62.4, 54.4, 51.7, 50.6, 50.5, 50.4, 41.1,
31.2, 29.2, 27.6, 27.5, 24.2, 24.2, 24.1, 23.0, 22.6, 22.5, 22.4,
22.0, 21.9, 21.6, 21.2.
[0256]
Morpholino-Ser(OBn)-Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Leu-.beta.-Lapac-
hone
[0257] To a solution of 544.9 mg (5.323.times.10.sup.-4 mol) of
Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Leu-.beta.-Lapachone-TFA salt and
164.2 mg 5.325.times.10.sup.-4 mol) of morpholino-Ser(OBn) in 2.15
mL of DMF was added 86.2 mg (6.379.times.10.sup.-4 mol) of
1-hydroxybenzotriazole. The mixture was cooled in an ice bath. Then
59 .mu.L (5.366.times.10.sup.-4 mol) of N-methylmorpholine were
added, followed by 120.7 mg (5.850.times.10.sup.-4 mol) of DCC. The
reaction mixture was stirred in the ice bath for 30 min and at room
temperature for 5.5 hr. The reaction mixture was then diluted with
CHCl.sub.3 and filtered. The filtrate was washed with 5% citric
acid (4.times.30 mL), with saturated NaHCO.sub.3 (4.times.30 mL),
with saturated NaCl (30 mL), dried with MgSO.sub.4, and evaporated
to dryness. Purification by column chromatography on silica gel
with 7% MeOH in CHCl.sub.3 afforded 515.8 mg (81%) of peptide as an
orange glassy solid: R.sub.f=0.17 (7% MeOH in CHCl.sub.3), 0.36
(10% MeOH in CHCl.sub.3); .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS)
.delta. 8.22 (br d, J=7 Hz, NH), 8.18 (br d, J=7 Hz, NH), 8.0-7.9
(m, 2H (1 quinone-H+1 NH)), 7.9-7.7 (m, 3H (2 quinone-H+1 NH)),
7.7-7.6 (m, 1H), 7.5-7.4 (m, 2H), 7.4-7.2 (m, 8H (2 Cl-Ph-H+5
Ph-H+1 NH)), 7.20 (br s, NH), 6.78 (br s, NH), 6.60 (br d, J=7 Hz,
NH), 5.1-5.0 (m, 4H), 4.50 (s, 2H), 4.4-4.3 (m, 1H), 4.3-4.1 (m,
4H), 3.7-3.6 (m, 2H), 3.6-3.5 (m, 4H), 3.3-3.2 (m, 4H), 3.0-2.9 (m,
2H), 2.8-2.6 (m, 1H), 2.5-2.4 (m, 1H), 2.1-2.0 (m, 2H), 1.9-1.4 (m,
14H), 1.46 (s, 1.5H), 1.42 (s, 1.5 H), 1.41 (s, 1.5H), 1.39 (s,
1.5H), 0.9-0.7 (m, 9H), 0.72 (d, J=5.4 Hz, 1.5H), 0.70 (d, J=5.3
Hz, 1.5H); .sup.13C NMR (52 MHz, DMSO-d.sub.6, TMS) .delta. 178.7,
177.8, 177.7, 173.6, 171.6, 171.5, 171.4, 171.3, 171.3, 170.8,
170.8, 159.9, 159.7, 157.3, 155.7, 138.2, 135.0, 134.5, 132.2,
131.5, 131.4, 131.0, 130.9, 129.9, 129.8, 129.5, 129.1, 128.1,
127.9, 127.8, 127.4, 127.3, 127.2, 123.8, 109.8, 109.6, 79.5, 79.3,
71.9, 69.6, 69.5, 65.8, 62.4, 54.6, 52.7, 51.7, 51.0, 50.5, 50.4,
43.9, 31.3, 31.3, 29.0, 27.8, 27.7, 24.2, 24.2, 24.1, 24.0, 22.9,
22.5, 22.5, 22.0, 21.8, 21.6, 21.4, 21.2.
[0258] Morpholino-Ser-Lys-Leu-Gln-Leu-.beta.-Lapachone
(SL-11154)
[0259] To a solution of 486.8 mg (4.057.times.10.sup.-4 mol) of
morpholino-Ser(OBn)-Lys(N.epsilon.-Cl-Cbz)-Leu-Gln-Leu-.beta.-Lapachone
in 9 mL of MeOH/CHCl.sub.3=1:9 was added 180.5 mg 10% Pd/C. Then
two drops of HCl were added. The reaction mixture was placed under
an atmosphere of H.sub.2 (balloon) and stirred at room temperature
for 15.5 hr. Removal of catalyst by filtration and evaporation of
solvent afforded a light brown solid. The material was dissolved in
12 mL of MeOH/CHCl.sub.3=1:9, and stirred at room temperature for 1
hr while bubbling air through the solution. Evaporation of solvent
afforded an orange glassy solid. Column chromatography on silica
gel with 20-30% MeOH in CHCl.sub.3 yielded 52.8 mg (14%) of
material as an orange solid. The material was further purified by
prep HPLC: R.sub.f=0.06 (20% MeOH in CHCl.sub.3).
Synthesis of
Morpholine-Ser-Lys-Leu-Gln-NHCH.sub.2CH.sub.2O-.beta.-Lapacho- ne
(Sl-11173)
[0260] (see FIG. 15)
[0261] 8-(N-Boc-(2-Aminoethoxy))-.beta.-Lapachone
[0262] To a solution of 507.1 mg (2.263 mmol) of
N-boc-2-bromethylamine and 562.3 mg (2.177 mmol) of
8-hydroxy-.beta.-Lapachone in 18 mL of DMF was added 727 mg (4.786
mmol) of CsF, followed by 2.2 mL of a solution of 1M TBAF in THF.
The reaction mixture was stirred under N.sub.2 at room temperature
for 48 hr. Then the reaction mixture was partitioned between 100 mL
of CHC 13 and 75 mL of water plus 10 mL of 5% citric acid. The
aqueous phase was extracted with CHCl.sub.3 (5.times.40 mL). The
CHCl.sub.3 extracts were combined, dried with MgSO.sub.4, and
evaporated. Column chromotography on silica gel with 5% MeOH in
CHCl.sub.3 afforded 305.8 mg (35%) of quinone as a red-orange
glassy solid; R.sub.f=0.49(5% MeOH in CHCl.sub.3); .sup.1H NMR (250
MHz, DMSO-d.sub.6, TMS) .delta. 7.68 (d, J=8.6 Hz, 1H), 7.35 (d,
J=2.7 Hz, 1H), 7.28 (dd, J=8.6, 2.7 Hz, 1H), 7.05 (br t, NH), 4.08
(t, J=5.6 Hz, 2H), 3.4-3.3 (m, 2H), 2.37 (t, J=6.5 Hz, 2H), 1.81
(t, J=6.5 Hz, 2H), 1.41 (s, 6H), 1.39 (s, 9H), .sup.13C NMR (52
MHz, DMSO-d.sub.6, TMS) .delta. 179.0, 177.8, 161.3, 160.3, 131.4,
125.6, 124.7, 120.5, 113.3, 110.3, 78.9, 77.8, 67.0, 30.8, 28.1,
26.2, 15.7.
[0263] 8-(2-Aminoethoxy)-.beta.-Lapachone (SL-11168)
[0264] To a solution of 219.8 mg (5.474.times.10.sup.-4 mol) of
8-(N-Boc-(2aminoethyoxy))-.beta.-lapachone in 6 mL of CHCl.sub.3
was added 6 mL of TFA. The reaction mixture was stirred at room
temperature for 20 min. The solvent was removed in vacuo. Column
chromatography on silica gel with 20% MeOH in CHCl.sub.3 afforded
210.7 mg (93%) of quinone (as the trifluoroacetate salt) as a red
glassy solid: R.sub.f=0.13 (10% MeOH in CHCl.sub.3); .sup.1H NMR
(250 MHz, DMSO-d.sub.6, TMS) .delta. 8.1-8.0 (v br s, NH), 7.74 (d,
J=8.6 Hz, 1H), 7.45 (d, J=2.6 Hz, 1H), 7.34 (dd, J=8.6, 2.6 Hz,
1H), 4.4-4.2 (m, 2H), 3.3-3.2 (m, 2H), 2.38 (t, 6.5 Hz, 2H), 1.82
(t, J=6.5 Hz, 2H), 1.42 (s, 6H).
[0265]
Morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu-Gln-NHCH.sub.2CH.sub.2O-
-.beta.-Lapachone
[0266] To a solution of 210.7 mg (5.072.times.10.sup.-4 mol) of
NH.sub.2CH.sub.2CH.sub.2O-.beta.-lapachone-TFA salt and 411.9 mg
(5.072.times.10.sup.4 mol) of
morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu- -Gln in 2.25 mL of DMF
was added 82.4 mg (6.098.times.10.sup.-4 mol) of
1-hydroxybenzotriazole. The mixture was cooled in an ice bath. Then
56 .mu.L (5.093.times.10.sup.-4 mol) of N-methylmorpholine were
added, followed by 115.1 mg (5.578.times.10.sup.-4 mol) of DCC. The
reaction mixture was stirred in the ice bath for 45 min and at room
temperature for 5 hr. The reaction mixture was then filtered and
the filtrate diluted with CHCl.sub.3. The filtrate was washed with
5% citric acid (4.times.30 mL), with saturated NaHCO.sub.3
(3.times.40 mL), with saturated NaCl (40 mL), dried with
MgSO.sub.4, and evaporated to dryness. Purification by column
chromatography on silica gel with 5% MeOH in CHCl.sub.3 afforded
139.6 mg (25%) of peptide as a red-orange glassy solid:
R.sub.f=0.07 (5% MeOH in CHCl.sub.3); 0.33 (10% MeOH in
CHCl.sub.3); .sup.1H NMR (250 MHz, DMSO-d.sub.6, TMS) .delta. 8.00
(br d, J=6 Hz, NH), 7.85 (br d, J=8 Hz, NH), 7.82 (br d, J=7 Hz,
NH), 7.68 (d, J=8.6 Hz, 1H (quinone)), 7.4-7.2 (m, 12H (2 quinone
+10 Ph)), 7.2-7.1 (m, NH), 6.75 (br s, NH), 6.60 (br d, J=7 Hz,
NH), 4.99 (s, 2H), 4.48 (s, 2H), 4.4-4.3 (m, 1H), 4.3-4.0 (m, 5H),
3.7-3.6 (m, 2H), 3.6-3.4 (m, 6H), 3.35-3.25 (m, 4H), 3.0-2.9 (m,
2H), 2.4-2.3 (m, 2H), 2.1-2.0 (m, 2H), 1.9-1.4 (m, 13H), 1.40 (s,
6H), 0.81 (d, J=6.4 Hz, 3H), 0.77 (d, J=6.3 Hz, 3H).
[0267]
Morpholino-Ser-Lys-Leu-Gln-NHCH.sub.2CH.sub.2O-.beta.-Lapachone
[0268] To a solution of 133.1 mg (1.215.times.10.sup.-4 mol) of
morpholino-Ser(OBn)-Lys(N.epsilon.-Cbz)-Leu-Gln-NHCH.sub.2CH.sub.2O-.beta-
.-lapachone in 45 mL MeOH plus 5 mL CHCl.sub.3 was added 57.9 mg of
10% Pd/C. Then two drops of HCl were added. The reaction mixture
was placed under an atmosphere of H.sub.2 (balloon) and stirred at
room temperature for 23 hr. Removal of catalyst by filtration and
evaporation of solvent afforded a reddish-brown solid. The material
was dissolved in 20 mL of MeOH and stirred at room temperature for
21 hr while bubbling air through the solution. Evaporation of
solvent afforded 107.0 mg of a dark red glassy solid. The material
was purified by prep HPLC to yield 55.1 mg (52%).
[0269] Synthesis of Morpholino-Ser-Lys-Leu-Gln-PABC-DOX (see FIG.
16)
[0270] Morpholino-Ser(OAloc) was prepared from Ser(OtBu)-OtBu.
Reaction of Ser(OtBu)-OtBu with 4-morpholinecarbonyl chloride in
pyridine yielded morpholino-Ser(OtBu)-OtBu.
Morpholino-Ser(OtBu)-OtBu was hydrolyzed with TFA to yield
morpholino-Ser. Esterification of morpholino-Ser with isobutylene
in the presence of a catalytic amount of H.sub.2SO.sub.4 afforded
morpholino-Ser-OtBu. Reaction of morpholino-Ser-OtBu with allyl
1-benzotriazolyl carbonate yielded morpholino-Ser(OAloc)-OtBu.
Morpholino-Ser(OAloc)-OtBu was hydrolyzed with TFA in CHCl.sub.3
(1:1) to yield morpholino-Ser(OAloc).
[0271] Preparation of the tetrapeptide was accomplished using
standard procedures. Fmoc-Leu was coupled to Gln-OtBu with DCC in
the presence of 1-hydroxybenzotriazole (HOBt) to give
Fmoc-Leu-Gln-OtBu. Removal of the Fmoc group from Fmoc-Leu-Gln-OtBu
with piperidine in CH.sub.2Cl.sub.2/DMF produced Leu-Gln-OtBu.
Fmoc-Lys(N.epsilon.-Aloc) was coupled to Leu-Gln-OtBu with DCC in
the presence of HOBt to give
Fmoc-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Removal of the MFmoc group
from Fmoc-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with piperidine in DMF
produced Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Morpholino-Ser(OAloc)
was coupled to Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with DCC in the
presence of HOBt to give
morpholino-Ser(OAloc)-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Hydrolysis
of morpholino-Ser(OAloc)-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with TFA
in CHCl.sub.3 (1:1) would give the tetrapeptide
morpholino-Ser(OAloc)-Lys(N.- epsilon.-Aloc)-Leu-Gln-OH. The
tetrapeptide is condensed with PABC-DOX as described elsewhere. De
Groot et al. (1999) J. Med. Chem. 42:5277-83. The amino acid side
chains are deprotected as described. De Groot et al. (1999) J. Med.
Chem. 42:5277-83. Morpholino-Ser-Lys-Leu-Gln-PABC-DOX has been used
as a substrate of the enzyme PSA as shown in FIG. 16.
Synthesis of
Morpholino-Ser-Lys-Leu-Gln-PABC-NHCH.sub.2CH.sub.2O-.beta.-La-
pachone (see FIG. 17)
[0272] Morpholino-Ser(OAloc) was prepared from SER(OtBu)-OtBu.
Reaction of Ser(OtBu)-OtBu with 4-morpholineacarbonyl chloride in
pyridine yielded morpholino-Ser(OtBu)-OtBu.
Morpholino-Ser(OtBu)-OtBu was hydrolyzed with TFA to yield
morpholino-Ser. Esterification of morpholino-Ser with isobutylene
in the presence of a catalytic amount of H.sub.2SO.sub.4 afforded
morpholino-Ser-OtBu. Reaction of morpholino-Ser-OtBu with allyl
1-benzotriazolyl carbonate yielded morpholino-Ser(OAloc)-OtBu.
Morpholino-Ser(OAloc)-OtBu was hydrolyzed with TFA in CHCl.sub.3
(1:1) to yield morpholino-Ser(OAloc).
[0273] Preparation of the tetrapeptide was accomplished using
standard procedures. Fmoc-Leu was coupled to Gln-OtBu with DCC in
the presence of 1-hydroxybenzotriazole (HOBt) to give
Fmoc-Leu-Gln-OtBu. Removal of the Fmoc group from Fmoc-Leu-Gln-OtBu
with piperidine in CH.sub.2C1.sub.2/DMF produced Leu-Gln-OtBu.
Fmoc-Lys(N.epsilon.-Aloc) was coupled to Leu-Gln-OtBu with DCC in
the presence of HOBt to give
Fmoc-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Removal of the Fmoc group
from Fmoc-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with piperidine in DMF
produced Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Morpholino-Ser(OAloc)
was coupled to Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with DCC in the
presence of HOBt to give
morpholino-Ser(OAloc)-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu. Hydrolysis
of morpholino-Ser(OAloc)-Lys(N.epsilon.-Aloc)-Leu-Gln-OtBu with TFA
in CHCl.sub.3 (1:1) would give the tetrapeptide
morpholino-Ser(OAloc)-Lys(N.- epsilon.-Aloc)-Leu-Gln-OH. The
tetrapeptide is condensed with
PABC-NHCH.sub.2CH.sub.2O-.beta.-lapachone in an analogous manner as
the condensation of the tetrapeptide with doxorubicin, described in
De Groot et al. (1999) J. Med. Chem. 42:5277-83; the amino acid
side chains are deprotected using the procedure described in that
reference.
Morpholino-Ser-Lys-Leu-Gln-PABC-NHCH.sub.2CH.sub.2O-.beta.-lapachone
is used as a substrate of the enzyme PSA as shown in FIG. 17.
Example 2
Cell Culture and Drug Testing Protocol
[0274] Cell Culture:
[0275] The human lung adenocarcinoma cell line, A549, and human
prostatic cancer cell line, DUPRO, were a gift from Dr. M. Eileen
Dolan, University of Chicago, Department of Medicine. A549 was
grown in Ham's F-12K medium (Fisher Scientific, Itasca, Ill.)
supplemented with 10% fetal bovine serum and 2 mM L-glutamine.
DUPRO was grown in RPMI-1640 supplemented with 10% fetal bovine
serum. The human colon carcinoma cell line, HT29, and the human
breast carcinoma cell line, MCF7, were obtained from the American
Type Culture Collection, Rockville, Md. HT29 cells were grown in
McCoy's 5A medium (Gibco, BRL, Gaithersburg, Md.) supplemented with
10% fetal bovine serum. MCF7 cells were grown in Richter's Improved
Modified Eagle's medium supplemented with 10% fetal bovine serum
and 2.2 g/L sodium bicarbonate. The human prostate adenocarcinoma
cell lines, LNCAP, PC-3 and DU145, were gifts from Dr. George
Wilding, University of Wisconsin Comprehensive Cancer Center and
the Department of Medicine, and were grown in Dulbecco's Modified
Eagle's medium supplemented with a 5% fetal bovine serum. The
malignant glioma cell line, U251MG NCI was obtained from the brain
tumor tissue bank at the University of Califormia, San Francisco
Department of Neurosurgery, and was grown in Dulbecco's Modified
Eagle's medium supplemented wth 10% fetal bovine serum. DUPRO, A549
and MCF7 cells were grown in 100 units/mL penicillin and 100
.mu.g/mL streptomycin. HT29 and U251MG NCI cells were grown in 50
.mu.g/mL gentamycin. LNCAP, PC-3 and DU145 cells were maintained in
1% antibiotic antimycotic solution (Sigma, St. Louis, Mo.). All
cell cultures were maintained at 37.degree. C. in 5% CO.sub.2/95%
humidified air.
[0276] MTT Assay.
[0277] Exponentially growing monolayer cells were plated in 96 well
plates at a density of 500 cells/well and allowed to grow for 24 h.
Serially diluted drug solutions were added such that the final drug
concentrations in the treatment media were between 0 and 35 .mu.M.
Cells were incubated with drug at either 4 hr or 72 hr. After 4 hr
and 72 hr treatment, drugs were removed, fresh media (without) drug
(100 uL) was added and cells were incubated for 6 days. After six
days, 25 .mu.L of a Dulbecco's phosphate-buffered saline solution
containing 5 mg/mL of MTT (Thiazolyl blue) (Sigma) was added to
each well and incubated for 4h at 37.degree. C. Then 100 .mu.L of
lysis buffer (20% sodium dodecyl sulfate, 50% N,N-dimethylformamide
and 0.8% acetic acid, pH 4.7) was added to each well and incubated
for an additional 22 h. A microplate reader (E max, Molecular
Devices, Sunnyvale, Calif.) set at 570 nm was used to determine the
optical density. Results were plotted as a ratio of the optical
density in drug treated wells to the optical density in wells
treated with vehicle alone. Plotting and estimation of ID.sub.50
values were accomplished with manufacturer supplied software.
1TABLE 1 ID.sub.50 (.mu.M) Values of Quinones in Various Cultured
Human Prostate Tumor Cell Lines Determined by the MTT assay
ID.sub.50 (.mu.M) of different prostate cells No. Structures of
Quinones PC-3 DUPRO DU145 LNCAP SL-11051 21 17.11 19.3 11.16
SL-11059 22 4.3 SL-11062 23 1.71 SL-11064 24 0.7 2.2 0.13 SL-11065
25 1.4 SL-11066 26 >31.25 SL-11067 27 0.25 SL-11068 28 1.5
SL-11074 29 4.6 SL-11075 30 2.0 SL-11076 31 1.8 SL-11078 32 18.4
SL-11079 33 22.5 SL-11080 34 7.3 SL-11081 35 5.6 SL-11082 36 5.4
SL-11083 37 5.2 SL-11084 38 5.9 SL-11085 39 >31.25 SL-11087 40
2.4 SL-11088 41 >31.25 SL-11089 42 11.03 SL-11095 43 4.2
SL-11096 44 3.6 SL-11106 45 >31.25 SL-11107 46 4.3 >31.25
17.2 SL-11112 47 >31.25 >27.9 22.9 SL-11113 48 27.9 >31.25
29.2 SL-11120 49 6.4 13.1 3.8 SL-11125 50 5.9 7.9 0.13 SL-11145 51
1.97 0.7 (4 hr) (4 hr) 0.51 0.8 (6 days) (6 days) SL-11147 52 6.3
28.08 (4 hr) (4 hr) 1.24 2.01 (72 hr) (72 hr) SL-11148 53 6.3
1.84
[0278]
2TABLE 2 ID.sub.50 (.mu.M) Values of Quinones in Various Cultured
Human Tumor Cell Lines Determined by the MTT Assay ID.sub.50
(.mu.M) of different Tumor cells Brain Lung Colon Breast U251- No.
Structures of Quinones A549 HT-29 MCF7 MG SL-11051 54 17.23 20.02
SL-11052 55 26.88 SL-11053 56 7.39 2.8 SL-11054 57 >31.25
>31.25 SL-11056 58 >31.25 >31.25 >31.25 >31.25
SL-11059 59 15.0 10.12 SL-11060 60 >31.25 >31.25 17.23
>31.25 SL-11062 61 18.64 SL-11064 62 9.3 SL-11065 63 2.13
SL-11066 64 >31.25 SL-11067 65 >31.25 0.53 SL-11068 66 24.0
SL-11074 67 SL-11075 68 SL-11076 69 1.8 1.7 10.24 SL-11078 70 18.9
19.3 30.85 SL-11079 71 SL-11080 72 SL-11081 73 SL-11082 74 SL-11083
75 SL-11084 76 SL-11085 77 SL-11087 78 19.8 6.05 4.0 SL-11088 79
>31.25 >31.25 >31.25 SL-11089 80 >31.25 SL-11095 81
>31.25 22.1 20.6 SL-11096 82 17.4 3.4 3.8 SL-11106 83 >31.25
SL-11107 84 >31.25 SL-11112 85 SL-11113 86 SL-11120 87 26.7 20.9
4.1 SL-11125 88 27.97 5.7 5.1 SL-11145 89 2.4 (4 hr) 1.0 (6 days)
SL-11147 90 SL-11148 91
[0279]
3TABLE 3 ID.sub.50 (.mu.M) Value(s) of Non-Quinone Structure in A
Cultured Human Prostate Tumor Cell Line Determined by the MTT Assay
ID.sub.50 (.mu.M) of different prostate cells No. Structures of
Compound PC-3 DUPRO DU145 LNCAP SL-11063 92 >31.25
[0280]
4TABLE 4 ID.sub.50 (.mu.M) Values of Selected Non-Quinone Compounds
in Various Cultured Human Tumor Cell Lines Determined by the MTT
Assay ID.sub.50 (.mu.M) of different Tumor cells Lung Colon Breast
Brain No. Structures of Non-Quinone Compounds A549 HT-29 MCF7
U251-MG SL-11055 93 >31.25 >31.25 >31.25 >31.25
SL-11058 94 >31.25 SL-11063 95 >31.25
[0281] Table 5 lists additional quinones and quinone derivatives
which are useful in the invention, either as therapeutics or, in
the case of quinones which are not already covalently linked to or
derivatized with peptides, as therapeutics in conjunction with
peptides.
5 TABLE 5 No. Name and/or Structure SL-11001 96 SL-11002 97
SL-11003 98 SL-11004 99 SL-11005 100 SL-11006 101 SL-11007 102
SL-11008 103 SL-11009 104 SL-11010 105 SL-11011 106 SL-11012 107
SL-11013 108 Sl-11014 109 SL-11015 110 SL-11016 111 SL-11017 112
SL-11018 113 SL-11019 114 SL-11020 115 SL-11021 116 SL-11022 117
SL-11023 118 SL-11024 119 SL-11025 120 SL-11026 121 SL-11031 122
SL-11039 123 SL-11041 124 SL-11042 125 SL-11045 126 SL-11046 127
SL-11049 128 SL-11057 129 SL-11142 130 SL-11146 131 SL-11151 132
SL-11152 133 SL-11153 134 SL-11154 135 SL-11168 136 SL-11173 137
SL-11185 138 SL-11186 139 SL-11187 140 SL-11188 141 SL-11189 142
SL-11190 143 SL-11191 144 SL-11192 145 SL-11193 146 SL-11194 147
SL-11195 148 SL-11196 149 SL-11205 150
[0282] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, it is apparent to those skilled in the art that
certain minor changes and modifications will be practiced.
Therefore, the description and examples should not be construed as
limiting the scope of the invention, which is delineated by the
appended claims.
* * * * *